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[57] ABSTRACT 
The present invention provides a method of treating a 
neurodegenerative pathology in a human patient. This 
method includes selecting a patient for monitoring for 
the presence of a neurodegenerative pathology associ-
ated with enhanced Calpain activity and monitoring the 
patient for indicia of the onset or existence of such a 
pathology. In response to the detection of any such 
indicium of the presence or onset of the pathology, a 
therapeutically efficacious amount of a Peptide Ketoa-
mide compound, or a pharmaceutically acceptable salt 
or derivative thereof, together with a pharmaceutically 
acceptable carrier is administered. The invention also 
provides additional methods of treatment and pharma-
ceutical compositions using Peptide Ketoamides, Pep-
tide Ketoacids and Peptide Ketoesters. 
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METHOD OF TREATMENT OF 
NEURODEGENERATION WITH CALPAIN 
INHIBITORS 
2 
cause they are poorly membrane permeant and, accord-
ingly, do not cross the blood brain barrier very well. 
Also, many of these inhibitors are poorly specific and 
will inhibit a wide variety of proteases in addition to 
RELATED APPLICATIONS 
This application is a continuation of Ser. No. 
07/816,120, filed Dec. 27, 1991, now abandoned, which 
is a continuation-in-part of Ser. No. 07 /682,925, filed 
Apr. 9, 1991, now abandoned, which is a continuation 
of Ser. No. 07/635,952, filed Dec. 28, 1990. 
5 Calpain. These commercially available compounds are 
based upon peptide structures that are believed to inter-
act with the substrate binding site of Calpain. Active 
groups associated with the Calpain inhibitors then ei-
ther block or attack the catalytic moiety of Calpain in 
10 order to inhibit the enzyme. 
BACKGROUND OF THE INVENTION 
The present invention relates generally to the field of 
neuroprotectants and more specifically to the use of 15 
inhibitors of calcium-stimulated proteases, such as cal-
pain, as therapeutics for neurodegeneration. 
Neural tissues, including brain, are known to possess 
a large variety of proteases, including at least two calci-
um-stimulated proteases, termed calpain I and calpain 20 
II, which are activated by micromolar and millimolar 
Ca2+o concentrations, respectively. Calpains are a fam-
ily of calcium activated thiol proteases that are present 
in many tissues. Calpain II is the predominant form, but 
calpain I is found at synapses and is thought to be the 25 
form involved in long term potentiation and synaptic 
plasticity. 
Thiol proteases are distinguished from serine pro-
teases, metalloproteases and other proteases by their 
mechanism of action and by the amino acid residue 30 
( cysteine) that participates in substrate attack. Although 
several thiol proteases are produced by plants, these 
proteases are not common in mammals, with cathepsin 
B (a lysosomal enzyme), other cathepsins and the cal-
pains being among the few representatives of this family 35 
that have been described in mammals. Calpain I and 
calpain II are the best described of these, but several 
other members of the calpain family have been re-
ported. 
Other Ca2+-activated thiol proteases may exist, such 40 
as those reported by Yoshihara et al. in J. Biol. Chem. 
265:5809-5815 (1990). The term "Calpain" is used here-
inafter to refer to any Ca2+-activated thiol proteases 
including the Yoshihara enzyme and calpains I and II. 
While Calpains degrade a wide variety of protein 45 
substrates, cytoskeletal proteins seem to be particularly 
susceptible to attack. In at least some cases, the products 
of the proteolytic digestion of these proteins by Cal pain 
are distinctive and persistent over time. Since cytoske-
letal proteins are major components of certain types of 50 
cells, this provides a simple method of detecting Cal-
pain activity in cells and tissues. Specifically, the accu-
mulation of the breakdown products ("BDP's") ofspec-
trin, a cytoskeletal protein, has been associated with the 
activation of Calpain. In neural tissues, activation of 55 
Calpains, as evidenced by accumulation of these BDP's, 
has been observed in many neurodegenerative condi-
tions, including denervation resulting from focal elec-
trolytic lesions, genetic abnormalities, excitotoxicity, 
Alzheimer's disease, following ischemia in gerbils and 60 
following administration of the toxins kainate and col-
chicine in rats, when administered peripherally or cen-
trally. 
Commercially available in vitro inhibitors of Calpain 
include peptide aldehydes such as leupeptin (Ac-Leu- 65 
Leu-Arg-H), as well as epoxysuccinates such as E-64. 
These compounds are not useful in inhibiting Calpain in 
Central Nervous System ("CNS") tissue in vivo be-
In addition, other types of compounds thought to 
possess in vitro Calpain inhibitory activity that are not 
commercially available have been reported. Examples 
of such compounds include the peptide diazomethanes. 
See Rich, D. H., Inhibitors of cysteine proteinases, in 
Protease Inhibitors, A. J. Barrett and G. Salversen, 
Eds., Elsevier, New York, 1986, pp153-178, the disclo-
sure of which is hereby incorporated by reference. 
These peptide diazomethanes are similarly thought to 
be poorly membrane permeant and non-specific. 
There is some evidence that certain particular inhibi-
tors of Calpain have certain therapeutic utilities. For 
example, leupeptin can facilitate nerve repair in pri-
mates. Loxastatin (also known as EST, Ep-460 or E-
64d), a derivative of E-64, is believed to have utility in 
the treatment of muscular dystrophy. E-64d, while not 
having significant protease inhibitory activity itself, is 
believed to be converted to more potent forms, such as 
to E-64c, inside a mammalian body. 
Evidence from electrophysiological studies suggests 
that one of the earliest factors in the chain of reactions 
leading to cell death is an increase in intracellular-free 
calcium as a consequence of Ca2+ channel opening 
and/or energy depletion. Intracellular calcium is likely 
to produce a large number of consequences, including 
the activation of a large number of enzymes, including 
proteases, such as Calpain, lipases and kinases. An in-
crease in intracellular calcium is also thought to induce 
changes in gene expression. 
Ischemia, head trauma and stroke have all been asso-
ciated with the release of glutamate in amounts large 
enough to lead to excitotoxicity, the toxicity resulting 
from the actions of certain amino acids on neurons of 
the CNS. The excess glutamate and other factors, such 
as free radical damage of membranes or energy deple-
tion, cause an increase in intracellular Ca2+. It is known 
that an excess of intracellular Ca2+ leads to several 
effects believed to be associated with neuronal cell 
damage, including destruction of cell structures 
through activation of phospholipase and Calpain, as 
well as free radical production resulting from activation 
of phospholipase and xanthine oxidase. Many other 
factors have been associated with neurotoxicity. For 
example, reductions in action potentials and changes in 
a wide variety of chemical markers are known to be 
associated with neurons exposed to ischemic conditions. 
Notwithstanding the foregoing understanding of cer-
tain aspects of neurotoxicity, no effective therapy has 
yet been developed for most neurodegenerative diseases 
and conditions of the CNS. Millions of individuals suf-
fer from these diseases and conditions. Thus, there is a 
need for therapies effective in treating and preventing 
these diseases and conditions. 
SUMMARY OF THE INVENTION 
One aspect of the present invention provides a 
method of treating a neurodegenerative pathology in a 
human patient. This method includes the steps of select-
3 
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4 
ing a patient for monitoring for the presence of a neuro- be a Dipeptide a-Ketoester such as Z-Ala-DL-Ala-
degenerative pathology having enhanced Calpain activ- COOEt, Z-Ala-DL-Ala-COOBzl, Z-Ala-DL-Ala-
ity associated therewith, monitoring the patient for COOnBu, Z-Leu-Nva-COOEt, Z-Leu-Nle-COOEt, 
indicia of the onset or existence of a neurodegenerative Z-Leu-Phe-COOEt, Z-Leu-Abu-COOEt, Z-Leu-Met-
pathology having enhanced Calpain activity associated 5 COOEt, Z-Phe-DL-Phe-COOEt, H-Gly-DL-Lys-
therewith, and in response to the detection of any such COOEt, H-Ala-DL-Lys-COOEt, H-Pro-DL-Lys-
indicium of the presence or onset of neurodegeneration COOEt, H-Phe-DL-Lys-COOEt, Z-Leu-Phe-COOEt, 
of the type associated with enhanced calpain activity, Z-Leu-4-Cl-Phe-COOEt, 2-NapS02-Leu-Abu-COOEt, 
administering a therapeutically efficacious amount of a Z-Leu-NLeu-C02Et, Z-Leu-Phe-C02Bu, Z-Leu-Abu-
Peptide Ketoamide compound, or a pharmaceutically IO C02Bu, Z-Leu-Phe-C02Bzl, MeO-Suc-Ala-DL-Ala-
acceptable salt or derivative thereof, together with a COOMe, or Z-Leu-Abu-C02Bzl. Still another active 
pharmaceutically acceptable carrier. The selecting step ingredient could be a Tripeptide a-Ketoester such as 
can comprise selecting a patient in which neurodegen- Z-Ala-Ala-DL-Ala-COOEt, Z-Ala-Pro-DL-Ala-
eration is occuring or is likely to occur, and the adminis- COOEt, Z-Ala-Ala-DL-Abu-COOEt, Z-Ala-Ala-DL-
tering step can comprise administering one of the fol- 15 Abu-COOBzl, Z-Ala-Ala-DL-Abu-COOCH2-C6-
lowing classes of compounds: Dipeptide a-Ketoamides l4-CF3 (para), H-Leu-Ala-DL-Lys-COOEt, Z-Leu-
(Subclass A), Dipeptide a-Ketoamides (Subclass B), Leu-Abu-COOEt, Z-Leu-Leu-Phe-COOEt, MeO-Suc-
Tripeptide a-Ketoamides, Tetrapeptide a-Ketoamides Val-Pro-DL-Phe-COOMe or 2-NapS02-Leu-Leu-Abu-
and Amino Acid a-Ketoamides. COOEt. A Tetrapeptide a-Ketoester, such as MeO-
Another aspect of the present invention provides a 20 Suc-Ala-Ala-Pro-DL-Abu-COOMe or Z-Ala-Ala-Ala-
method of inhibiting or treating neurodegeneration in a DL-Ala-COOEt, could also be the active ingredient. 
mammal having or likely to experience a neuropathol- Still another type of active ingredient would be a Pep-
ogy. This method includes the administration to the tide a-Ketoamide such as Z-Leu-Phe-CONH-Et, Z-
mammal of a therapeutically efficacious amount of Pep- Leu-Phe-CONH-nPr, Z-Leu-Phe-CONH-nBu, Z-Leu-
tide Ketoamide compound that has Calpain inhibitory 25 Phe-CONH-iBu, Z-Leu-Phe-CONH-Bzl, Z-Leu-Phe-
activity or a pharmaceutically acceptable salt or deriva- CONH-(CH2)2Ph, Z-Leu-Abu-CONH-Et, Z-Leu-
tive thereof. This Peptide Ketoamide compound is pref- Abu-CONH-nPr, Z-Leu-Abu-CONH-nBu, Z-Leu-
erably from one of the following classes: Dipeptide Abu-CONH-iBu, Z-Leu-Abu-CONH-Bzl, Z-Leu-Abu-
a-Ketoamides (Subclass A), Dipeptide a-Ketoamides CONH-(CH2)2Ph, Z-Leu-Abu-CONH-(CH2. 
(Subclass B), Tripeptide a-Ketoamides, Tetrapeptide 30 )3-N(CH2CH2)20, Z-Leu-Abu-CONH-(CH2)7CH3, 
a-Ketoamides and Amino Acid a-Ketoamides. The Z-Leu-Abu-CONH-(CH2)20H, Z-Leu-Abu-CON-
method can also include identifying, prior to adminis- H-(CH2)20(CH2)20H, Z-Leu-Abu-CON-
tration of the compound with Calpain inhibitory activ- H-(CH2)11CH3, Z-Leu-Abu-CONH-CH2-C6H-
ity, a mammal in which neurodegeneration of the CNS 3(0CH3)2 or Z-Leu-Abu-CONH-CH2-C4lf4N. 
is occurring or is likely to occur. The method is useful 35 In yet another aspect of the present invention, there is 
where the neurodegeneration is associated with a condi- provided a method of minimizing proteolysis in a bio-
tion selected from the group consisting of excitotox- logical sample containing peptides or proteins, during 
icity, HIV-induced neuropathy, ischemia, subarachnoid the processing, production, isolation, purification, stor-
hemorrhage, stroke, brain seizure, major heart attack, age or transport of the samples. This method includes 
multiple infarction dementia, Alzheimer's Disease, 40 the addition to the sample of a Peptide a-Ketoacid 
Huntington's Disease, surgery-related brain damage compound having Calpain activity or a form thereof 
and Parkinson's Disease. The administering step of this having Calpain inhibitory activity. Preferred com-
method can be any of a variety of adminstering proce- pounds in this method include Bz-DL-Lys-COOH, 
dures known to those of ordinary skill in the art, such as Bz-DL-Ala-COOH, Z-Leu-Phe-COOH and Z-Leu-
parenteral administration of a Calpain Inhibitor in a 45 Abu-COOR. Example of biological samples which can 
pharmaceutically acceptable carrier or oral administra- be used in this method include an in vitro sample, a 
tion of a Calpain Inhibitor in a form suitable for oral use. tissue sample or a whole organ. 
Parenteral administration is preferably by transdermal The present invention also provides pharmaceutical 
administration, subcutaneous injection, intravenous, compositions for the treatment or inhibition of neurode-
intramuscular or intrasternal injection, intrathecal injec- 50 generation comprising a pharmacologically effective 
tion directly into the CNS or infusion techniques. neuroprotective amount of a Peptide Ketoamide or a 
Still another aspect of the present invention provides pharmaceutically acceptable salt or derivative thereof 
methods of intervening early in the process of neurode- in a pharmaceutically acceptable formulation contain-
generation occurring in neural tissue of a mammal using ing a carrier material. The Peptide Ketoamide prefera-
an active ingredient which protects and assists in recov- 55 bly comprises a compound from the following sub-
ery of neural tissue, comprising administering a pharma- classes: Dipeptide a-Ketoamides (Subclass A), Dipep-
ceutically acceptable form of the active ingredient to tide a-Ketoamides (Subclass B), Tripeptide a-Ketoa-
the mammal. The active ingredient can be a Peptide mides, Tetrapeptide a-Ketoamides and Amino Acid 
a-Ketoacid such as Bz-DL-Lys-COOH, Bz-DL-Ala- a-Ketoamides. Particular Peptide Ketoamide com-
COOH, Z-Leu-Phe-COOH or Z-Leu-Abu-COOH. The 60 pounds which are believed effective include Z-Leu-
active ingredient can also be an Amino Acid Peptide Phe-CONH-Et, Z-Leu-Phe-CONH-nPr, Z-Leu-Phe-
a-Ketoester, such as Bz-DL-Ala-COOEt, Bz-DL-Ala- CONH-nBu, Z-Leu-Phe-CONH-iBu, Z-Leu-Phe-
COOBzl, Bz-DL-Ala-COOnBu, Bz-DL-Phe-COOEt, CONH-Bzl, Z-Leu-Phe-CONH-(CH2)2Ph, Z-Leu-
Bz-DL-Ala-COOCH2-C6!4-CF3 (para), Bz-DL- Abu-CONH-Et, Z-Leu-Abu-CONH-nPr, Z-Leu-Abu-
Arg-COOEt, Bz-DL-Lys-COOEt, PhCO-Abu- 65 CONH-nBu, Z-Leu-Abu-CONH-iBu, Z-Leu-Abu-
COOEt, (CH3)2CH(CH2)2CO-Abu-COOEt, CONH-Bzl, Z-Leu-Abu-CONH-(CH2)2Ph, Z-Leu-
CH3CH2CH)2CHCO-Abu-COOEt or Ph(CH2)6CO- Abu-CONH-(CH2)3-N(CH2CH2)20, Z-Leu-Abu-
Abu-COOEt. Another useful active ingredient would CONH-(CH2)7CH3, Z-Leu-Abu-CONH-(CH2)20H, 
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Z-Leu-Abu-CONH-(CH2)20(CH2)20H, Z-Leu-Abu-
CONH-(CH2)11CH3, Z-Leu-Abu-CONH-CH-
2-C6H3(0CH3)2 and Z-Leu-Abu-CONH-CH-
2-C.µLiN. Additional pharmaceutical compositions for 
the treatment or inhibition of neurodegeneration are 5 
also provided by the present invention. These composi-
tions include a pharmacologically effective neuropro-
tective amount of an active ingredient or a pharmaceuti-
cally acceptable salt or derivative thereof in a pharma-
ceutically acceptable formulation containing a carrier 10 
material. In these compositions the active ingredient 
can be an Amino Acid Peptide Ketoester compound 
such as Bz-DL-Ala-COOEt, Bz-DL-Ala-COOCH-
2-C6!4-CF3 (para), Bz-DL-Lys-COOEt, PhCO-
Abu-COOEt, (CH3)2CH(CH2)2CO-Abu-COOEt, 15 
CH3CH2CH)2CHCO-Abu-COOEt or Ph(CH2)6CO-
Abu-COOEt. Another active ingredient would be a 
Dipeptide Ketoester compound such as Z-Ala-DL-Ala-
COOEt, Z-Ala-DL-Ala-COOBzl, Z-Ala-DL-Ala-
COOnBu, Z-Leu-Nva-COOEt, Z-Leu-Nle-COOEt, 20 
Z-Leu-Abu-COOEt, Z-Leu-Met-COOEt, Z-Leu-Phe-
COOEt, Z-Leu-4-Cl-Phe-COOEt, 2-NapS02-Leu-
Abu-COOEt, Z-Leu-NLeu-C02Et, Z-Leu-Phe-
C02Bu, Z-Leu-Abu-C02Bu, Z-Leu-Phe-C02Bzl, 25 MeO-Suc-Ala-DL-Ala-COOMe or Z-Leu-Abu-
C02Bzl. Still another active ingredient would be a Tri-
peptide Ketoester compound such as Z-Ala-Ala-DL-
Ala-COOEt, Z-Ala-Pro-DL-Ala-COOEt, Z-Ala-Ala-
DL-Abu-COOEt, Z-Ala-Ala-DL-Abu-COOBzl, Z- 30 Ala-Ala-DL-Abu-COOCH2-C6H.4-CF3 (para), H-
Leu-Ala-DL-Lys-COOEt, Z-Leu-Leu-Abu-COOEt, 
Z-Leu-Leu-Phe-COOEt, MeO-Suc-Val-Pro-DL-Phe-
COOMe or 2-NapS02-Leu-Leu-Abu-COOEt. A Tetra-
peptide Ketoester, such as Z-Ala-Ala-Ala-DL-Ala- 35 
COOEt or MeO-Suc-Ala-Ala-Pro-DL-Abu-COOMe, 
could also be the active ingredient. In addition, a Pep-
tide Ketoacid, such as Bz-DL-Lys-COOH, Bz-DL-Ala-
COOH, Z-Leu-Phe-COOH and Z-Leu-Abu-COOH 
could be the active ingredient. 40 
These and other features and advantages of the pres-
ent invention will become apparent from the detailed 
description of preferred embodiments which follows, 
when considered together with the attached drawings 
and claims. 45 
BRIEF SUMMARY OF THE FIGURES 
FIG. 1 shows the percentage of inhibition of gluta-
mate-induced cell death through the addition of gluta-
mate and various Calpain Inhibitors relative to control 50 
where no glutamate was added. 
FIG. 2 graphically depicts the effects of Z-Leu-Phe-
CONH-Et (CX269) and Z-Leu-Abu-CONH-Et 
(CX275) on the size of infarction produced upon MCA 
occlusion in male rats. 55 
FIG. 3 shows the effects of CX216 (Z-Leu-Phe-
C02Et, a Peptide Keto-Compound), and Cll (Ac-Leu-
Leu-Nle-H) relative to control slices on survival of 
hippocampal slices exposed to 10 minutes exposure of 
anoxic atmosphere where both of these compounds 60 
were added at their optimal inhibitory concentration at 
both 1 hour and 2 hour incubation times. 
FIG. 4 shows the evoked potential amplitude for 
control, Cll treated and CX2 l 8 treated hippocampal 
slices over a time course during which the slices are 65 
exposed to anoxic atmosphere. 
FIG. 5 shows the percent recovery of EPSP from 
severe hypoxia over the course of one hour incubation 
6 
for Z-Leu-Phe-CONH-Et (CX269) and Z-Leu-Phe-
C02Et (CX216). 
FIG. 6 shows a comparison of the effect of the pres-
ence of Cll or CX2 l 6 on survival of,hippocampal slices 
expressed as the duration of anoxia (in minutes) before 
fiber volley disappearance. 
FIG. 7 shows the effects of Cll compared with con-
trol on the behavioral and convulsive effects of kainic 
acid. 
FIG. 8 shows the amount of spectrin BDP's in rat 
brains exposed to kainate for control and en treated 
rats. 
DETAILED DESCRIPTION OF THE 
INVENTION 
A. INTRODUCTION 
We have discovered that Calpain activation is an 
event central to many cases of brain atrophy and degen-
eration and that inhibition of Calpain alone is sufficient 
to inhibit or prevent cell deterioration and loss. Thus, 
we have further discovered that inhibition of Calpain 
provides protection from neurotoxicity associated with 
many neurodegenerative conditions and diseases. 
In accordance with the foregoing discoveries, we 
believe that the elevation of intracellular calcium asso-
ciated with neuropathological conditions in neuronal 
cells activates Calpain and sets in motion the digestion 
of neuronal cells from within. We believe there may be 
other mechanisms of activation of Calpains associated 
with these conditions. Accordingly, one aspect of the 
present invention is directed to inhibition and treatment 
of the neurodegeneration and other diseases associated 
with this digestion through the inhibition of Calpain 
activity. Thus, part of this aspect of the present inven-
tion is to prevent the neurodegeneration and other pa-
thology caused by this digestion through the in vivo 
administration of Calpain inhibitors. By way of exam-
ple, and not oflimitation, diseases and conditions which 
can be treated using this aspect of the present invention 
include neurodegeneration following excitotoxicity, 
HIV-induced neuropathy, ischernia, denervation fol-
lowing ischemia or injury, subarachnoid hemorrhage, 
stroke, multiple infarction dementia, Alzheimer's Dis-
ease (AD), Parkinson's Disease, Huntington's Disease, 
surgery-related brain damage and other neuropatholog-
ical conditions. 
As stated above, spectrin BDP's have been found to 
be associated with Calpain activation in vivo. We have 
observed that in each instance of neurodegeneration in 
which BDP's characteristic of Calpain activation are 
detected, Calpain activation is localized to the brain 
areas most vulnerable to the particular pathogenic ma-
nipulation. In addition, as judged by histological meth-
ods, Cal pain activation precedes overt evidence of neu-
rodegeneration. Accordingly, Calpain activation is spa-
tially and temporally linked to impending or ongoing 
cell death in the brain. Thus, we believe that Calpain 
activation is an important mechanism of cell damage 
and death in many pathological conditions, including 
neuropathological conditions. Moreover, there is evi-
dence that the activation of Calpains is an early event in 
the death of cells including neural cells. This is in con-
trast to other known proteases which are activated at 
later stages of cell death. Thus, we believe that, advan-
tageously, inhibition of Calpain activity provides inter-
vention at an early stage of cell death, prior to signifi-
cant deterioration of cellular machinery. 
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Another aspect of the involvement of Calpains in 
neurodegeneration is the involvement of these proteins 
in regenerating systems. It is known that developing or 
regenerating axons are somehow inhibited from further 
development in a stabilization process called the "stop 5 
pathway." This stabilization can occur when axons 
have reached their targets; however, in some systems 
stabilization can also occur at inappropriate places. One 
researcher has developed evidence that this stop path-
way operates at least in part by the activation of intra- 10 
cellular Calpain and that inhibition of Cal pain can inter-
fere with stabilization (Luizzi, 1990). We believe that 
Calpain inhibitors, when used in accordance with the 
present invention, can advantageously aid regeneration 
15 
and recovery of neural tissue after injury, in addition to 
inhibiting neurodegeneration. 
Another aspect of the present invention is our discov-
ery that at least three classes of compounds, the substi-
tuted isocoumarins, the peptide keto-compounds and 20 
the Halo-Ketone Peptides have Calpain inhibitory ac-
tivity. We have further discovered, as will be described 
hereinbelow, that these three classes of compounds 
exhibit additional properties that render them especially 
useful as therapeutically effective compounds in the 25 
treatment of neurodegenerative conditions and diseases. 
B. SUBSTITUTED HETEROCYCLIC COM-
POUNDS 
One particular class of compounds exhibiting Calpain 
inhibitory activity, when used in accordance with the 30 
present invention, are the substituted heterocyclic com-
pounds. These compounds include the substituted 
isocoumarins. The substituted heterocyclic compounds 
are known to be excellent inhibitors of serine proteases. 
As discussed hereinbelow, we have now discovered 35 
that these compounds are also inhibitors of cal pain I and 
calpain II, and also of other Calpains. Additionally, as 
also discussed below, we have found that, unlike most 
known inhibitors of Calpains, these substituted hetero-
cyclic compounds are not effective as inhibitors of pa- 40 
pain or cathepsin B. Thus, we believe that the substi-
tuted heterocyclic compounds provide a relatively spe-
cific means of inhibiting Calpains while not affecting 
other thiol proteases. 
One particular class of substituted heterocyclic com- 45 
pounds with Calpain inhibitory activity are the 
isocoumarins having cationic substituents. These substi-
tuted heterocyclic compounds are referred to herein as 
the "Class I Substituted Isocoumarins." The Class I 
Substituted Isocoumarins are known to be excellent 50 
inhibitors of several serine proteases, including bovine 
thrombin, human thrombin, human factor Xa, human 
factor Xla, human factor XIIa, bovine trypsin, human 
plasma plasmin, human tissue plasminogen activator, 55 human lung tryptase, rat skin tryptase, human leukocyte 
elastase, porcine pancreatic elastase, bovine chymotryp-
sin and human leukocyte cathepsin G. The Class I Sub-
stituted Isocoumarins inhibit the serine proteases by 
reaction with the active site serine to form an acyl en- 60 
zyme, which in some cases may further react with an-
other active site nucleophile to form an additional cova-
lent bond. We have discovered that the Class I Substi-
tuted Isocoumarins also react with Calpain. We believe 
that the mechanism of action of Calpain inhibition is 65 
similar to that of the inhibition of serine proteases since 
the reaction mechanism of Calpains is similar to that of 
the serine proteases. 
8 
The Class I Substituted Isocoumarins having Calpain 
inhibitory activity have the following structural for-
mula: 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt, wherein 
(I) 
Z is selected from the group consisting of Cl-6 alk-
oxy with an amino group attached to the alkoxy 
group, Cl-6 alkoxy with an isothiureido group 
attached to the alkoxy group, Cl-6 alkoxy with a 
guanidino group attached to the alkoxy group, 
Cl-6 alkoxy with an amidino group attached to the 
alkoxy group, Cl-6 alkyl with an amino group 
attached to the alkyl group, Cl-6 alkyl with an 
isothiureido group attached to the alkyl group, 
Cl-6 alkyl with an guanidino group attached to the 
alkyl group, Cl-6 alkyl with an amidino group 
attached to the alkyl group, 
R is selected from the group consisting of O=C-
N-, S=C=N-, AA-NH-, AA-AA-NH-, 
AA-0, AA-AA-0-, M-NH-, M-AA-NH, M-
AA-AA-NH-, M-0-, M-AA-0-, M-AA-AA-
0-
wherein AA represents alanine, valine, leucine, iso-
leucine, proline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, cit-
rulline, hydroxyproline, ornithine or sarcosine, 
wherein M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS, 
X-NH-S02, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-, 
wherein X represents Cl-6 alkyl, Cl-6 fluoroalkyl, 
Cl-6 alkyl substituted with K, Cl-6 fluoroalkyl 
substituted with K, phenyl, phenyl substituted with 
J, phenyl disubstituted with J, phenyl trisubstituted 
with J, naphthyl, naphthyl substituted with J, 
naphthyl disubstituted with J, naphthyl trisubstitu-
ted with J, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with J, or Cl-6 alkyl with two attached 
phenyl groups substituted with J, 
wherein J represents halogen, COOR, OH, CN, 
N02, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylamine, 
Cl-6 dialkylamine, or Cl-6 alkyl-0-CO-, 
wherein K represents halogen, COOH, OH, CN, 
N02, NH2, Cl-6 alkylamine, Cl-6 dialkylamine, 
or Cl-6 alkyl-0-CO-, 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
The compounds of Formula (I) can also contain one 
or more substituents at position B as shown in the fol-
lowing structure: 
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B 
R 
7-( 1-naphthy lcarbamoy lamina )-4-chloro-3-(2-isothi-
ureidoethoxy )isocoumarin (NaphthylNH-
CiTEtOIC) 
7-((S)-a-methylbenzylcarbamoylamino)-4-chloro-3-(2-
B z 
5 isothiureidoethoxy)isocoumarin (S-
C6H5(CH3)CHNHCONH-CiTEtOIC) 
B y 
wherein electronegative substituents such as N02, CN, 10 
CI, COOR, and COOH will increase the reactivity of 
the isocoumarin, and electropositive substituents such 
as NH2, OH, alkoxy, thioalkyl, alkyl, alkylamino, and 
dialkylamino will increase its stability. Neutral substitu-
ents could also increase the stability of acyl enzyme and 15 
improve the effectiveness of the inhibitors. 
The following compounds are representative of the 
Class I Substituted Isocoumarins of the present inven-
tion: 
20 
4-chloro-3-(3-isothiureidopropoxy)isocoumarin (CiT-
PrOIC) 
7-(benzy lcarbamoylamino )-4-chloro-3-(3-isothiureido-
7-( (R)-a-methylbenzylcarbamoylamino )-4-chloro-3-(2-
isothiureidoethoxy )isocoumarin (R-
C6H5(CH3)CHNHCONH-CiTEtOIC) 
7-dansylamino-4-chloro-3-(2-isothiureidoethox-
y )isocoumarin (DansylNH-CiTEtOIC) 
7-phenylthiocarbamoy lamino-4-chloro-3-(2-isothi-
ureidoethoxy )isocoumarin (PhNHCSNH-
CiTEtOIC) 
7-(m-carboxyphenylthiocarbamoyl)amino-4-chloro-3-
(2-isothiureidoethoxy)isocoumarin (m-COOH-
PhNHCSNH-CiTEtOIC) 
7-(p-carboxyphenylthiocarbamoyl)amino-4-chloro-3-
(2-isothiureidoethoxy )isocoumarin (p-COO H-
PhNH CSNH-CiTEtO IC) 
7-amino-4-chloro-3-(3-isothiureidopropoxy )isocouma-
rin (ACITIC) 
propoxy )isocoumarin (PhCH2NHCONH-CiT-PrOIC) 25 Isocoumarins with basic substituents are also known 
7-(phenylcarbamoylamino )-4-chloro-3-(3-isothiureido- to be effective inhibitors of serine uroteases. See Powers 
propoxy)isocoumarin (PhNHCONH-CiTPrOIC) et al, U.S. Pat. No. 4,845,242, the disclosure of which is 
7-(acetylamino)-4-chloro-3-(3-isothiureidopropox- hereby incorporated by reference. This class of com-
y)isocoumarin (CH3CONH-CiTPrOIC) pounds, referred to herein as the "Class II Substituted 
7-(3-phenylpropionylamino)-4-chloro-3-(3-isothiureido- 30 Isocoumarins," along with the other substituted hetero-
propoxy)isocoumarin (PhCH2CH2CONH-CiT- cyclic compounds, is believed to be effective in the use 
PrOIC) of the present invention. 
7-(phenylacetylamino)-4-chloro-3-(3-isothiureido- The Class II Substituted Isocoumarins have the fol-
propoxy)isocoumarin (PhCH2CONH-CiTRrOIC) lowing structural formula: 
7-(L-pheny lalanylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin (L-Phe-NH-CiTPrOIC) 
7-(N-t-buty loxycarbony 1-L-phenylalany lamina )-4-
chloro-3-(3-isothiureidopropoxy )isocoumarin (Boc-
L-Phe-NH-CiTRrOIC) 
35 
7-(D-phenylalanylamino)-4-chloro-3-(3-isothiureido- 4D 
propoxy )isocoumarin (D-Phe-NH-CiTPrOI C) 
7-(N-t-butyloxycarbonyl-D-pheny lalanylamino )-4-
chloro-3-(3-isothiureidopropoxy )isocoumarin (Boc-
D-Phe-NH-CiTPrOIC) 
7-(benzylcarbamoylamino )-4-chloro-3-(2-isothiureidoe- 45 
thoxy)isocoumarin (PhCH2NHCONH-CiTEtOIC) 
7-(phenylcarbamoylamino )-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin (PhNHCONH-CiTEtOIC) 
7-(isopropylcarbamoylamino )-4-chloro-3-(2-isothi-
ureidoethoxy )isocoumarin ((CH3)2CHNHCONH- 50 
CiTEtOIC) 
7-(phenylacetylamino )-4-chloro-3-(2-isothiureidoethox-
y )isocoumarin (PhCH2CONH-CiTEtOIC) 
7-(L-phenylalanylamino )-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin (L-Phe-NH-CiTEtOIC) 
7-(N-t-butyloxycarbonyl-L-pheny lalanylamino )-4-
chloro-3-(2-isothiureidoethoxy )isocoumarin (Boc-L-
Phe-NH-CiTEtOI C) 
7-(D-phenylalanylamino )-4-chloro-3-(2-isothiureidoe-
thoxy )isocoumarin (D-Phe-NH-CiTEtOIC) 
7-(N-t-buty loxycarbony 1-D-pheny lalanylamino )-4-
chloro-3-(2-isothiureidoethoxy )isocoumarin (Boc-D-
Phe-NH-CiTEtOIC) 
7-(N-t-butyloxycarbonyl-L-alanyl-L-alanylamino)-4-
55 
60 
chloro-3-(2-isothiureidoethoxy)isocoumarin (Boe- 65 
Ala-Ala-NH-CiTEtOIC) 
7-(L-alanyl-L-alanylamino)-4-chloro-3-(2-isothiureido-
ethoxy)isocoumarin (ala-Ala-NH-CiTEtOIC) 
0 
R~~ 
~z 
y 
or a pharmaceutically acceptable salt, wherein 
(II) 
R is selected from the group consisting of -N--
H-C( NH)-NH2, -C(=NH)NH2, C1-6 alkyl 
with an attached amino, and C1-6 alkyl with an 
attached isothiureido of the formula 
-S-C( +NH2 + )NH2, 
Z is selected from the group consisting ofH, halogen, 
C1-6 alkyl, C1-6 alkyl with an attached phenyl, C1-6 
fluorinated alkyl, C1-6 alkyl with an attached hy-
droxyl, C1-6 alkyl with an attached C1-6 alkoxy, 
C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 alkoxy 
with an attached phenyl, benzyloxy, 4-fluoroben-
zyloxy, -OCH2C6f4R' (2-substituent), 
-OCH2C6li4.R' (3-substituent), -OCH2C6f4R' 
(4-substituent), -OCH2C6H3R2' (2,3-substituents), 
-OCH2C6H3R2' (2,4-substituents), 
-OCH2C6li3R2' (2,5-substituents ), 
-OCH2C6H3R2' (2,6-substituents), 
-OCH2C6H3R2' (3,4-substituents), and 
OCH2C6H3R2' (3,5-substituents). 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino. 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH, and methoxy. 
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Alternately, the Class II Substituted Isocoumarins are 
represented by structure (II) where, 
Z is selected from the group consisting of C1-6 alkoxy 
with an attached isothiureido, C1-6 alkoxy with an 5 
attached guanidino, C1-6 alkoxy with an attached 
amidino, C1-6 alkyl with an attached amino, C1-6 
alkyl with an attached isothiureido, C1-6 alkyl with 
an attached guanidino, C1-6 alkyl with an attached 
amidino, 
R is selected from the group consisting of H, OH, 
NH2, N02 halogen, C1-6 alkoxy, C1-6 fluorinated 
alkoxy, C1-6 alkyl, C1-6 alkyl with an attached 
amino, M-AA-NH-, M-AA-0-, 
10 
wherein AA represents alanine, valine, leucine, iso- 15 
leucine, proline, methionine, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, beta-alanine, norleucine, 20 
norvaline, alpha-aminobutyric and epsilon-
aminocaponic acid, citrulline, hydroxyproline, or-
nithine and sarcosine, 
wherein M represents H, lower alkanoyl having 1 to 
6 carbons, carboxyalkanoyl, hydroxyalkanoyl, am- 25 
in-alkanoyl, benzene sulfonyl, tosyl, benzoyl, and 
lower alkyl sulfonyl having 1 to 6 carbons, 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy. 30 
As a further alternative, the Class II Substituted 
Isocoumarins are represented by structure (II) where 
R is selected from the group consisting of -N--
H-C( NH)-NH2, -C( NH)NH2, C1-6 alkyl 
with an attached amino, C1-6 alkyl with an attached 35 
isothiureido, 
Z is selected from the group consisting of C1-6 alkoxy 
with an attached amino, C1-6 alkoxy with an at-
tached isothiureido, C1-6 alkoxy with an attached 40 
guanidino, C1-6 alkoxy with an attached amidino, 
C1-6 alkyl with an attached amino, C1-6 alkyl with 
an attached guanidino, C1-6 alkyl with an attached 
amidino, 
Y is selected from the group consisting of H, halogen, 45 
trifluoromethyl, methyl, OH and methoxy. 
The following compounds are representative of the 
Class II Substituted Isocoumarins: 
0 
wherein 
z, 
y 
A 
X R 
12 
(III) 
Z is selected from the group consisting of CO, SO, 
S02, CCI and CF, 
Y is selected from the group consisting of 0, S and 
NH, 
X is selected from the group consisting of N and CH, 
and 
R is selected from the group consisting of C1-6 alkyl 
(such as methyl, ethyl and propyl), C1-4 alkyl con-
taining a phenyl (such as benzyl), and C1-6 fluoroal-
kyl (such as trifluoromethyl, pentafluoroethyl, and 
heptafluoropropyl). 
The Z group must be electrophilic since it interacts 
with the active site serine OH group of the serine prote-
ase. The R group must be uncharged and hydrophobic. 
One or more of the carbons in the R group could be 
replaced by 0, S, NH and other such atomic groups as 
long as the R group maintains its hydrophobic charac-
ter. 
The following compounds are representative of the 
Class III Heterocyclic Compounds: 
2-trifluoromethy l-4H-3, 1-benzoxazine-4-one, 
2-pentafluoroethyl-4H-3,l-benzoxazine-4-one, 
2-heptafluoropropyl-4H-3,l-benzoxazine-4-one, 
2-methyl-4H-3, 1-benzoaxazine-4-one, 
2-propyl-4H-3, 1-benzoaxazine-4-one, 
2-benzyl-4H-3, 1-benxoaxazine-4-one, 
2-heptafluoropropyl-4-quinazolinone, 
2-propyl-4-quinazolinone, 
2-benzyl-4-quinazolinone, 
2-( C6HsCC}i)-4-chloroquinazoline, and 
2-propyl-4-chloroquinazoline. 
The Class III Heterocyclic Compounds are disclosed in 
Powers et al., U.S. Pat. No. 4,847,202, the disclosure of 
which is hereby incorporated by reference. 
Other substituted heterocyclic compounds have been 
prepared earlier for other purposes, such as 3-
chloroisocoumarin, Davies and Poole, J. Chem. Soc., 
pp. 1616-1629 (1928); 3-chloro and 3,4-
dichloroisocoumarin, Milevskaya, Belinskaya, and 
3-(3-aminopropoxy)isocoumarin, 
3-(3-aminopropoxy )-4-chloroisocoumarin, 
3-(2-isothiureidoethoxy)-4-chloroisocoumarin, 
3-(3-isothiureidopropoxy)-4-chloroisocoumarin, 
7-amino-3-(3-isothiureidopropoxy)-4-chloroisocouma-
50 Yagupol'skii, Zhur. Org. Khim. 9, pp. 2145-2149 (1973); 
3-methyl and 4-carboxy-3-methylisocoumarin, Tirod-
kar and Usgaonkar, Ind. J. Chem. 7, pp. 1114-1116 
(1969); 7-nitro and 7-aminoisocoumarin, Choksey and 
Usgaonkar, Ind. J. Chem. 14B, pp. 596-598 (1976). The 
rin, 
7-guanidino-3-methoxyisocoumarin, 
7-guanidino-3-methoxy-4-chloroisocoumarin, 
7-guanidino-3-ethoxyisocoumarin, 
7-guanidino-3-ethoxy-4-chloroisocoumarin, 
7-guanidino-3-(2-phenylethoxy)isocoumarin, 
7-guanidino-3-(2-phenylethoxy)-4-chloroisocoumarin. 
55 disclosures of all of the preceding articles are hereby 
incorporated by reference. These other substituted 
isocoumarins are also believed to exhibit Calpain inhibi-
tory activity when used in accordance with the present 
invention. 
60 Still other substituted isocoumarins which have been 
prepared recently for inhibition of serine proteases are 
3-chloroisocoumarin, Harper, Hemmi, and Powers, J. 
A. Chem. Soc. 105, pp. 6518-6520 (1983); 3,4-
Still another class of susbstituted heterocyclic com- 65 
pounds useful in the present invention is referred to 
herein as the "Class III Heterocyclic Compounds" and 
have the following structural formula: 
dichloroisocoumarin, Harper, Hemmi, and Powers, 
Biochemistry 24, pp. 1831-1841 (1985); 3-alkoxy-7-
amino-4-chloroisocoumarin, Harper and Powers, J. 
Am. Chem. Soc. 106, pp. 7618-7619 (1984), Harper and 
Powers, Biochemistry 24, 7200-7213 (1983); additional 
5,444,042 
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substituted isocoumarins with basic groups (aminoalk-
oxy, guanidino or isothiureidoalkoxy), Kam, Fujikawa 
and Powers, Biochemistry 27, pp. 2547-2557 (1988); 
7-substituted 3-alkoxy-4-chloroisocoumarins, Powers, 
Kam, Narasimhan, Oleksyszyn, Hernandez and Ueda, J. 5 
Cell Biochem. 39, pp. 33-46 (1989) and Powers, Olek-
syszyn, Narasimhan, Kam, Radhakrishnan and Meyer, 
Jr. Biochemistry 29, 3108-3118 (1990). The disclosures 
of all of the preceding articles are hereby incorporated 
14 
(acetylamino )-4-chloro-3-(3-bromopropoxy) isocourna-
rin, m.p. 170°-172° C.; mass spectrum: m/e=375 (M+ ). 
The acetylated isocoumarin (0.15 g, 0.4 mmole) was 
treated with thiourea (0.036 g, 0.47 mmole) to give 0.9 
g of the final product, (yield 50% ), m. p. 180° -181° C., 
mass spectrum m/e=370 (M+-Br). Anal. Cale. for 
C15H17N304ClBrS: C, 39.97; H, 3.80; N, 9.32; Cl 7.87. 
Found: C, 39.86; H 3.83; N, 9.29; Cl, 7.85. 
7-trifluoroacetylamino-4-chloro-3-(3-isothiureido-
propoxy) isocoumarin, 7-heptafluorobutyroylarnino-4-
chloro-3-(3-isothiureidopropoxy) isocoumarin, 7-suc-
cinylamino-4-chloro-3-(3-isothiureidopropoxy) 
isocoumarin, and 7-(o-phthalyl)amino-4-chloro-3-(3-iso-
thiureidopropoxy) isocoumarin can be prepared by the 
same procedure. 
EXAMPLE SHC3 
by reference. We believe that the foregoing com- 10 
pounds, which exhibit serine protease inhibitory activ-
ity, also exhibit Calpain inhibitory activity when used in 
accordance with the present invention. All of the fore-
going isocoumarin compounds, including the Class I 
and II Substituted Isocoumarins, the Class III Substi- 15 
tuted Heterocyclic Compounds and the other substi-
tuted heterocyclic compounds useful in the practice of 
the present invention shall be referred to collectively 
hereinafter as the "Substituted Heterocyclic Com- Preparation of 7-(benzylearbamoylamino)-4-chloro-3-
pounds." The term "Substituted Heterocyclic Com- 20 (3-isothiureidopropoxy) isocoumarin: 
pound" shall be used to refer to any particular species of 7-(benzylearbamoylamino)-4-chloro-3(3-bromo-
these compounds. propoxy) isocoumarin was prepared from the reaction 
The preparation of the various Substituted Heterocy- of benzyl isocyanate with 7-amino-4-chloro-3-(3-
clic Compounds is illustrated by Examples SHCl- bromopropoxy) isocoumarin as described above, m.p. 
SHC9. 25 188°-189° C., mass spectrum: m/e=359 (M+-benzyl). 
EXAMPLE SHCl 
The final product was obtained from the reaction of 
7-(benzylearbamoylamino )-4-chloro-3-(3-bromo-
Preparation of 7-(phenylcarbamoylamino)-4- propoxy) isocoumarin with thiourea as described above 
chloroisocoumarin was synthesized as previously de- (yield 74%), m.p. 165°-166° C.; mass spectrum (FAB+) 
scribed (Powers, et al., Biochemistry 29, 3108-3118 30 m/e=461 (M+-Br). Anal. Cale. for 
(1990)). This compound (0.32 g, 1 mmole) was mixed C21H22N404ClBrS:0.75 THF: C, 48.36; H, 4.70; N, 9.40; 
with phenyl isocyanate (0.12 g, 1 mmole) in 5 ml of Cl, 6.56. Found: C, 48.13; H, 4.87; N, 9.65; Cl, 6.15. 
THF and the reaction mixture was stirred at r.t. over-
night. The product 7-(phenylearbamoylamino)-4- EXAMPLE SHC4 
chloro-3-(2-bromoethoxy)isocoumarin precipitated out, 35 Preparation of 7-(phenylacetylamino )-4-chloro-3-(2-iso-
yield 40%, m.p. 215°-217° C., mass spectrum thiureidoethoxy) isocoumarin: 
m/e=437.9 (M+ )> Anal. Cale. for C1sH1~204ClBr: 7-Amino-4-chloro-3-(2-bromoethoxy) isocoumarin 
C, 49.40; H, 3.22; N, 6.40; Cl, 8.10. Found: C,49.48; H, (0.15 g, 0.47 mmole) was first mixed with phenylacetyl 
3.25; N,6.34; Cl, 8.12. The phenylcarbamoylamino com- chloride (0.09 g, 0.55 mmole) in 10 ml of THF, triethyl-
pound (0.1 g, 0.23 mmole) was heated with 0.02 g of 40 amine (0.05 g, 0.47 mmole) was then added and the 
thiourea (0.26 mmole) in 10 ml of THF at 70° C. over- reaction mixture was stirred at r.t. overnight. After 
night. The final product precipitated out, yield 0.04 g, Et3N.HC1 salt was removed by filtration, the product 
36%, m.p. 161°-163° C. (dee.), mass spectrum (FAB+) 7-(phenylacetylamino)-4-chloro-3-(2-bromoethoxy) 
m/e=433 (M-Br). Anal. Cale. for isocoumarin was crystallized from THF and Pet. ether 
C19H1sN404ClBrS:0.25 THF: C, 45.12; H, 3.86; N, 45 (yield, 73%), m.p. 165°-169° C.; mass spectrum; 
10.53; Cl, 6.67. Found: C, 44.83; H, 3.92; N, 10.12; Cl, m/e=436.7 (M+). The phenylacetyamino derivative 
6.41. . . . . (0.1 g) was heated with thiourea (0.02 g) to give the 7-(Et~ylcarbam?ylarmno)-4-chloro-3-(2-1sothn~re1do- product 0_05 g (yield, 40%), m.p. 115°-120° C.; mass ethhloxy)~so(2c~umh3:fln,.d h7-(t-b)~tylearb~oyl7arm(bno)-4-l spectrum (FAB+) m/e=432 (M+-Br). Anal. Cale. 
c oro-.)- -1sot iure1 oet oxy ISocoumann, - enzy - 50 c C H N 0 ClB s 0 - H O· c 45 99. H 3 83· N h. b 1 · ) A ~hl 3 (2 · h. ·d h ior 20 19 3 4 r .. ::i 2 . . , , . , i , t ~ocar amo.Y ammo~. oro- - -isot I~rei oet ox- 8.05· Cl 6.80. Found: C 46.09· H 4.17· N 8.02· Cl 6.79. 
y)1socoumann, 7-(ethylthiocarbamoylammo)-4-chloro- ' ' ' ' ' ' ' ' ' 
3-(2-isothiureidoethoxy)isocoumarin, 7-(4-fluoroben- EXAMPLE SHC5 
zyl) thiocarbamoylamino-4-chloro-3-(2-isothiureidoe-
thoxy) isocoumarin, and 7-(2,5-dimethylbenzyl) thi- 55 
ocarbamoylamino-4-chloro-3-(2-isothiureidoethoxy) 
isocoumarin can be prepared by the same procedure. 
EXAMPLE SHC2 
Preparation of 7-(acetylamino )-4-chloro-3-(3-isothi- 60 
ureidopropoxy) isocoumarin: 
7-Amino-3(3-bromopropoxy)-4-chloroisocoumarin 
was synthesized as previously described (Kam, et al., 
1988). This compound (0.33 g, 1 mmole) was heated 
with 0.15 g of acetic anhydride (1.5 mmole) in 20 ml of 65 
dry THF. After a few minutes, a yellow solid precipi-
tated out. After 3 hrs, the solution was concentrated to 
5 ml, and the solid was filtered to give 0.37 g of 7-
Preparation of 7-(R-a-methylbenzylearbamoylamino)-
4-chloro-3-(2-isothiureidoethoxy) isocoumarin: 
7-(R-a-methylbenzylcarbamoylamino )-4-chloro-3-(2-
bromoethoxy) isocoumarin was synthesized in the same 
manner as described above, m.p. 183°-185° C.; mass 
spectrum m/e=464 (M+). This compound (0.1 g) re-
acted with thiourea (0.02 g) under the same condition 
described above to form the final product 7-(R-a-
methylbenzylearbamoylamino )-4-chloro-3-(2-isothi-
ureidoethoxy) isocoumarin (0.078 g), m.p. 143°-150° C.; 
mass spectrum (FAB+) m/e=461 (M+-Br). Anal. 
Cale. for C21H22N404ClBrS.0.5H20: C, 45.75; H, 4.35; 
N, 10.17; Cl, 6.44. Found: C, 44.95; H 4.31; N, 10.02; Cl, 
6.36. 
15 
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EXAMPLE SHC6 
Preparation of 7-(D-phenylalanylamino)-4-chloro-3(2-
isothiureidoethoxy) isocoumarin: 
Boc-D-Phe (0.33 g, 1.2 mmole) reacted with 1,3-dicy- 5 
clohexylcarbodiimide (0.13 g, 0.6 mmole) in 10 ml THF 
at 0° C. for 1 hour to form the symmetric anhydride, 
and then 7-amino-4-chloro-3(2-bromoethoxy) 
isocoumarin (0.2 g, 0.6 mmole) was added. The reaction 
was stirred at r.t. overnight and the precipitate 7-(Boc- 10 
D-Phe-amino)-4-chloro-3-(2-bromoethoxy) isocouma-
rin was formed (0.29 g, 71%). TLC one spot, m.p. 
180°-182° C.; mass spectrum m/3=566(M+). Anal. 
Cale. for C25H26N206C1Br: C, 53.07; H, 4.63; N, 4.95; 
Cl 6.27. Found: C, 53.25: H, 4.66; N, 4.87; Cl, 6.24. 15 
Boc-D-Phe compound (0.2 g, 0.35 mmole) was reacted 
with thiourea (0.027 g, 0.35 mmole) in the same manner 
to give 7-(Boc-D-phenylalanylamino )-4-chloro-3-(2-iso-
thiureidoethoxy) isocoumarin (0.14 g), yield 62%, mass 
spectrum (FAB+) m/e=561 (M+-Br). This com- 20 
pound (0.1 g) was dissolved in 3 ml of THF at 0° C. and 
then the solvent was evaporated to dryness. The final 
product precipitated out after addition of ether, one 
spot on TLC (CH3CN:H20:Ac0H=8:1:1); mass spec-
trum (FAB+) m/e=462 (M+-Br-CF3COO). 25 
7-Boc-alanylamino-4-chloro-3-(2-isothiureidoethoxy) 
isocoumarin, 7-benzoylamino-Ala-4-chloro-3(2-isothi-
ureidoethoxy) isocoumarin, 7-benzoylamino-Phe-4-
chloro-3-(2-isothiureidoethoxy) isocoumarin and 7-
Boc-valylamino-4-chloro-3-(2-isothiureidoethoxy) 30 
isocoumarin can be prepared by the same procedure. 
EXAMPLE SHC7 
Preparation of 7-(Boc-alanylalanylamino)-4-chloro-3-
(2-isothiureidoethoxy) isocoumarin: 35 
7-(Boc-alanylalanylamino )-4-chloro-3-(2-bromoe-
thoxy) isocoumarin was synthesized in the same man-
ner, m.p. 147°-151° C.; mass spectrum m/e=561 (M+). 
Anal. Cale: C, 47.12: H, 4.85. Found: C, 47.18; H, 4.87. 
This compound (0.2 g) was reacted with thiourea (0.03 40 
g) by the same procedure to form 7-(Boc-
alanylalanylamino )-4-chloro-3-(2-isothiureidoethoxy) 
isocoumarin (0.04 g), mass spectrum m/e=556 
(M+-Br). 
7-(Alanylalanylamino )-4-chloro-3(2-isothiureidoe- 45 
thoxy) isocoumarin was prepared by deblocking of 
Boc-Ala-Ala-NH-CiTEtOIC with trifluoroacetic 
acid, mass spectrum (FAB+) m/e=456 (M+-
Br-CF3COO). 
16 
thoxy) isocoumarin, yield 64%, m.p. 157°-158° C.; mass 
spectrum m/e 361 (M+-(COOH)PhNH+-Br). 
7-(3-Fluorobenzoyl)amino-4-chloro-3-(2-isothi-
ureidoethoxy) isocoumarin, 7-(3-nitrobenzoyl) amino-4-
chloro-3-(2-isothiureidoethoxy) isocoumarin, 7-
diphenylacetylamino-4-chloro-3-(2-isothiureidoethoxy) 
isocoumarin, 7-diphenylpropionylamino-4-chloro-3-(2-
isothiureidoethoxy) isocoumarin, 7-(p-toluenesulfonyl) 
amino-4-chloro-3-(2-isothiureidoethoxy) isocoumarin, 
and 7-(a.-toluenesulfonyl) amino-4-chloro-3-(2-isothi-
ureidoethoxy) isocoumarin can be prepared from the 
reaction of corresponding 7-substituted-4-chloro-3-(2-
bromoethoxy) isocoumarin with thiourea as described 
above. 7-substituted-4-chloro-3-(2bromoethoxy) 
isocoumarin can be synthesized by reacting 7-amino-4-
chloro-3-(2bromoethoxy) isocoumarin with appropriate 
acid chloride or sulfonyl chloride in the presence of 
Et3N. 
7-Ethoxycarbonylamino-4-chloro-3-(2-isothiureidoe-
thoxy) isocoumarin, 7-benzyloxycarbonylamino-4-
chloro-3-(2-isothiureidoethoxy) isocoumarin, and 7-
phenoxycarbonylamino-4-chloro-3-(2-isothiureidoe-
thoxy) isocoumarin can be prepared from the reaction 
of 7-substituted-4-chloro-3-(2-bromoethoxy) isocouma-
rin with thiourea. 7-Ethoxycarbonylamino-4-chloro-3-
(2-bromoethoxy) isocoumarin, 7-benzyloxycar-
bonylamino-4-chloro-3-(2-bromoethoxy) isocoumarin 
and 7-phenoxycarbonylamino-4-chloro-3-(2-bromoe-
thoxy) isocoumarin can be synthesized by reacting 7-
amino-4-chloro-3-(2-bromoethoxy) isocoumarin with 
the corresponding chloroformate. 
C. PEPTIDE KETO-COMPOUNDS 
Peptide a.-ketoesters, peptide a.-ketoacids, and pep-
tide a-ketoamides are transition state analog inhibitors 
for serine proteases and cysteine proteases. While these 
subclasses of compounds are chemically distinguish-
able, for simplicity, all of these compounds will be re-
ferred to collectively herein as the "Peptide Keto-Com-
pounds". 
The interactions of peptides with serine and cysteine 
proteases are designated herein using the nomenclature 
of Schechter, I., and Berger, A., 1967, Biochem. Bio-
phys. Res. Commun. 27:157-162 (incorporated herein 
by reference). The individual amino acid residues of a 
substrate or inhibitor are designated Pl, P2, etc. and the 
corresponding subsites of the enzyme are designated SI, 
S2, etc. The scissile bond of the substrate is Pl-Pl'. The 
primary recognition site of serine proteases is S 1. The 
EXAMPLE SHC8 
50 most important recognition subsites of cysteine pro-
teases are S 1 and S2. 
Preparation of 7-(phenylthiocarbamoylamino)-4-
chloro-3-(2-isothiureidoethoxy) isocoumarin: 
7-(Phenylthiocarbamoylamino )-4-chloro-3-(2-bromo-
ethoxy) isocoumarin was prepared from the reaction of 55 
phenyl isothiocyanate with 7-amino-4-chloro-3-(2-
bromoethoxy) isocoumarin, yield 59%, m.p. 157°-158° 
C.; mass spectrum m/e=361 (M+-PhNH+l). Anal. 
Cale.: C, 48.36; H, 3.39. Found: C, 48.26; H, 3.40. The 
bromoethoxy compound was then reacted with thio- 60 
urea by the same procedure to give the final product, 
yield 32%; mass spectrum (FAB+) m/e 449 (M+-Br). 
EXAMPLE SHC9 
Preparation of 7-(m-carboxyphenylthiocar- 65 
bamoylamino )-4-chloro-3-(2-bromoethoxy) isocouma-
rin was prepared from the reaction of m-carboxyphenyl 
isothiocyanate with 7-amino-4-chloro-3-(2-bromoe-
Amino acid residues and blocking groups are desig-
nated using standard abbreviations [see J. Biol. Chem. 
260, 14-42 (1985) for nomenclature rules; incorporated 
herein by reference]. An amino acid residue (AA) in a 
peptide or inhibitor structure refers to the part structure 
-NH-CHRl-CO-, where RI is the side chain of 
the amino acid AA. A peptide a.-ketoester residue 
would be designated -AA-CO-OR which represents 
the part structure -NH-CHRl-CO-CO-OR. 
Thus, the ethyl ketoester derived from benzoyl alanine 
would be designated Bz-Ala-CO-OEt which repre-
sents C6H5CO-NH-CHMe-CO-CO-OEt. Like-
wise, peptide ketoacid residues residues would be desig-
nated -AA-CO-OH. Further, peptide ketoamide resi-
dues are designated -AA-CO-NH-R. Thus, the ethyl 
keto amide derived from Z-Leu-Phe-OH would be des-
ignated Z-Leu-Phe-CO-NH-Et which represents 
5,444,042 
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C6lfsCH20CO-NH-CH(CH2CHMe2)-CO-N-
H-CH(CH2Ph)-CO-CO-NH-Et. 
Peptide a-ketoesters containing amino acid residues 
with hydrophobic side chain at the Pl site have also 
been found to be excellent inhibitors of several cysteine 5 
proteases including papain, cathepsin B and calpain. 
Calpains can be inhibited by peptide inhibitors having 
several different active groups. Structure-activity rela-
tionships with the commercially available in vitro inhib-
itors of Calpain, such as peptide aldehydes, have re- 10 
vealed that Calpains strongly prefer Leu or Val in the 
P2 position. These enzymes are inhibited by inhibitors 
having a wide variety of amino acids in the Pl position, 
but are generally more effectively inhibited by inhibi-
tors having amino acids with nonpolar or hydrophobic 15 
side chains in the Pl position. Thus, we have discovered 
that another particular class of compounds exhibiting 
Calpain inhibitory activity, when used in accordance 
with the present invention, are the Peptide Keto-Com-
pounds. These are compounds of the general structure: 20 
0 
18 
Q is 0 or NH, 
R represents H, Cl-6 alkyl, Cl-6 fluoroalkyl, Cl-6 
chloroalkyl, benzyl, Cl-6 alkyl substituted with 
phenyl, Cl-6 alkyl with an attached phenyl group 
substituted with K. 
Thus, the Peptide Keto-Compounds can be divided 
into the Peptide Ketoesters, Peptide Ketoacids and 
Peptide Ketoamides. Each of the compounds can also 
be classified based on the number of amino acids con-
tained within the compound, such as an amino acid 
peptide, dipeptide, tripeptide, tetrapeptide, pentapep-
tide and so on. 
We have found certain subclasses of Peptide a-Keto-
ester compounds to be particularly useful as Calpain 
Inhibitors when used in accordance with the present 
invention. These subclasses are referred to herein as the 
Dipeptide a-Ketoesters (Subclass A), the Dipeptide 
a-Ketoesters (Subclass B), the Tripeptide a-Ketoesters 
(Subclass A), the Tripeptide a-Ketoesters (Subclass B), 
the Tetrapeptide a-Ketoesters and the Amino Acid 
Peptide a-Ketoesters. All of these subclasses are consid-
ered to be to be within the class of Peptide Keto-Com-
pounds. 
II 
M-(aa)n-C-Q-R 
The Dipeptide a-Ketoesters (Subclass A) are com-
25 pounds of the formula: 
or a pharmaceutically acceptable salt, wherein: 
M represents NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X-NH-CS-, 
X-NH-S02-, X-CO-, X-CS-, 30 
X-S02-, X-0-CO-, or X-0-CS-, H, 
acetyl, carbobenzoxy, succinyl, methyloxysucci-
nyl, butyloxycarbonyl; 
Xis selected from the group consisting ofCl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 35 
Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu- 4D 
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 45 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; 50 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
C2-12 dialkylamino, Cl-6 acyl, and Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 55 
aa represents a blocked or unblocked amino acid of 
the Lor D configuration, preferably selected from 
the group consisting of: alanine, valine, leucine, 
isoleucine, proline, methionine, methionine sulfox-
ide, phenylalanine, tryptophan, glycine, serine, 60 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, phenylglycine, beta-alanine, norleucine 
(nle), norvaline (nva), alpha-aminobutyric acid 
(abu), epsilon-aminocaproic acid, citrulline, hy- 65 
droxyproline, homoarginine, ornithine or sarco-
sine; 
n is a number from 1 to 20; 
M1-AA2-AA1-CO-O-R1 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting ofC1.JOalkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1-10 alkyl with an attached phenyl 
group, Ci.JO alkyl with two attached phenyl 
groups, Ci.JO alkyl with an attached phenyl group 
substituted with K, and CJ.JO alkyl with two at-
tached phenyl groups substituted with K, C1.10 
alkyl with an attached phenoxy group, and CJ.JO 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1-10 alkoxy, Ci.JO 
alkylamine, C2.12 dialkylamine, Ci.JO alkyl-
0-CO-, Ci.JO alkyl-0-CO-NH-, and Ci.JO 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Ci.JO alkyl, C1-JO perfluoroalkyl, Ci.JO alkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2.12 
dialkylamino, Ci.JO acyl, and Ci.JO alkoxy-CO-, 
and C1-10 alkyl-S-; 
AA1 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glu-
tamic acid, lysine, arginine, histidine, phenylgly-
cine, beta-alanine, norleucine, norvaline, alpha-
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aminobutyric acid, epsilon-aminocaproic acid, cit-
rulline, hydroxyproline, ornithine, homoarginine, 
sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse- 5 
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 10 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
AAi is a side chain blocked or unblocked amino acid 15 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of leucine, isoleucine, praline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 20 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine, norvaline, alpha-aminobutyric 
acid, epsilon-aminocaproic acid, citrulline, hydrox-
yproline, ornithine, homoarginine, sarcosine, indo- 25 
line 2-carboxylic acid, 2-azetidinecarboxylic acid, 
pipecolinic acid (2-piperidine carboxylic acid), 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-CH(CH2. 
CHEt2)-COOH, alpha-aminoheptanoic acid, 30 NH2-CH(CH2- l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri- 35 
fluoroleucine, and hexafluoroleucine; 
Riis selected from the group consisting of H, C1.20 
alkyl, C1.20 alkyl with a phenyl group attached to 
the C1.20 alkyl, and C1.20 alkyl with an attached 
phenyl group substituted with K. 40 
The Dipeptide a-Ketoesters (Subclass B) are com-
pounds of the structure: 
alkylamine, C2.12 dialkylamine, C1.10 alkyl-
0-CO-, C1.10 alkyl-0-CO-NH-, and C1.10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1.10alkyl, C1.10perfluoroalkyl, C1.1oalkoxy, N02, 
CN, OH, C02H, amino, C1.10 alkylamino, C2.12 
dialkylamino, C1-C10acyl, and C1.10alkoxy-CO-, 
and C1.10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEti)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
Ri represents C1.s branched and unbranched alkyl, 
C1-s branched and unbranched cyclized alkyl, or 
C1-s branched and unbranched fluoroalkyl; 
R is selected from the group consisting of H, C1.20 
alkyl, C1-20 alkyl with a phenyl group attached to 
the C1.20 alkyl, and C1.20 alkyl with an attached 
phenyl group substituted with K. 
The Tripeptide a-Ketoesters (Subclass A) are com-
pounds of the structure: 
MJ·AA-AA-AA-C0-0-R 
M1-AA-NH-CHR2-CO-CO-O-R 
45 or a pharmaceutically acceptable salt, wherein 
or a pharmaceutically acceptable salt, wherein 
Mi represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-SO-, X-CO-, X-CS-, X-S02-, 50 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting ofC1.10alkyl, 
C1.10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 55 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1.10 alkyl with an attached phenyl 
group, C1.10 alkyl with two attached phenyl 60 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, and C1.10 alkyl with two at-
tached phenyl groups substituted with K, C1.10 
alkyl with an attached phenoxy group, and C1.10 
alkyl with an attached phenoxy group substituted 65 
with K on the phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C10 alkoxy, C1.10 
M3 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
T-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1.10 alkyl, 
C1-10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1-10 alkyl with an attached phenyl 
group, C1.10 alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K, C1.10 
alkyl with an attached phenoxy group, and C1.10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
Tis selected from the group consisting of C1.10 alkyl, 
C1.10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
5,444,042 
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9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C2-io alkyl with an attached phenyl 5 
group, C1.10 alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, and C1.10 alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 10 
COOH, OH, CN, N02, NH2, C1.JO alkoxy, Ci.JO 
alkylamine, C2.12 dialkylamine, Ci.JO alkyl-
0-CO-, Ci.JO alkyl-0-CO-NH-, and Ci.JO 
alkyl-S-; 
K is selected from the group consisting of halogen, 15 
C1.10alkyl, Ci.JOperfluoroalkyl, C1.J0alkoxy, N02, 
CN, OH, C02H, amino, Ci.10 alkylamino, C2.12 
dialkylamino, Ci-Cio acyl, and C1-10 alkoxy-CO-, 
and C1-10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 20 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 25 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar- 30 ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha- 35 
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri- 40 
fluoroleucine, and hexafluoroleucine; 
R is selected from the group consisting of H, C2.20 
alkyl, C1-20 alkyl with a phenyl group attached to 
the C1.10 alkyl, and C1-20 alkyl with an attached 
phenyl group substituted with K. 45 
The Tripeptide a-Ketoesters (Subclass B) are com-
pounds of the structure: 
M3-AA-.o.A-NH-CHR2-CO-CO-O-R 
or a pharmaceutically acceptable salt, wherein 
50 
M3 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 55 
T-0-CO-, or X-0-CS-; 
Xis selected from the group consisting ofC1.JOalkyl, 
CJ-10 fluoroalkyl, C1-10 alkyl substituted with J, 
CJ.JO fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 60 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ci.JO alkyl with an attached phenyl 
group, Ci.JO alkyl with two attached phenyl 65 
groups, Ci.JO alkyl with an attached phenyl group 
substituted with K, and Ci.JO alkyl with two at-
tached phenyl groups substituted with K, Ci.JO 
22 
alkyl with an attached phenoxy group, and Ci.JO 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
Tis selected from the group consisting of CJ.JO alkyl, 
Ci.JO fluoroalkyl, Ci.JO alkyl substituted with J, 
Ci.JO fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C2.10 alkyl with an attached phenyl 
group, Ci-10 alkyl with two attached phenyl 
groups, CJ.JO alkyl with an attached phenyl group 
substituted with K, and Ci.JO alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1.10 alkoxy, Ci.JO 
alkylamine, Ci.JO dialkylamine, Ci.JO alkyl-
0-CO-, Ci.JO alkyl-0-CO-NH-, and CJ.JO 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Ci.JO alkyl, C1.10 perfluoroalkyl, Ci.JO alkoxy, N02, 
CN, OH, C02H, amino, CJ.JO alkylamino, C2.12 
dialkylamino, C1-CJO acyl, and Ci.JO alkoxy-CO-, 
and Ci.JO alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-arninobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, omithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, NH2-
CH(CH2-cyclopropyl)-COOH, trifluoroleucine, 
and hexafluoroleucine; 
R1 represents C1-s branched and unbranched alkyl, 
C1.s branched and unbranched cyclized alkyl, or 
C1-s branched and unbranched fluoroalkyl; 
R is selected from the group consisting of H, C1-20 
alkyl, C1-20 alkyl with a phenyl group attached to 
the C1.20 alkyl, and C1.20 alkyl with an attached 
phenyl group substituted with K. 
The Tetrapeptide a-Ketoesters are compounds of the 
structure: 
Mi-AA-AA-AA-AA-C0-0-R 
or a pharmaceutically acceptable salt, wherein 
M3 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
T-0-CO-, or X-0-CS-; 
23 
5,444,042 
24 
Xis selected from the group consisting of Ct-to alkyl, 
C1-10 fluoroalkyl, Ct-JO alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 5 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ct.JO alkyl with an attached phenyl 
group, Ct-to alkyl with two attached phenyl 
groups, Ct.JO alkyl with an attached phenyl group IO 
substituted with K, and Ct.JO alkyl with two at-
tached phenyl groups substituted with K, Ci.JO 
alkyl with an attached phenoxy group, and Ci.JO 
alkyl with an attached phenoxy group substituted 
with Kon the phenoxy group; 15 
Tis selected from the group consisting of CJ.JO alkyl, 
Ct-to fluoroalkyl, Ct-JO alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 20 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C2-JO alkyl with an attached phenyl 
group, Ci-to alkyl with two attached phenyl 
groups, Ct-to alkyl with an attached phenyl group 25 
substituted with K, and Ci-to alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1.10 alkoxy, C1.10 
alkylamine, C2.12 dialkylamine, Ct-to alkyl- 30 
0-CO-, C1.10 alkyl-0-CO-NH-, and C1.10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Ct.10alkyl, C1.10perfluoroalkyl, Ct-1oalkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2.12 35 
dialkylamino, C1-C10acyl, and Ct-1oalkoxy-CO-, 
and C1.10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 40 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe- 45 
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi- 50 
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 55 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 60 
AA4 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of leucine, isoleucine, methionine, me-
thionine sulfoxide, phenylalanine, tryptophan, gly- 65 
cine, serine, threonine, cysteine, tyrosine, aspara-
gine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, beta-alanine, 
norleucine, norvaline, alpha-aminobutyric acid, 
epsilon-aminocaproic acid, citrulline, hydroxypro-
line, ornithine, homoarginine, sarcosine, indoline 
2-carboxylic acid, 2-azetidinecarboxylic acid, 
pipecolinic acid (2-piperidine carboxylic acid), 
0-methylserine, 0-ethylserine, S-methylcysteine, 
S-ethylcysteine, S-benzylcysteine, NH2-CH(CH2. 
CHEti)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
R is selected from the group consisting of H, Ct-20 
alkyl, C1-20 alkyl with a phenyl group attached to 
the C1-20 alkyl, and Ct-20 alkyl with an attached 
phenyl group substituted with K. 
The Amino Add Peptide a-Ketoesters are com-
pounds of the structure: 
M1-AA-CO-O-R 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, Y-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1-10 alkyl, 
Ct-to fluoroalkyl, Ci-to alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ct-JO alkyl with an attached phenyl 
group, Ct-JO alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, and Ct-to alkyl with two at-
tached phenyl groups substituted with K, Ct-to 
alkyl with an attached phenoxy group, and C1.10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
Y is selected from the group consisting ofC6-toalkyl, 
Ct-to fluoroalkyl, CJ.JO alkyl substituted with J, 
Ct.JO fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl substituted with K, phenyl 
disubstituted with K, phenyl trisubstituted with K, 
naphthyl, naphthyl substituted with K, naphthyl 
disubstituted with K, naphthyl trisubstituted with 
K, Ct-to alkyl with an attached phenyl group, Ct-to 
alkyl with two attached phenyl groups, C1.10 alkyl 
with an attached phenyl group substituted with K, 
and C1.10 alkyl .with two attached phenyl groups 
substituted with K; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1.10 alkoxy, C1-to 
alkylamine, C2-t2 dialkylamine, Ct-to alkyl-
0-CO-, C1-to alkyl-0-CO-NH-, and Ct-to 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1.10alkyl, C1-10perfluoroalkyl, C1-10alkoxy, N02, 
CN, OH, C02H, amino, C1.10 alkylamino, C2-12 
dialkylamino, C1-C10 acyl, and C1.10 alkoxy-CO-, 
and C1-to alkyl-S-; 
25 
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AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl- 5 
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 10 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl- 15 
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 20 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
R is selected from the group consisting of H, C1-20 
alkyl, C1-20 alkyl with a phenyl group attached to 25 
the C1-20 alkyl, and C1-20 alkyl with an attached 
phenyl group substituted with K. 
The following Peptide Ketoester compounds are 
representative of the Peptide Keto-Compounds found 
to be useful as Calpain inhibitors within the context of 30 
the present invention: 
Bz-DL-Ala-COOEt 
Bz-DL-Ala-COOBzl 
Bz-DL-Ala-COOnBu 35 
Bz-DL-Phe-COOEt 
Bz-DL-Ala-COOCH2-C6I4-CF3 (para) 
Bz-DL-Arg-COOEt 
Bz-DL-Lys-COOEt 
Z-Ala-DL-Ala-COOEt 40 
Z-Ala-DL-Ala-COOBzl 
Z-Ala-DL-Ala-COOnBu 
MeO-Suc-Ala-DL-Ala-COOMe 
Z-Leu-Nva-COOEt 
Z-Leu-Nle-COOEt 45 
Z-Leu-Phe-COOEt 
Z-Leu-Abu-COOEt 
Z-Leu-Met-COOEt 
Z-Phe-DL-Phe-COOEt 
H-Gly-DL-Lys-COOEt 50 
H-Ala-DL-Lys-COOEt 
H-Pro-DL-Lys-COOEt 
H-Phe-DL-Lys-COOEt 
Z-Ala-Ala-DL-Ala-COOEt 
Z-Ala-Pro-DL-Ala-COOEt 55 
Z-Ala-Ala-DL-Abu-COOEt 
Z-Ala-Ala-DL-Abu-COOBzl 
Z-Ala-Ala-DL-Abu-COOCH2-C6I4-CF3 (para) 
MeO-Suc-Val-Pro-DL-Phe-COOMe 
H-Leu-Ala-DL-Lys-COOEt 60 
Z-Ala-Ala-Ala-DL-Ala-COOEt 
MeO-Suc-Ala-Ala-Pro-DL-Abu-COOMe. 
Z-Leu-Phe-COOEt 
PhCO-Abu-COOEt 
(CH3)zCH(CH2)zCO-Abu-COOEt 65 
CH3CH2CH)zCHCO-Abu-COOEt 
Ph( CH2)6CO-Abu-COOEt 
Z-Leu-4-Cl-Phe-COOEt 
26 
Z-Leu-Leu-Abu-COOEt 
Z-Leu-Leu-Phe-COOEt 
2-NapS02-Leu-Abu-COOEt 
2-NapS02-Leu-Leu-Abu-COOEt 
Z-Leu-NLeu-C02Et 
Z-Leu-Phe-C02Bu 
Z-Leu-Abu-C02Bu 
Z-Leu-Phe-C02Bzl 
Z-Leu-Abu-C02Bzl. 
We have found certain subclasses of Peptide Ketoa-
cid Compounds to be particularly useful when used in 
accordance with the present invention. These are sub-
classes are the Dipeptide a-Ketoacids (Subclass A), the 
Dipeptide a~Ketoacids (Subclass B), the Tripeptide 
a-Ketoacids, the Tetrapeptide a-Ketoacids and the 
Amino Acid peptide a-Ketoacids. All of these are con-
sidered to be within the class of Peptide Keto-Com-
pounds. 
The Dipeptide a-Ketoacids (Subclass A) are com-
pounds of the structure: 
Mi-AA-NH-CHR2-CO-CO-OH 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-CS-; 
Xis selected from the group consisting of C1-10 alkyl, 
C1.10 fluoroalkyl, C1-10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1-10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, C1-10 alkyl with two attached 
phenyl groups substituted with K, C1-10 alkyl with 
an attached phenoxy group, and C1-10alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1-10 alkoxy, C1-10 
alkylamine, C2-12 dialkylamine, C1-10 alkyl-
0-CO-, C1-10 alkyl-0-CO-NH-, and C1-10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1-10alkyl, C1-10perfluoroalkyl, C1-10alkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2-12 
dialkylamino, C1-10 acyl, and C1-10 alkoxy-CO-, 
and C1-10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
27 
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dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 5 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; IO 
R1 represents C1-s branched and unbranched alkyl, 
C1-s branched and unbranched cyclized alkyl, or 
C1.s branched and unbranched fluoroalkyl. 
The Dipeptide a-Ketoacids (Subclass B) are com-
pounds of the structure: 15 
M1-AA2-AA1-CO-OH 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 20 NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1.10 alkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 25 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu- 30 
ted with K, C1.10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K, C1-10 35 
alkyl with an attached phenoxy group, and C1-10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1-10 alkoxy, C1-10 40 
alkylamine, C2.12 dialkylamine, C1.10 alkyl-
0-CO-, C1.10 alkyl-0-CO-NH-, and C1-10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1.10alkyl, C1.10perfluoroalkyl, C1.10alkoxy, N02, 45 
CN, OH, C02H, amino, C1-10 alkylamino, C2.12 
dialkylamino, C1-C1oacyl, and C1.10alkoxy-CO-, 
and C1-10 alkyl-S-; 
AA1 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 50 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glu- 55 
tamic acid, lysine, arginine, histidine, phenylgly-
cine, beta-alanine, norleucine, norvaline, alpha-
aminobutyric acid, epsilon-aminocaproic acid, cit-
rulline, hydroxyproline, ornithine, homoarginine, 
sarcosine, indoline 2-carboxylic acid, 2- 60 
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)- 65 
COOR, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
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NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
AA2 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEtz)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine. 
The Tripeptide a-Ketoacids are compounds of the 
structure: 
M1-AA-AA-AA-CO-OH 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1-10 alkyl, 
C1-10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1-10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K, C1-10 
alkyl with an attached phenoxy group, and C1-10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1-10 alkoxy, C1-10 
alkylamine, C2-12 dialkylamine, C1-10 alkyl-
0-CO-, C1.10 alkyl-0-CO-NH-, and C1-10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1-10 alkyl, C1-10 perfluoroalkyl, C1-10 alkoxy, Nz, 
CN, OH, C02H, amino, C1.10 alkylamino, C2-12 
dialkylamino, C1-10 acyl, and C1-10 alkoxy-CO-, 
and C1.10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
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alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 5 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl- 10 
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 15 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine. 
The Tetrapeptide a-Ketoacids are compounds of the 
structure: 20 
M1-AA-AA-AA-AA-CO-OH 
or a pharmaceutically acceptable salt, wherein 
Mi represents H, NH2-CO-, NH2-CS-, 25 NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, Yi-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1-10 alkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 30 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu- 35 
ted with K, C1-10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K, C1-10 40 
alkyl with an attached phenoxy group, and C1-10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
Y l is selected from the group consisting of C2-10alkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 45 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu- 50 
ted with K, C1-10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K; 55 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1-10 alkoxy, C1-10 
alkylamine, C2-12 dialkylamine, C1-10 alkyl-
0-CO-, C1-10 alkyl-0-CO-NH-, and C1-10 
alkyl-S-; 60 
K is selected from the group consisting of halogen, 
C1-10alkyl, C1-10perfluoroalkyl, C1-10alkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2-12 
dialkylamino, C1-C10acyl, and C1-10alkoxy-CO-, 
and C1-10 alkyl-S-; 65 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
cons1stmg of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
add, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
alpha-aminobutyric acid, epsilon-aminocaproic 
acid, citrulline, hydroxyproline, ornithine, homoar-
ginine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine. 
The Amino Acid Peptide a-Ketoacids are com-
pounds of the structure: 
M1-AA-CO-OH 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, Y2-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1-10 alkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1-10 alkyl with an attached phenyl 
group, C1-10 alkyl with two attached phenyl 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, and C1-10 alkyl with two at-
tached phenyl groups substituted with K, C1-10 
alkyl with an attached phenoxy group, and C1-10 
alkyl with an attached phenoxy group substituted 
with K on the phenoxy group; 
Y 2is selected from the group consisting of C1-10alkyl, 
C1-10 fluoroalkyl, C1-10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl substituted with K, phenyl 
disubstituted with K, phenyl trisubstituted with K, 
naphthyl, naphthyl substituted with K, naphthyl 
disubstituted with K, naphthyl trisubstituted with 
K, C1-10alkyl with an attached phenyl group, C1-10 
alkyl with two attached phenyl groups, C1-10 alkyl 
with an attached phenyl group substituted with K, 
and C1-10 alkyl with two attached phenyl groups 
substituted with K; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1-10 alkoxy, C1-10 
alkylamine, C2-12 dialkylamine, C1-10 alkyl-
0-CO-, C1-10 alkyl-0-CO-NH-, and C1-10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1-10 alkyl, C1-10 perfluoroalkyl, C1-10 alkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2-12 
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dialkylamino, CJ.to acyl, and COJ-10 alkoxy-CO-, 
and CJ.JO alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 5 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe- 10 
nylglycine, beta-alanine, norleucine, norleucine, 
norvaline, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, or-
nithine, homoarginine, sarcosine, indoline 2-car-
boxylic acid, 2-azetidinecarboxylic acid, pipeco- 15 
linic acid (2-piperidine carboxylic acid), 0-
methylserine, 0-ethylserine, S-methylcysteine, S-
ethylcysteine, S-benzylcysteine, NH2-CH(CH2. 
CHEt2)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2- l-napthyl)-COOH, 
NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl-COOH, 
20 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, 
fluoroleucine, and hexafluoroleucine. 
tri- 25 
The following Peptide Ketoacid compounds are rep-
resentative of the Peptide Keto-Compounds found to be 
useful as Calpain inhibitors within the context of the 
present invention: 
Bz-DL-Lys-COOH 
Bz-DL-Ala-COOH 
Z-Leu-Phe-COOH 
Z-Leu-Abu-COOH. 
30 
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The peptide a-ketoamides are transition state ana-
logue inhibitors for cysteine proteases, such as Calpain. 
We have found that Peptide a-ketoamides containing 
amino acid residues with hydrophobic side chains at the 
PJ site are excellent inhibitors of several cysteine pro- 40 
teases including calpain I and calpain IL 
We have found five subclasses of the peptide ketoa-
mides to be particularly effective in inhibiting Calpain. 
These subclasses are referred to herein as Dipeptide 
a-Ketoamides (Subclass A), Dipeptide a-Ketoamides 45 
(Subclass B), Tripeptide a-Ketoamides, Tetrapeptide 
a-Ketoamides and Amino Acid a-Ketoamides. All of 
these subclasses are considered herein to be within the 
class of Peptide Keto-Compounds. 
The Dipeptide a-Ketoamides (Subclass A) have the 50 
following structural formula: 
M1-AA-NH-CHR2-CO-CO-NR3}4 
or a pharmaceutically acceptable salt, wherein 55 
MJ represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CS-; 60 
Xis selected from the group consisting of CJ-to alkyl, 
CJ-10 fluoroalkyl, CJ-10 alkyl substituted with J, 
CJ-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 65 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, CJ.to alkyl with an attached phenyl 
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group, CJ-to alkyl with two attached phenyl 
groups, CJ-10 alkyl with an attached phenyl group 
substituted with K, CJ-10 alkyl with two attached 
phenyl groups substituted with K, CJ.to alkyl with 
an attached phenoxy group, and CJ.to alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, CJ.JO alkoxy, CJ-to 
alkylamine, C2.J2 dialkylamine, CJ-10 alkyl-
0-CO-, CJ.JO alkyl-0-CO-NH-, and CJ.JO 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1.Joalkyl, CJ.10perfluoroalkyl, CJ-toalkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2-J2 
dialkylamino, C1-C10acyl, CJ-toalkoxy-CO-, and 
C1-10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
a-aminobutyric acid, epsilon-aminocaproic acid, 
citrulline, hydroxyproline, ornithine, homoargi-
nine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
Ri is selected from the group consisting of C1-s 
branched and unbranched-alkyl, C1-s branched and 
unbranched cyclized alkyl, and CJ-8 branched and 
unbranched fluoroalkyl; 
R3 and R4 are selected independently from the group 
consisting of H, C1.20 alkyl, C1.20 cyclized alkyl, 
C1.20 alkyl with a phenyl group attached to the 
CJ-20 alkyl, C1.20 cyclized alkyl with an attached 
phenyl group, CJ-20 alkyl with an attached phenyl 
group substituted with K, CJ-20 alkyl with an at-
tached phenyl group disubstituted with K, CJ-20 
alkyl with an attached phenyl group trisubstituted 
with K, C1-20 cyclized alkyl with an attached 
phenyl group substituted with K, CJ-to alkyl with a 
morpholine [-:-N(CH2CH2)0] ring attached 
through nitrogen to the alkyl, CJ-10 alkyl with a 
piperidine ring attached through nitrogen to the 
alkyl, CJ-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, CJ-20 alkyl with an 
OH group attached to the alkyl, -CH2C-
H20CH2CH20H, CJ.to with an attached 4-pyridyl 
group, C1.10 with an attached 3-pyridyl group, 
CJ.to with an attached 2-pyridyl group, CJ.to with 
an attached cyclohexyl group, -NH-CH2CH2-
(4-hydroxyphenyl), and -NH-CH2CH2-(3-indo-
lyl). 
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The Dipeptide a-Ketoamides (Subclass B) have the 
following structural formula: 
Mi-AA2-AA1-CO-NR3R,i 
or a pharmaceutically acceptable salt, wherein 
5 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 10 X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of Ci-10 alkyl, 
C1.10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 15 phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ci.JO alkyl with an attached phenyl 
group, Ci-io alkyl with two attached phenyl 
groups, Ci.JO alkyl with an attached phenyl group 20 
substituted with K, Ci.JO alkyl with two attached 
phenyl groups substituted with K, C1.10 alkyl with 
an attached phenoxy group, and C1-10alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 25 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1.10 alkoxy, Ci.JO 
alkylamine, C2.12 dialkylamine, C1.10 alkyl-
0-CO-, C1-10 alkyl-0-CO-NH-, and Ci.JO 
alkyl-S-; 30 
K is selected from the group consisting of halogen, 
Ci.JO alkyl, C1.10 perfluoroalkyl, C1.10 alkoxy, N02, 
CN, OH, C02H, amino, C1.10 alkylamino, C2.12 
dialkylamino, Ci.JO acyl, and Ci.JO alkoxy-CO-, 
and Ci.JO alkyl-S-; 35 
AA1 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl- 40 
alanine, tryptophan, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glu-
tamic acid, lysine, arginine, histidine, phenylgly-
cine, beta-alanine, norleucine, norvaline, a-
aminobutyric acid, epsilon-aminocaproic acid, cit- 45 
rulline, hydroxyproline, ornithine, homoarginine, 
sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl- 50 
cysteine, NH2-CH(CH2CHEt2)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 55 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
AA2 is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 60 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
praline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 65 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
a-aminobutyric acid, epsilon-aminocaproic acid, 
34 
citrulline, hydroxyproline, ornithine, homoargi-
nine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
R3 and ~are selected independently from the group 
consisting of H, C1.20 alkyl, C1.20 cyclized alkyl, 
C1.20 alkyl with a phenyl group attached to the 
Ci.20 alkyl, C1-20 cyclized alkyl with an attached 
phenyl group, C1.20 alkyl with an attached phenyl 
group substituted with K, C1.20 alkyl with an at-
tached phenyl group disubstituted with K, C1.20 
alkyl with an attached phenyl group trisubstituted 
with K, C1.20 cyclized alkyl with an attached 
phenyl group substituted with K, C1.10 alkyl with a 
morpholine [-N(CH2CH2)0] ring attached 
through nitrogen to the alkyl, Ci.JO alkyl with a 
piperidine ring attached through nitrogen to the 
alkyl, Ci.JO alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1.20 alkyl with an 
OH group attached to the alkyl, -CH2C-
H20CH2CH20H, C1.10 with an attached 4-pyridyl 
group, C1.10 with an attached 3-pyridyl group, 
Ci.JO with an attached 2-pyridyl group, CJ.JO with 
an attached cyclohexyl group, -NH-CH2CH2-
(4-hydroxyphenyl), and -NH-CH2CH2-(3-indo-
lyl). 
The Tripeptide a-Ketoamides have the following 
structural formula: 
M1-AA-AA-AA-CO-NR3R,i 
or a pharmaceutically acceptable salt, wherein 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-N-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of C1.10 alkyl, 
C1-io fluoroalkyl, C1.10 alkyl substituted with J, 
C1.10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ci.JO alkyl with an attached phenyl 
group, C1.10 alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, C1.io alkyl with two attached 
phenyl groups substituted with K, Ci.JO alkyl with 
an attached phenoxy group, and C1.10alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, Ci.JO alkoxy, C1.10 
alkylamine, C2.12 dialkylamine, C1.10 alkyl-
0-CO-, C1.10 alkyl-0-CO-NH-, and Ci.JO 
alkyl-S-; 
35 
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K is selected from the group consisting of halogen, 
C1-1oalkyl, C1-10perfluoroalkyl, C1-10alkoxy, N02, 
CN, OH, C02H, amino, C1-10 alkylamino, C2-12 
dialkylamino, C1-10 acyl, and C1-10 alkoxy-CO-, 
and C1-10 alkyl-S-; 5 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl- 10 
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
a-aminobutyric acid, epsilon-aminocaproic acid, 15 
citrulline, hydroxyproline, ornithine, homoargi-
nine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl- 20 
cysteine, NH2-CH(CH2CHEti)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 25 NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, 
fluoroleucine, and hexafluoroleucine; 
tri-
R3 and R4 are selected independently from the group 
consisting of H, C1-20 alkyl, C1-20 cyclized alkyl, 30 C1-20 alkyl with a phenyl group attached to the 
C1-20 alkyl, C1-20 cyclized alkyl with an attached 
phenyl group, C1-20 alkyl with an attached phenyl 
group substituted with K, C1-20 alkyl with an at-
tached phenyl group disubstituted with K, C1.20 
alkyl with an attached phenyl group trisubstituted 35 
with K, C1-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1.10alkyl with a 
morpholine [-N(CH2CH2)0] ring attached 
through nitrogen to the alkyl, C1-10 alkyl with a 
piperidine ring attached through nitrogen to the 40 
alkyl, C1-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1-20 alkyl with an 
OH group attached to the alkyl, -CH2C-
H20CH2CH20H, C1-10 with an attached 4-pyridyl 
group, C1.10 with an attached 3-pyridyl group, 45 
C1.10 with an attached 2-pyridyl group, C1.10 with 
an attached cyclohexyl group, -NH-CH2CH2-
(4-hydroxyphenyl), and -NH-CH2CH2-(3-indo-
lyl). 
The Tetrapeptide a-Ketoamides have the following 50 
structural formula: 
M1-AA-AA-AA-AA-CO-NR3~ 
or a pharmaceutically acceptable salt, wherein 55 
M1 represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 
X-0-CO-, or X-0-CS-; 60 
Xis selected from the group consisting of C1.10 alkyl, 
C1-10 fluoroalkyl, C1.10 alkyl substituted with J, 
C1-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 65 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, C1.10 alkyl with an attached phenyl 
group, C1.10 alkyl with two attached phenyl 
groups, C1.10 alkyl with an attached phenyl group 
substituted with K, C1.10 alkyl with two attached 
phenyl groups substituted with K, C1.10 alkyl with 
an attached phenoxy group, and C1-10alkyl with an 
attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of halogen, 
COOR, OH, CN, N02, NH2, C1-10 alkoxy, C1.10 
alkylamine, C2.12 dialkylamine, C1-10 alkyl-
0-CO-, C1-10 alkyl-0-CO-NH-, and C1.10 
alkyl-S-; 
K is selected from the group consisting of halogen, 
C1-10alkyl, C1-10perfluoroalkyl, C1-10alkoxy, N02, 
CN, OH, C02H, amino, C1.10 alkylamino, C2.12 
dialkylamino, C1-C10 acyl, and C1.10 alkoxy-CO-, 
and C1-10 alkyl-S-; 
AA is a side chain blocked or unblocked amino acid 
with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, 
proline, methionine, methionine sulfoxide, phenyl-
alanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic 
acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, 
a-aminobutyric acid, epsilon-aminocaproic acid, 
citrulline, hydroxyproline, ornithine, homoargi-
nine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse-
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, tri-
fluoroleucine, and hexafluoroleucine; 
R3 and R4 are selected independently from the group 
consisting of H, C1.20 alkyl, C1.20 cyclized alkyl, 
C1.20 alkyl with a phenyl group attached to the 
C1-20 alkyl, C1.20 cyclized alkyl with an attached 
phenyl group, C1.20 alkyl with an attached phenyl 
group substituted with K, C1.20 alkyl with an at-
tached phenyl group disubstituted with K, C1.20 
alkyl with an attached phenyl group trisubstituted 
with K, C1.20 cyclized alkyl with an attached 
phenyl group substituted with K, C1-10 alkyl with a 
morpholine [-N(CH2CH2)0] ring attached 
through nitrogen to the alkyl, C1-10 alkyl with a 
piperidine ring attached through nitrogen to the 
alkyl, C1-10 alkyl with a pyrrolidine ring attached 
through nitrogen to the alkyl, C1-20 alkyl with an 
OH group attached to the alkyl, -CH2C-
H20CH2CH20H, C1.10 with an attached 4-pyridyl 
group, C1.10 with an attached 3-pyridyl group, 
C1-10 with an attached 2-pyridyl group, C1.10 with 
an attached cyclohexyl group, -NH-CH2CH2-
(4-hydroxyphenyl), and -NH-CH2CH2-(3-indo-
lyl). 
The Amino Acid a-Ketoamides have the following 
structural formula: 
5,444,042 
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or a pharmaceutically acceptable salt, wherein 
Mi represents H, NH2-CO-, NH2-CS-, 
NH2-S02-, X-NH-CO-, X2N-CO-, 
X-NH-CS-, X2N-CS-, X-NH-S02-, 
X2N-S02-, X-CO-, X-CS-, X-S02-, 5 
X-0-CO-, or X-0-CS-; 
Xis selected from the group consisting of Ci.JO alkyl, 
Ci.JO fluoroalkyl, C1-JO alkyl substituted with J, 
CJ.JO fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 10 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Ci.JO alkyl with an attached phenyl 
group, Cr.JO alkyl with two attached phenyl 15 
groups, C1-10 alkyl with an attached phenyl group 
substituted with K, C1-10 alkyl with two attached 
phenyl groups substituted with K, Ci.JO alkyl with 
an attached phenoxy group, and Ci.JO alkyl with an 
38 
through nitrogen to the alkyl, C1.20 alkyl with an 
OH group attached to the alkyl, -CH2C-
H20CH2CH20H, Ci.JO with an attached 4-pyridyl 
group, CJ.JO with an attached 3-pyridyl group, 
C1.10 with an attached 2-pyridyl group, CJ.JO with 
an attached cyclohexyl group, -NH-CH2CH2-
(4-hydroxyphenyl), and -NH-CH2CH2-(3-indo-
lyl). 
The Applicants are aware of only a single peptide 
ketoamide reported in the literature. This compound is 
Z-Phe-NHCH2CO-CO-NH-Et (Z-Phe-Gly-
CO-NH-Et). The compound is reported in Hu and 
Abeles [Arch. Biochem. Biophys .. 281, 271-274 (1990)] to 
be an inhibitor of papain and cathepsin B. 
The following Peptide Ketoamide compounds are 
representative of the Peptide Keto-Compounds found 
to be useful as Calpain inhibitors within the context of 
the present invention: 
attached phenoxy group substituted with Kon the 20 Z-Leu-Phe-CONH-Et 
phenoxy group; Z-Leu-Phe-CONH-nPr 
J is selected from the group consisting of halogen, Z-Leu-Phe-CONH-nBu 
COOH, OH, CN, N02, NH2, Ci.JO alkoxy, Cr.JO Z-Leu-Phe-CONH-iBu 
alkylamine, C2-12 dialkylamine, Ci.JO alkyl- Z-Leu-Phe-CONH-Bzl 
0-CO-, Ci.JO alkyl-0-CO-NH-, and Ci.JO 25 Z-Leu-Phe-CONH-(CH2)2Ph 
alkyl-S-; Z-Leu-Abu-CONH-Et 
K is selected from the group consisting of halogen, Z-Leu-Abu-CONH-nPr 
C1.10 alkyl, C1.10 perfluoroalkyl, C1.10 alkoxy, N02, Z-Leu-Abu-CONH-nBu 
CN, OH, C02H, amino, Ci.JO alkylamino, C2-12 Z-Leu-Abu-CONH-iBu 
dialkylamino, C1.10 acyl, and Ci.JO alkoxy-CO-, 30 Z-Leu-Abu-CONH-Bzl 
and Ci.JO alkyl-S-; Z-Leu-Abu-CO NH-(CH2)2Ph 
AA is a side chain blocked or unblocked amino acid Z-Leu-Abu-CO NH-(CH2)3-N(CH2CH2)20 
with the L configuration, D configuration, or no Z-Leu-Abu-CONH-(CH2)7CH3 
chirality at the a-carbon selected from the group Z-Leu-Abu-CONH-(CH2)20H 
consisting of alanine, valine, leucine, isoleucine, 35 Z-Leu-Abu-CONH-(CH2)20(CH2)20H 
proline, methionine, methionine sulfoxide, phenyl- Z-Leu-Abu-CONH-(CH2)17CH3 
alanine, tryptophan, glycine, serine, threonine, Z-Leu-Abu-CONH-CH2-C6H3(0CH3)2 
cysteine, tyrosine, asparagine, glutamine, aspartic Z-Leu-Abu-CONH-CHz-C4-R4N 
acid, glutamic acid, lysine, arginine, histidine, phe-
We studied the inhibition mechanism of the Peptide 
Keto-Compounds in both serine and thiol proteases. A 
crystal structure of one a-ketoester bound into the ac-
tive site of the serine protease, porcine pancreatic elas-
nylglycine, beta-alanine, norleucine, norvaline, 40 
a-aminobutyric acid, epsilon-aminocaproic acid, 
citrulline, hydroxyproline, ornithine, homoargi-
nine, sarcosine, indoline 2-carboxylic acid, 2-
azetidinecarboxylic acid, pipecolinic acid (2-piperi-
dine carboxylic acid), 0-methylserine, 0-ethylse- 45 
rine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2-CHEt2)-COOH, a-
aminoheptanoic acid, NH2-CH(CH2-l-napthyl)-
COOH, NH2-CH(CH2-2-napthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
NH2-CH(CH2-cyclopropyl)-COOH, 
fluoroleucine, and hexafluoroleucine; 
tri-
tase, has been completed. The active site Ser-195 oxy-
gen of the enzyme adds to the carbonyl group of the 
ketoester to form a tetrahedral intermediate which is 
stabilized by interactions with the oxyanion hole. This 
structure resembles the tetrahedral intermediate in-
volved in peptide bond hydrolysis and proves that a-
5o ketoesters are transition-state analogs. His-57 is hydro-
gen bonded to the carbonyl group of the ester func-
tional group, the peptide backbone on a section of the 
polypeptide backbone hydrogen bonds to the inhibitor 
R3 and ~are selected independently from the group 55 
consisting of H, C1-20 alkyl, C1.20 cyclized alkyl, 
C1.20 alkyl with a phenyl group attached to the 
C1.20 alkyl, C1-20 cyclized alkyl with an attached 
phenyl group, C1.20 alkyl with an attached phenyl 
group substituted with K, C1.20 alkyl with an at- 60 
tached phenyl group disubstituted with K, C1.20 
alkyl with an attached phenyl group trisubstituted 
with K, C1-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1.10 alkyl with a 
morpholine [-N(CH2CH2)0] ring attached 65 
through nitrogen to the alkyl, C1.10 alkyl with a 
piperidine ring attached through nitrogen to the 
alkyl, Ci.Jo alkyl with a pyrrolidine ring attached 
to form a ,8-sheet, and the benzyl ester is directed 
toward the S' subsites. The side chain of the Pl amino 
acid residue is located in the Sl pocket of the enzyme. 
Interactions with ketoamides would be similar except 
that there is the possibility of forming an additional 
hydrogen bond with the NH group of the ketoamide 
functional group. 
In the case of ketoacids, there would be no R group 
to interact with the S' subsites. Therefore, these inhibi-
tors would be expected to be slightly less potent than 
the ketoesters and ketoamides. However, unexpectedly, 
certain ketoacid compounds have been found to have 
surprisingly high activity when used in the context of 
the present invention. In particular, Z-Leu-Phe-COOH 
39 
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and Z-Leu-Abu-COOH have been found to be ex-
tremely potent inhibitors of Calpains. 
The active site of cysteine proteases shares several 
features in common with serine proteases including an 
active site histidine residue. In place of the Ser-195, 5 
cysteine proteases have an active site cysteine residue 
which would add to the ketonic carbonyl group of the 
peptide ketoacids, ketoesters, or ketoamides to form an 
adduct very similar to the structure described above 
except with a cysteine residue replacing the serine-195 10 
residue. Additional interactions would occur between 
the extended substrate binding site of the cysteine prote-
ase and the inhibitor that would increase the binding 
affinity and specificity of the inhibitors. 
The Peptide Keto-Compounds bind to the proteases 15 
inhibited thereby using many of the interactions that are 
found in complexes of a particular individual enzyme 
with its substrates. In order to design an inhibitor for a 
particular cysteine protease, it is necessary to: 1) find 
the amino acid sequences of good peptide substrates for 20 
that enzyme, and 2) place those or similar amino acid 
sequences into a Peptide Keto-Compound. This design 
strategy will also work when other classes of peptide 
inhibitors are used in place of the peptide substrate to 
gain information on the appropriate sequence to place in 25 
the Peptide Keto-Compound inhibitor. Thus, we are 
able to predict the structure of new inhibitors for other 
proteases based on knowledge of their substrate specifi-
cities. Once a good inhibitor structure for a particular 
enzyme is found, it is then possible to change other 30 
characteristics such as solubility or hydrophobicity by 
adding substituents to the M or R groups. 
In the case of Calpain, a known inhibitor sequence is 
the peptide aldehyde, Ac-Leu-Leu-Nle-H (also known 
as Calpain Inhibitor I and hereinafter designated as 35 
"Cll"). This inhibitor, in addition to a related peptide 
aldehyde inhibitor Ac-Leu-Leu-Nme-H (also known as 
Calpain Inhibitor II) are commercially available from 
Calbiochem of La Jolla, Calif. We have discovered that 
peptide a-ketoesters with aromatic amino acid residues 40 
in Pl are good inhibitors of the thiol proteases, cathep-
sin B, papain and Calpain. Additionally, we have dis-
covered that peptide a-ketoester and peptide a-ketoa-
mides with either aromatic amino acid residues or small 
hydrophobic alkyl amino acid residues at Pl are good 45 
inhibitors of Calpain. 
Our discovery of Peptide Keto-Compounds effective 
as Calpain Inhibitors was made through assay of the 
Peptide Keto-Compounds as reversible inhibitors. Vari-
ous concentrations of inhibitors in dimethylsulfoxide SO 
(DMSO) were added to the assay mixture, which con-
tained buffer and substrate. The reaction was started by 
the addition of the enzyme and the hydrolysis rates 
were followed spectrophotometrically or fluorimetri-
cally. 88 mM KH2P04, 12 mM Na2HP04, 1.33 mM 55 
EDTA, 2.7 mM cysteine, pH 6.0 was used as a buffer 
for cathepsin B; and 20 mM Hepes, 10 mM CaClz, 10 
mM J3-mercaptoethanol, pH 7.2 buffer was utilized for 
calpain I and calpain II. 
All peptide thioester hydrolysis rates were measured 60 
with assay mixtures containing 4,4' -dithiodipyridine 
[e324= 19800 M-1 cm-1; Grasetti & Murray, Arch. 
Biochem. Biophys. 119, pp 41-49 (1967)]. Papain was 
assayed with Bz-Arg-AMC or Bz-Arg-NA [Kanaoka et 
al., Chem. Pharm. Bull. 25, 3126-3128 (1977)], and the 65 
AMC (7-amino-4-methylcoumarin) release was fol-
lowed fluorimetrically (excitation at 380 nm, and emis-
sion at 460 nm). Cathepsin B was assayed with Z-Arg-
40 
Arg-AFC [Barrett and Kirschke, Methods Enzymol. 
80, 535-561 (1981)], and the AFC (7-amino-4-tri-
fluoromethylcoumarin) release was followed fluorimet-
rically (excitation at 400 run, and emission at 505 nm). 
Calpain I from human erythrocytes and calpain II from 
rabbit were assayed using Suc-Leu-Tyr-AMC [Sasaki et 
al., J. Biol. Chem. 259, 12489-12494 (1984), hereby 
incorporated by reference], and the AMC (7-amino-4-
methylcoumarin) release was followed fluorimetrically 
(excitation at 380 nm, and emission at 460 nm). Enzy-
matic hydrolysis rates were measured at various sub-
strate and inhibitor concentrations, and Ki values were 
determined by Dixon plot. 
Table PKCl shows the inhibition constants (Ki) for 
papain, cathepsin B, calpain I, and calpain II. 
The inhibition constants for papain shown in Table 
PKCl were measured in 0.05M Tris-HCI, pH 7.5 buffer, 
containing 2 mM EDT A, 5 mM cysteine (freshly pre-
pared), 1 % DMSO, at 25° C., using Nn-Benzoyl-Arg-
AMC as a substrate, except that those values of inhibi-
tion constants for papain marked with an "e" in Table 
PKCl were measured in 50 mM Tris-HCl, pH 7.5 
buffer, containing 20 mM EDT A, 5 mM cysteine, 9% 
DMSO, at 25° C., using Nn-Benzoyl-Arg-NA as a sub-
strate. 
TABLEPKCl 
Inhibition of Cysteine Proteases by 
Peptide Ketoesters and Ketoacids 
K,{mM) 
Compounds pa CBb CI' CIId 
Z-Leu-Abu-COOEt 0.4 0.04 
Z-Leu-Phe-COOEt 0.4 0.23 
Z-Leu-Nle-COOEt 0.18 0.12 
Z-Leu-Nva-COOEt 1.2 30 
Bz-DL-Phe-COOEt 
Z-Phe-DL-Phe-COOEt 
Z-Phe-DL-Ala-COOEt 
Z-Ala-Ala-DL-Ala-COOEt 
Z-Ala-Ala-DL-Abu-COOEt 
· Z-Ala-Ala-DL-Abu-COOBzl 
Z-Ala-Ala-DL-Nva-COOEt 
Z-Ala-Pro-DL-Ala-COOEt 
MeO-Suc-V al-Pro-DL-Phe-COOMe 
Z-Ala-Ala-Ala-DL-Ala-COOEt 
MeO-Suc-Ala-Ala-Pro-Abu-COOMe 
"P = Papain 
bcB = Cathepsin B 
<cJ = Calpain I 
den = Calpain II 
sooe 
1.8 
3.6 
1.5 
0.9 
30 
30 
26 
I.I 
2.9' 
2.1 
0.7 
64 
0.1 
3.2 
2.2 200 
10 50 200 
60 
0.1 
66 
0.1 
10.0 
6.0 JOO 
It can be seen from the data in Table PKCl that the 
dipeptide ketoesters with Abu, Phe, or Nie in the Pl site 
and Leu in the P2 site are potent inhibitors of calpain I 
and calpain II. Tripeptides with Abu or Ala in the Pl 
site and Ala in the P2 site are also seen to be inhibitors 
of Calpain, albeit soinewhat weaker inhibitors than the 
dipeptides. Thus, in accordance with the foregoing 
description of the design of Peptide Keto-Compound 
inhibitors, we believe that Peptide Keto-Compounds 
based on these and similar structures will exhibit Cal-
pain inhibitory activity. 
The peptide a-ketoesters are prepared by a two step 
Dakin-West procedure. This procedure can be utilized 
with either amino acid derivatives, dipeptide deriva-
tives, tripeptide derivatives, or tetrapeptide derivatives 
as shown in the following scheme: 
5,444,042 
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II 
M-(AA)i!OH-7Enol Ester-7M-(AA)i!CO-R. 
42 
could also be prepared directly from H-AA-AA-OH, 
H-AA-AA-AA-OH, or H-AA-AA-AA-AA-OH using 
the reactions described above for introduction of the M 
group. Alternately, the M group could be introduced by 
5 reaction with carboxyl blocked peptides M-AA-
The precursor peptide ((AA)n) can be prepared using AA-OR', M-AA-AA-AA-OR', or M-AA-AA-AA-
standard peptide chemistry procedures, including those 
that are well described in publications such as The Pep- AA-OR', followed by the removal of the blocking 
tides, Analysis, Synthesis, Biology, Vol. 1-9, published group R'. 
in 1979-1987 by Academic Press ("The Peptides") and 10 The R group in the ketoester structures is introduced 
Houben-Wey! Methoden der Organischen Chemie, during the Dakin-West reaction by reaction with an 
Vol. 15, Parts 1 and 2, Synthese von Peptiden, pub- oxalyl chloride Cl-CO-C0-0-R. For example, 
lished by Georg Thieme Verlag, Stuttgart in 1974 reaction of M-AA-AA-OH with ethyl oxalyl chloride 
("Houben-Wey!") (both references hereby incorpo- Cl-CO-C0-0-Et gives the keto ester M-AA-
rated herein by reference). 15 AA-C0-0-Et. Reaction ofM-AA-AA-AA-AA-OH 
The M group can be introduced using a number of with Cl-CO-C0-0-Bzl would give the ketoester 
different reaction schemes. For example, it could be M-AA-AA-AA-AA-C0-0-Bzl. Clearly a wide vari-
introduced directly on an amino acid as shown in the ety of R groups can be introduced into the ketoester 
fo11owing scheme: structure by reaction with various alkyl or arylalkyl 
H-(AA)n-OH-..M-(AA)n-OH. 20 oxalyl chlorides (Cl-CO-C0-0-R). 
Alternatively, the M group can be introduced by reac-
tion with an amino acid ester, followed by removal of 
the ester group to give the same product, as shown in 
the following scheme: 25 
H-(AA)n-OR'-..M-(AA)n-OR'-..M-(AA)n-OH. 
These and other techniques for introduction of the M 
group are well documented in the The Peptides, Houb- 30 
en-Weyl, and many other textbooks on organic synthe-
sis. For example reaction with cyanate or p-nitrophenyl 
cyanate would introduce a carbamyl group 
(M=N"H2CO-). Reaction with p-nitrophenyl thiocar-
bamate would introduce a thio carbamyl group 35 
(M=NH2CS-). Reaction with NH2S402Cl would 
introduce the NH2S02- group. Reaction with a substi-
tuted alkyl or aryl isocyanate would introduce the 
X-NH-CO- group where Xis a substituted alkyl or 
aryl group. Reaction with a substituted alkyl or aryl 40 
isothiocyanate would introduce the X-NH-CS-
group where X is a substituted alkyl or aryl group. 
Reaction with X-S02-Cl would introduce the 
X-S02- group. Reaction with a substituted alkyl or 
aryl acid chloride would introduce an acyl group 45 
(M=Y-CO-). For example, reaction with MeO--
CO-CH2CH2-CO-Cl would give the Y-CO-
group when Y is a C2 alkyl substituted with a Cl alkyl-
OCO- group. Reaction with a substituted alkyl or aryl 
thioacid chloride would introduce a thioacyl group 50 
(M= Y-CS-). Reaction with an a substituted alkyl or 
aryl sulfonyl chloride would introduce an X-502-
group. For example reaction with dansyl chloride 
would give the X-S02- derivative where X was a 
napthyl group monosubstituted with a dimethylamino 55 
group. Reaction with a substituted alkyl or aryl chloro-
formate would introduce a X-0-CO- group. Reac-
tion with a substituted alkyl or aryl chlorothioformate 
would introduce a X-0-CS-. There are many alter-
nate reaction schemes which could be used to introduce 60 
all of the above M groups to give either M-AA-OH or 
M-AA-OR'. The M-AA-OH derivatives could then be 
used directly in the Dakin-West reaction or could be 
converted into the dipeptides, tripeptides, and tetrapep-
tides M-AA-AA-OH, M-AA-AA-AA-OH, or M-AA- 65 
AA-AA-AA-OH which could be be used in the Dakin-
West reaction. The substituted peptides M-AA-AA-
OH, M-AA-AA-AA-OH, or M-AA-AA-AA-AA-OH 
The oxalyl chlorides are easily prepared by reaction 
of an alkyl or arylalkyl alcohol with oxalyl chloride 
Cl-CO-CO-Cl. For example, Bzl-
0-CO-CO-Cl and n-Bu-0-CO-CO-Cl are pre-
pared by reaction ofbenzyl alcohol and butanol, respec-
tively, with oxalyl chloride in yields of 50% and 80% 
[Warren, C. B., and Malee, E. J., J. Chromatography 64, 
219-222 (1972); incorporated herein by reference]. 
Ketoacids M-AA-CO-OH, M-AA-AA-CO-OH, 
M-AA-AA-AA-CO-OH, M-AA-AA-AA-AA-
CO-OH, are generally prepared from the correspond-
ing ketoesters M-AA-CO-OR, M-AA-AA-CO-OR, 
M-AA-AA-AA-CO-OR, M-AA-AA-AA-AA-
CO-OR by alkaline hydrolysis. In some cases, it may 
be necessary to use other methods such as hydrogenoly-
sis of a benzyl group (R=Bzl) or acid cleavage (R=t-
butyl) to obtain the ketoacid. The alternate methods 
would be used when the M group was labile to alkaline 
hydrolysis. 
The various peptide ketoamide subclasses (M-AA-
NH-CHR2-CO-CO-NR3~ (Dipeptide Ketoa-
mides (Subclass A)), M-AA-AA-CO-NR3~ (Dipep-
tide Ketoamides (Subclass B)), M-AA-AA-AA-
CO-NR3~ (Tripeptide Ketoamides), M-AA-AA-
AA-AA-CO-NR3~ (tetrapeptide ketoamides) and 
M1-AA-CO-NR3~ (Amino Acid Ketoamides)) were 
prepared indirectly from the corresponding ketoesters. 
The ketone carbonyl group was first protected as 
shown in the following scheme and then the ketoamide 
was prepared by reaction with an amine H-NR3~. 
The illustrated procedure should also work with other 
protecting groups. 
43 
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N-Acylamino acids with 4-methylpentanoic, 2-(1-
propyl)pentanoic and 7-phenylheptanoic group was 
synthesized in a two step synthesis. The N-acylamino 
acid methyl ester was obtained first and then was hy-
5 drolysed to the free N-acylamino acid. 
In addition to the scheme outlined above, a ketoacid 
could be used as a precursor to produce a correspond-
ing ketoamide. Blocking the ketone carbonyl group of 10 
the ketoacid and then coupling with an amine 
H-NR31l4 using standard peptide coupling reagents 
would yield an intermediate which could then be de-
blocked to form the ketoamide. 
N-Acylamino Acid Methyl Esters (General Proce-
dure). To a chilled (10° C.) slurry of the appropriate 
amino acid methyl ester hydrochloride (20 mmol) in 100 
ml benzene was added slowly (temp. 10°-15° C.) 40 
mmol triethylamine or N-methylmorpholine and then 
the reaction mixture was stirred for 30 minutes at this 
temperature. Then 18 mmol of appropriate acid chlo-
ride (temp. 10°-15° C.) was added slowly to the reaction 
mixture and the reaction mixture was stirred overnight 
General Synthetic Methods for Peptide 
Keto-Compounds 
15 at room temperature. The precipitated hydrochloride 
was filtered, washed on a funnel with 2 X 20 ml benzene, 
and the collected filtrate was washed successively with 
2X50 ml IM HCl, 2X50 ml 5% NaHC03, lXlOO ml Unless otherwise noted, materials were obtained from commercial suppliers and used without further 
purification. Melting points were taken with a Biichi 2o 
capillary apparatus and are uncorrected. lH NMR spec-
tra were determined on a Varian Gemini 300. Chemical 
shifts are expressed in ppm (o) relative to internal tet-
ramethylsilane. Flash column chromatography was 
H20, 2 X 50 ml satd. NaCl and dried over MgS04. After 
evaporation of the solvent in vacuo (rotavaporator), the 
residue was checked for purity (TLC) and used for the 
next step (hydrolysis). 
performed with Universal Scientific Inc. silica gel 0-63. 25 _______________ Y_ie_1d_(.;..%...:.o) __ m...:p_(".:-°C_ . .;....) 
Electron-impact mass spectra (MS) of novel com- (CH3)2CH(CHz)2CO-DL-Abu-OCH3 80 oil 
Pounds were determined with a Varian MAT 112S (CH3CH2CH2)2CHCO-DL-Abu-OCH3 96 117-118 
spectrometer. The purity of all compounds was Ph(CH2)6CO-DL-Abu-OCH3 72 oil 
checked by thin-layer chromatography on Baker 
Si250F silica gel plates using the following solvent sys- 30 
tern: A, CHCl3:Me0H=20:1 v/v; B, 
CHCl3:MeOH=lOO:l v/v; C, AcOEt; D, 
CHCl3:MeOH=lO:l v/v; E, n-BuOH:AcOH;py:H-
20=4:1:1:2 v/v; F, CHCh:Me0H=5:1 v/v; G, AcO-
Et:MeOH= 10:1 v/v; H, (i-Pr)20; I, CHCh:MeOH- 35 
:Ac0H=80:10:5 v/v; J, CHCh:MeOH:Ac0H=95:5:3 
v/v; K, Ac0Et:Ac0H=200:1 v/v; L, CHCh; M, 
CHCl3:Me0H=50:1 v/v 
Amino acid methyl ester hydrochlorides were pre-
pared according to M. Brenner et al.[Helv. Chem. Acta 40 
33, 568 (1950); 36, 1109 (1953)] in a scale over 10 mmol 
or according to Rachele [J. Org. Chem. 28, 2898 (1963)] 
in a scale of 0.1-1.0 mmol. 
Hydrolysis (General Procedure). To a solution of 10 
mmole of the appropriate N-acylamino acid methyl 
ester in 100 ml of methanol was added in one portion 
11.25 ml of IM NaOH (11.25 mmol) and the reaction 
mixture was stirred three hours at room temperature. 
Then the reaction mixture was cooled to 0° C. (ice-salt 
bath) and acidified to pH=2 with IM HCl aq. To this 
reaction mixture was added 100 ml ethyl acetate, trans-
ferred to a separatory funnel and organic layer· sepa-
rated. The water layer was saturated with solid NaCl or 
(Nli4)2S04 and reextracted with 2 X 50 ml AcOEt. The 
collected organic layer was washed with 2 X 50 ml H20, 
decolorized with carbon, and dried over MgS04. After 
evaporation of the solvent in vacuo (rotavaporator), the 
residue was checked for purity (TLC) and in the case of 
--------------------- 45 contamination was crystallized from an appropriate Yield(%) mp (°c.) m.p. (literature) 
DL-Nva-OCH3.HCl, 100 113-116 116-117 solvent. 
L-Ile-OCH3.HCl, 98 90-91 98-100 
L-Phe-OCH3.HCl, 98 159-161 158-160 
100 148-150 150-151 Yield DL-Abu-OCH3.HCl, 
L-Leu-OCH3.HCl 100 145-5-146.5 147 50 --------------(~%~) ___ m...:p_(~"C_.~)-
DL-Nle-OCH3.HCI 93 120-121 122-123 
4-Cl-Phe-OCH3.HCl 98 184-185 185-186 (decomp.) 
N-Acylamino acids was synthesized via Schotten- 55 
Baumann reaction [M. Bergmann, L. Zervas, Chem. 
Ber. 65, 1192 (1932)] in the case when the acyl group 
was phenylsulphonyl, 2-naphthylsulphonyl or benzoyl. 
60 
Yield (%) mp (°C.) TLC (Rf eluent) 
2-NapSOz-L-Leu-OH 49 115-116 0.581 
2-NapSOz-DL-Abu-OH 51 150-151 0.50! 
2-NapS02-L-Phe-OH 57 148-148.5 0.48K 65 
PheS02-DL-Abu-OH 44 142-143 0.51K 
PhCO-DL-Abu-OH 64 141-142 0.64K 
(CH3)2CH(CH2)2CO-DL-Abu-OH 
(CH3CH2CH2)2CHCO-DL-Abu-OH 
Ph(CH2)6CO-DL-Abu-OH 
92 110.5-112 
99 126-127 
89 
(n-octane) 
110-112 
(n-octane) 
N-Acyldipeptide methyl esters were synthesized via 
the HOBt-DCC method in a DMF solution [Konig and 
Geiger, Chem. Ber. 103, 788 (1970)]. 
Yield TLC (%) mp (°C.) (Rf eluent) 
Z-Leu-DL-NV a-OCH3 80 112-113 0.37 B 
Z-Leu-L-Phe-OCH3 83 86-87 0.85 A 
0.39 B 
Z-Leu-L-Ile-OCH3 97 oil 0.79 A 
0.43 B 
Z-Leu-DL-Abu-OCH3 99 86-88 0.33 B 
0.26H 
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Yield TLC 
(%) mp (°c.) (Rf eluent) 
Z-Leu-L-Leu-OCH3 80 91-92 0.79 G 
Z-Leu-DL-NLeu-OCH3 97 111-111.5 
Z-Leu-4-Cl-Phe-OCH3 65 112-132 0.77 J 
(liquid 0.68 K 
crystal?) 
2-NapS02-Leu-DL-Abu-OCH3 99 oil 0.59 A 
2-NapS02-Leu-L-Leu-OCH3 90 97-98.5 0.63 A 
N-Acyldipeptides were obtained by hydrolysis of the 
appropriate methyl esters via a general hydrolysis pro-
cedure. In the case of N-sulphonyldipeptide methyl 
esters, 1 equivalent of the methyl ester was hydrolyzed 
with 2.25 equivalent of 1 molar NaOH because of form 
a sulfonamide sodium salt. 
Yield TLC 
(%) mp(°C.) (Rf eluent) 
Z-Leu-DL-NVa-OH 100 117-118.5 0.11 A 
Z-Leu-L-Phe-OH 92 105-106.5 0.28 c 
0.55 G 
Z-Leu-L-ILe-OH 79 77-79 0.22 A 
0.52 c 
Z-Leu-DL-Abu-OH 99 glass 0.61 G 
Z-Leu-L-Leu-OH 97 glass 0.56 I 
Z-Leu-DL-NLeu-OH 98 95-96 
Z-Leu-4-Cl-Phe-OH 87 104-114 0.48 K 
(liquid 
crystal?) 
2-NapSOz-Leu-DL-Abu-OH 97.4 180-195 0.58 I 
(decomp) 
2-NapS02-Leu-L-Leu-OH 94.0 68-70 0.52 I 
5 
10 
46 
4-dimethylaminopyridine (15 mg, 0.31 mmole), and 
pyridine (0.8 mL, 10 mmole) in tetrahydrofuran (3 mL) 
was added ethyl oxalyl chloride (0.7 mL, 6 mmole) at a 
rate sufficient to initiate refluxing. The mixture was 
gently refluxed for 3.5 h. The mixture was treated with 
water (3 mL) and stirred vigorously at room tempera-
ture for 30 min. The mixture was extracted with ethyl 
acetate. The organic extracts were dried and evapo-
rated to obtain the residue (1.45 g). The residue was 
chromatographed on silica gel and eluted with CH2Clz 
to give the enol ester product, oil (500 mg, 37%); single 
spot on tlc, Rj=0.67 (CHC1}:Me0H=9:1); MS, 
m/e=451(M++1). To a stirred suspension of the enol 
ester (210 mg, 0.47 mmol) in anhydrous ethanol (1 mL) 
15 at room temperature was added dropwise a solution of 
sodium ethoxide in ethanol until a clear yellow solution 
resulted. The ethanol was then removed and the residue 
was treated with ether. The ether solution was washed 
with water, dried, and evaporated to give a residue. 
20 This residue was chromatographed on a silica gel and 
the product was eluted with methylene chloride. The 
solvent was removed, and the peptide ketoester Z-Ala-
DL-Ala-C02Et was obtained as an semi-solid (150 mg, 
92%); single spot on tlc, RJ 0.58 (CHCl3:Me0H=5:1); 
25 MS, m/e=351(M++1). Anal. Calcd. for C17H2206N-
2.k H20: C, 57.29; H, 6.22; N, 7.86. Found: C, 57.23; H, 
6.36; N, 8.17. 
EXAMPLE PKC2 
30 
N-Acytripeptide methyl esters were synthesized via 35 
HOBt-DCC method in DMF solution [Konig and Gei-
ger, Chem. Ber. 103, 788 (1970)]. 
Z-Ala-Ala-DL-Ala-C02Et. This compound was pre-
pared from Z-Ala-Ala-Ala-OH using the same proce-
dure as described in Example PKCl. The product was 
crystallized from ethyl ether in 23% yield; single spot 
on tlc, Rj=0.31 (CHCl3:Me0H=9:1); mp 143°-144° 
C.; MS, m/e=421 (M+). Anal. Calcd. for C20H2107N3: 
C, 56.99; H, 6.46; N, 9.97. Found: C, 56.96; H, 6.49; N, 
9.92. 
Yield TLC 40 (%) mp (°C.) (Rf eluent) 
Z-Leu-Leu-Abu-OCH3 87 140-141.5 0.50A 
Z-Leu-Leu-Phe-OCH3 76 158-159 0.83 J 
2-NapS02-Leu-Leu-Abu-OCH3 97 >200 0.52 A 
N-Acyltripeptide were obtained through hydrolysis 45 
of the appropriate methyl esters via general hydrolysis 
procedure. In the case ofN-sulphonyltripeptide methyl 
ester, 1 equivalent of methyl ester was hydrolyzed with 
2.25 equivalent of 1 molar NaOH to form the sulfona- 50 
mide sodium salt. 
Z-Leu-Leu-Abu-OH 
Z-Leu-Leu-Phe-OH 
2-NapS02-Leu-Leu-Abu-OH 
Yield 
97 
98 
85 
mp (°c.) 
glass 
glass 
193-195 
(decamp.) 
TLC 
(Rf eluent) 
0.69 I 
0.44K 
0.53 I 
0.32 J 
55 
EXAMPLE PKC3 
Z-Ala-Ala-DL-Abu-C02Et. This compound was 
prepared from Z-Ala-Ala-DL-Abu-OH in 11 % yield by 
the procedure described in Example PKCl; single spot 
on tlc, RJ0.60 (CHCl3:MeOH=9:1); mp 111°-113° C.; 
MS, m/e=436 (M++l). Anal. Calcd. for C21H2901N-
3.~ H20: C, 57.13; H, 6.75; N, 9.51. Found: C, 57.38; H, 
6.82; N, 9.62. 
EXAMPLE PKC4 
Z-Ala-Ala-DL-Nva-C02Et. This compound was 
prepared from Z-Ala-Nva-OH in 20% yield by the 
procedure described in Example PKCl; single spot on 
tlc, RJ=0.64 (CHCl3:MeOH=5:1); MS, m/e=450 
(M++l). Anal. Calcd. for C22H3101N3.H20: C, 56.51; 
H, 7.11; N, 8.99. Found: C, 56.42; H, 7.08; N, 9.06. 
EXAMPLE PKC5 
Z-Ala-Pro-DL-Ala-C02Et. This compound was pre-
pared from Z-Ala-Pro-Ala-OH.dicydohexylamine in 
19% yield by the procedure described in Example 
The following examples, Examples PKC1-PKC65, 60 PKCl; single spot on tlc, RJ=0.55 
are given to illustrate the synthesis of Peptide Keto- (CHCl3:MeOH=9:1); MS, m/e=447 (M+). Anal. 
Compounds: Calcd. for C22H2907N3.~ H20: C, 57.88; H, 6.62; N, 
EXAMPLE PKCl 
Z-Ala-DL-Ala-COOEt. This compound was synthe- 65 
sized by a modified Dakin-West procedure [Charles et 
al., J. Chem. Soc. Perkin I, 1139-1146, (1980)]. To a 
stirred solution of Z-Ala-Ala-OH (880 mg, 3 mmole), 
9.21. Found: C, 57.65; H, 6.68; N, 9.17. 
EXAMPLE PKC6 
Z-Ala-Ala-Ala-DL-Ala-C02Et. The compound was 
prepared from Z-Ala-Ala-Ala-Ala-OH in 7% yield by 
the procedure described in Example PKCI; single spot 
5,444,042 
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on tlc, R}=0.40 (CHCl3:Me0H=9:1); mp. 163°-165° 
C.; MS, m/e=493 (M++l). Anal. Calcd. for 
C23H320s N4.! H20: C, 55.08; H, 6.63; N, 11.17. Found: 
C, 54.85; H, 6.53; N, 11.14. 
EXAMPLE PKC7 5 
48 
(CHCl3:MeOH=9:1); MS, m/e=378 (M+). Anal. 
Calcd. for C19H2606N2.! H20: C, 59.35; H, 7.00; N, 
7.29. Found: C, 59.41; H, 7.03; N, 7.10. 
EXAMPLE PKC14 
Z-Ala-DL-Ala-C02Bzl. This compound was pre-
pared from Z-Ala-Ala-OH in 36% yield by the proce-
dure described in Example PKCl, except that benzyl 
oxalyl chloride was used in the Dakin-West reaction 
Bz-DL-Phe-C02Et. This compound was prepared 
from Bz-Phe-OH in 36% yield by the procedure de-
scribed in Example PKCl, oil, single spot on tlc, 
R}0.61 (CHCl3:Me0H=9:1); MS, m/e=325 (M+). 
Anal. Calcd. for C19H190~.! H20: C, 68.86; H, 5.98; 
N, 4.22. Found: C, 69.10; H, 6.09; N, 4.38. 
EXAMPLE PKC8 
10 and sodium benzyloxide in benzyl alcohol was used for 
enol ester hydrolysis; single spot on tlc, R}=0.55 
(CHCb:MeOH=9:1); MS, m/e=413 (M++l). Anal. 
Calcd. for C22H2406N2: C, 64.06; H, 5.87; N, 6.79. 
MeO-Suc-Ala-DL-Ala-C02Me. This compound was 15 
prepared from MeO-Suc-Ala-Ala-OH in 22% yield by 
Found: C, 63.79; H, 5.95; N, 6.72. 
EXAMPLE PKC15 
the same procedure as described in Example PKCl, Z-Ala-Ala-DL-Abu-C02Bzl. This compound was 
except that sodium methoxide in methanol was used for prepared from Z-Ala-Ala-Abu-OH in 31 % yield by the 
enol ester hydrolysis, single spot on tlc, R}=0.43 procedure described in Example PKCl, except that 
(CHCl3:Me0H=9:1); MS, m/e=317 (M++ 1). Anal. 20 benzyl oxalyl chloride was used in the Dakin-West 
Calcd. for C13H2007N4.! H20: C, 48.44; H, 6.46; N, reaction and sodium benzyloxide in benzyl alcohol was 
8.69. Found: C, 48.56; H, 6.39; N, 8.69. used for enol ester hydrolysis; single spot on tlc, 
EXAMPLE PKC9 R}=0.40 (CHCb:Me0H=9:1); mp 124°-125° C.; MS, m/e=498 (M++l). Anal. Calcd. for C26H3107N3.~ 
H20: C, 61.28; H, 6.39; N, 8.24. Found: C, 61.14; H, 
6.65; N, 7.94. 
MeO-Suc-Ala-Ala-Pro-DL-Abu-C02Me. This com- 25 
pound was prepared from MeO-Suc-Ala-Ala-Pro-DL-. 
Abu-OH in 22% yield by the procedure described in 
Example PKC8; foam, single spot on tlc, RJ=0.66 EXAMPLE PKC16 
(CHCl3:Me0H=5:1). Anal. Calcd. for C22H3409N4.- Bz-DL-Ala-COOH. The hydrolysis procedure of 
H20: C, 51.53; H, 7.02; N, 10.85. Found: C. 51.11; H, 30 Tsushima et al. [J. Org. Chem. 49, 1163-1169 (1984)] 
7.03; N, 10.88. was used. Bz-DL-Ala-C02Et (540 mg, 2.2 mmol) was 
EXAMPLE PKClO added to a solution of 650 mg of sodium bicarbonate in an aqueous 50% 2-propanol solution (7.5 mL of H20 
MeO-Suc-Val-Pro-DL-Phe-C02Me. This compound and 2-propanol) and stirred at 40° C. under nitrogen. 
was prepared from MeO-Suc-Val-Pro-Phe-OH in 42% 35 After adding ethyl acetate and a saline solution to the 
yield by the same procedure as described in Example reaction mixture, the aqueous layer was separated and 
PKC8; foam, single spot on tic, R} 0.57 acidified with 2N HCl and extracted with ethyl acetate. 
(CHCb:Me0H=9:1); MS, m/e=517 (M+). Anal. The organic layer was dried over magnesium sulfate 
Calcd. for C26H350gN3.~ H20: C, 58.96; H, 6.90; N, and the solvent was removed under reduced pressure. 
7.93. Found: C, 58.92; H, 6.96; N, 7.89. 40 The crude hydrolysis product was chromatographed on 
EXAMPLE PKCl l silica gel and eluted with methylene chloride and meth-
anol to obtain an oil (150 mg, 31%); single spot on tlc, 
Rf=0.68 (n-butanol:acetic acid:pyridine:H-
20=4: 1:1:2). Anal. Calcd. for C11H110~.~ H20: C, 
56.28; H, 5.37; N, 5.97. Found: C, 56.21; H, 5.46; 5.66. 
Bz-DL-Ala-C02-n-Bu. This compound was prepared 
from Bz-Ala-OH in 45% yield by the procedure de-
scribed in Example PKCl, except that n-butyl oxalyl- 45 
chloride was used for the Dakin-West reaction and 
sodium n-butoxide in n-butanol was used for enol ester 
hydrolysis; colorless oil, single spot on tlc, R}=0.72 
(CHCl3:Me0H=9:1); MS, m/e=277 (M+). 
EXAMPLE PKC17 
Z-Leu-DL-Nva-COOEt. This compound was pre-
pared from Z-Leu-Nva-OH in 60% yield by the proce-
EXAMPLE PKC12 50 dure described in Example PKCI; oil, one spot on tlc, Rp0.49 (CHCl3:MeOH=20:l). NMR (CDCl3) 8: 0.91 
(t, 9H), CH3; 1.25 (t, 3H), CH3; 1.38 (q, 2H), OCH2CH3; 
1.64 (m, 6H), CH2; 1.85 (m, lH), CH(CH3)2; 4.34 (m, 
Bz-DL-Ala-C02Bzl. This compound was prepared 
from Bz-Ala-OH in 26% yield by the procedure de-
scribed in Example PKCl, except that benzyl oxalyl 
chloride was used in place of ethyl oxayl chloride and 55 
sodium benzyloxide in benzyl alcohol was used for enol 
ester hydrolysis; single spot on tlc, R}=0.69 
(CHCl3:Me0H=9:1); mp 95°-97° C.; MS, m/e=312 
(M+ + 1). Anal. Calcd. for C1sH1704N.! H20: C, 67.48; 
lH) CH2CH(NHCOOCH2Ph)CONH; 5.12 (d, 3H) 
NHCH(CO)CH2 and OCH2Ph; 5.32 (d, lH) NH; 6.71 
(d, lH) NH; 7.36 (s, 5H) Ph. 
Z-Leu-DL-Nva-enol ester, the precursor of Z-Leu-
DL-Nva-COOEt was synthesized by the same proce-
dure as described in Example PKCl and purified by 
H, 5.66; N, 4.37. Found: C, 67.78; H, 5.55; N, 4.66. 
EXAMPLE PKC13 
60 column chromatography, oil, one spot on tlc. NMR 
(CDCb) 8: 0.96 (t, 9H); 1.25 (t, 3H); 1.41 (t, 2H); 1.54 
(m, 4H); 1.72 (m, 3H); 2.80 (t, 2H); 4.20 (q, 2H); 4.43 (q, 
2H); 5.16 (q, 2H); 5.23 (s, lH); 7.37 (m, 5H); 11.33 (s, 
lH). 
Z-Ala-DL-Ala-C02-n-Bu. This compound was pre-
pared from Z-Ala-Ala-OH in 14% yield by the proce-
dure described in Example PKCl, except that n-butyl 65 
oxalyl chloride was used in the Dakin-West reaction 
and sodium n-butoxide was used for enol ester hydroly-
sis; oil, single spot on tlc, R}=0.45 
EXAMPLE PKC18 
Z-Leu-DL-Phe-COOEt. This compound was pre-
pared from Z-Leu-Phe-OH in 30% yield by the proce-
49 
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dure described in Example PKCl; oil, one spot on tlc, 
Rp0.47 (CHCb:MeOH=50:1). NMR (CDCb) o: 0.88 
(d, 9H), OCH2CH3 and (CH3)2CH; 1.35 (q, 2H), 
OCH2CH3; 1.56 (q, 2H), (CH3)2CHCH2CH; 3.03 (m, 
lH), (CH3)2CH; 4.32 (m, 2H), NHCH(CO)CH2; 5.08 (s, 5 
4H) CH2Ph; 5.40 (m, lH) NH; 6.61 (d, lH) NH; 7.31 (s, 
5H) Ph; 7.35.(s, 5H) Ph. 
50 
tion, and ethanol was removed in vacuo. The residue 
was washed by decantation with ether to give a semi 
solid (216 mg, 100% ); single spot on tlc (n-butanol:a-
cetic acid:pyridine:H20=4:l:1 :2). 
EXAMPLE PKC21 
Bz-DL-Lys-COOEt.HCl. This compound was pre-
pared from Bz-DL-Lys(Z)-COOEt in 62% yield by the 
procedure described in Example PKC20; one spot on 
tlc, R/=0.S7 (n-butanol:acetic acid:pyridine:H-
20=4:1:1:2). The precursor, Bz-DL-Lys(Z)-COOEt 
was prepared from Bz-Lys(Z)-OH in 100% yield by the 
procedure described in Example PKCl; powder, one 
spot on tlc, RJ=0.75 (CHCl3:Me0H=9:1); MS, 
Z-Leu-DL-Phe-enol ester, the precursor of Z-Leu-
DL-Phe-COOEt was synthesized by the same proce-
dure as described in Example PKCl and purified by 10 
column chromatography, oil, one spot on tlc. NMR 
(CDCl3) o: 0.86 (t, 3H); 0.99 (t, 3H); 1.24 (t, 3H); 1.40 (t, 
3H); 1.S2 (m, 2H); 1.83 (m, 2H); 4.23 (m, 4H); 4.39 (q, 
2H); 5.10 (t, 2H); S.18 (s, lH); 7.26 (m, SH); 7.34 (m, 
SH); 8.89 (s, lH). 15 m/e=440 (M+). Anal. Calcd. for C24H2s06N2.~ H20: 
EXAMPLE PKC19 
Z-Leu-DL-Abu-COOEt. This compound was pre-
pared from Z-Leu-Abu-OH in 33% yield by the proce-
dure described in Example PKCl; oil, one spot on tlc, 20 
Rp0.66 (CHCl3:Me0H=20:1). NMR (CDCb) 8: 0.96 
(t, 9H), OCH2CH3 and (CH3)2CH; 1.26 (t, 3H), 
CH2CH2CH3; 1.37 (q, 2H), OCH2CH3; 1.66 (q, 2H), 
(CH3)2CHCH2CH; 2.00 (m, lH), CH(CH3)2; 4.12 (q, 
2H) CHCH2CH3; 4.34 (m, lH) 25 
NHCH(CONH)CH2CH(CH3)2; S.12 (q, 3H) CH2Ph 
and CONH(Et)CHCOCOO; S.29 (t, lH) NH; 6.79 (d, 
lH) NH; 7.3S (s, SH) Ph. 
Z-Leu-DL-Abu-enol ester, the precursor of Z-Leu-
DL-Abu-COOEt was synthesized by the same proce- 30 
dure as described in Example PKCl and purified by 
column chromatography, oil, one spot on tic. NMR 
(CDCl3) 8: 0.98 (t, 6H); 1.12 (t, 3H); 1.24 (t, 3H); 1.41 (t, 
3H); 1.73 (m, 4H); 2.86 (q, 2H); 4.20 (q, 2H); 4.31 (m, 
lH); 4.42 (q, 2H); S.15 (q, 2H); S.21 (s, lH); 7.34 (m, SH); 35 
11.29 (s, lH). 
EXAMPLE PKC20 
Ala-DL-Lys-COOEt.HCI. To a solution of N-car-
bobenzyloxyalanyl-Ne-carbobenzyloxylysine (1.88 g, 40 
3.9 mmol), 4-dimethylaminopyridine (21 mg, 0.17 
mmol), and pyridine (1.0 mL, 12.4 mmol) in THF (7 
mL) was added ethyl oxalyl chloride (0.9 mL, 8.0 
mmol) at a rate sufficient to start refluxing. The mixture 
was refluxed gently for 3 hr, treated with water (4 mL), 45 
and stirred vigorously at room temperature for 30 min. 
The mixture was extracted with ethyl acetate, the or-
ganic extracts were washed with water, dried over 
MgS04 and evaporated to give an oily residue (1.S6 g). 
To a solution of the enol ester (1.S6 g, 2.7 mmol) in 50 
anhydrous ethanol was added dropwise a solution of 
sodium ethoxide in ethanol at room temperature until 
the solution turned clear yellow. Ethanol was removed 
and the residue was dissolved in ethyl acetate. The 
organic solution was washed with water, dried over 55 
MgS04, and evaporated to give a residue. This residue 
was then purified by column chromatography and the 
product was eluted with chloroform-methanol. The 
solvent was removed and Z-Ala-DL-Lys(Z)-C02Et 
was obtained as a hygroscopic powder (328 mg, 16% ), 60 
single spot on tlc, RJ=0.53 (CHCb:Me0H=9:1); MS, 
m/e=S42 (M++l). 
N-Carbobenzoxyalanyl-DL-Necarbobenzoxylysine 
keto ethyl ester, Z-Ala-DL-Lys(Z)-C02Et (328 mg, 
0.61 mmol) was deprotected with liquid HF containing 65 
anisole at 0° C. for 30 min. The HF was removed under 
reduced pressure. The residual oil was dissolved in 
absolute ethanol. HCl/ethanol was added to the solu-
C, 63.70; H, 6.S3; N, 6.19. Found: C, 63.49; H, 6.51; N, 
5.92. 
EXAMPLE PKC22 
Bz-DL-Arg-COOEt.HCl. This compound was pre-
pared from Bz-DL-Arg(Z)-COOEt in 99% yield by the 
procedure described in Example PKC20; one spot on 
tlc, R/=0.71 (n-butanol:acetic acid:pyridine:H-
20=4:1:1:2), Sakaguchi reagent positive. Bz-DL-
Arg(Z)-COOEt was prepared from Bz-DL-Arg(Z)-OH 
in 19% yield by the procedure described in Example 
PKC20, Rf=0.38 (CHC!3:Me0H=9:1); mp 140°-142° 
C.; MS, m/e=468 (M+). Anal. Calcd. for C24H2s06N4: 
C, 61.S3; H, 6.02; N, 11.96. Found: C, 61.96; H, 6.48; N, 
12.34. 
EXAMPLE PKC23 
H-Gly-DL-Lys-COOEt.2HCl. This compound was 
prepared from Z-Gly-DL-Lys(Z)-COOEt in 92% yield 
by the procedure described in Example PKC20; 
R/=0.21 (n-butanol:acetic acid:pyridine:H-
20=4: 1:1:2). Z-Gly-DL-Lys(Z)-COOEt was prepared 
from Z-Gly-Lys(Z)-OH in 9% yield by the procedure 
described in Example PKC20, one spot on tlc, 
RJ=0.68 (CHC13:MeOH=S:l); MS, m/e=528 
(M++l). 
EXAMPLE PKC24 
H-Pro-DL-Lys-COOEt.2HCl. This compound was 
prepared from Z-Pro-DL-Lys(Z)-COOEt in 100% 
yield by the procedure described in Example PKC20; 
one spot on tlc (n-butanol:acetic acid:pyridine:H-
20=4:1:1:2). Z-Pro-DL-Lys(Z)-COOEt was prepared 
from Z-Pro-Lys(Z)-OH in 15% yield by the procedure 
described in Example PKC20; RJ2=0.73 
(CHCb:MeOH=9:1); MS, m/e 568 (M++l). 
EXAMPLE PKC25 
H-Phe-DL-Lys-COOEt.2HCl. This compound was 
prepared from Z-Phe-DL-Lys(Z)-COOEt in 39% yield 
by the procedure described in Example PKC20; one 
spot on tlc (n-butanol:acetic acid:pyridine:H-
20 =4: l:l :2). Z-Phe-DL-Lys(Z)-COOEt was prepared 
from Z-Phe-Lys(Z)-OH as previously described in 9% 
yield, Rf=0.68 (CHCl3:Me0H=9:1); MS, m/e=482 
(M+). 
EXAMPLE PKC26 
H-Leu-Ala-DL-Lys-COOEt.2HCl. This compound 
was prepared from Z-Leu-Ala-DL-Lys(Z)-COOEt in 
52% yield by the procedure described in Example 
PKC20; one spot on tlc (n-butanol:acetic acid:-
pyridine:H20=4:1: 1 :2). 
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Z-Leu-Leu-Abu-EE. This compound was prepared 
from Z2-Leu- Leu-Abu-OH in 62% yield by the general 
procedure described above. Purification by flash chro-
matography on silica gel. Element CHCh:Me0H=50:1 
Z-Leu-Ala-DL-Lys(Z)-COOEt was prepared from 
Z-Leu-Ala-DL-Lys(Z)-OH in 5% yield by the previ-
ously described Dakin West reaction, RJ = 0.34 
(CHCh:MeOH= 19:1); MS, m/e=609 
(M +-OCH2CH3). 5 v/v. Single spot on TLC, Rp0.89, A; 0.75, M. 
EXAMPLE PKC27 Z-Leu-Leu-Phe-EE. This compound was prepared from Z-Leu-Leu-Phe-OH in 60% yield by the general 
procedure described above. Purification by flash chro-
matography on silica gel. Eluent CHCh:Me0H=50:1 
Simple Amino Acid, Di- and Tripeptide Enol Esters 
(General Procedure). A modified Dakin-West proce-
dure was used [Charles et al., J. Chem Soc. Perkin L 
1139 (1980)) and is illustrated with the synthesis of Z-
Leu-DL-Phe-EE. To a stirred solution of Z-Leu-Phe-
OH (6.19 g, 15.0 mmol), 4- dimethylaminopyridine 
(0.183 g; 1,5 mmol) and pyridine (4.75 g, 4,85 ml, 60 
mmol) in tetrahydrofuran (45 ml) warmed 50° c. was 
added ethyl oxalyl chloride (4.30 g, 3.52 ml, 31.5 mmol) 
10 v/v. Single spot on TLC, Rp0.80, K; 0.70, M. 
2-NapS02-Leu-Leu-Abu-EE. This compound was 
prepared from 2-NapS02-Leu-Abu-OH in 73% yield by 
the general procedure described above. Purification by 
flash chromatography on silica gel. Eluent AcOEt, 
15 single spot on TLC, Rp0.71, K; 0.54, C. 
at a rate sufficient to initiate refluxing. The mixture was 
then heated at a gentle reflux for 4 h. After cooling to 
room temperature the mixture was treated with water 
(25 ml) and stirred vigorously at room temperature for 20 
30 min. The mixture was extracted with ethyl acetate 
(150 ml) and after separation of the organic layer, the 
water layer was saturated with solid (NR4)zS04 and 
re-extracted 2-times with 25 ml ethyl acetate. The com-
bined organic phases were washed 2-times with 75 ml 25 
water, 2-times with 50 ml of satd. NaCl, decolorized 
with carbon and dried over MgS04. After evaporation 
of the solvent, the crude enol ester (8,36 g, 98%) was 
flash-chromatographed on silica gel and the product 
was eluted with a AcOEt. The solvent was evaporated 30 
in vacuo (rotavaporator) and the pure enol ester was 
obtained as a oil (7.22 g, 85%); single spot on TLC, 
Rp0.84, A; 0.68, C. 
Z-Leu-Nva-EE. This compound was prepared from 
Z-Leu-Nva-OH using the general procedure and puri- 35 
fied by flash chromatography on silica gel using 
CHCl3:Me0H=50:1 v/v as eluent. Yield 95%, single 
spot on TLC, Rp0.92, C; 0.28, L. 
Z-Leu-Abu-EE. This compound was prepared from 
Z-Leu-Abu- OH in 78% yield the general procedure 40 
described above. Purification by flash chromatography 
on silica gel. Eluent, CHCh:Me0H=50:1 v/v, single 
spot on TLC, Rf=0,86, A. 
PhCO-Abu-EE. This compound was prepared from 
2-NapS02-Leu-Leu-Abu-EE. This compound was 
prepared from 2-NapS02-Leu-Leu-Abu-OH in 74% 
yield by the general procedure described above. Purifi-
cation by flash chromatography on silica gel. Eluent 
AcOEt: Ac0H=200:1 v/v. Single spot. on TLC, 
Rp0.69. K. 
Z-Leu-Phe-COOEt. Single Aminoacid, Di- and Tri-
peptide-ketoesters (General Procedure). To a stirred 
solution of 8.53 g (15.0 mmol) of Z-Leu-Phe-EE in 40 
ml anhydrous ethanol at room temperature was added 
dropwise a solution of sodium ethoxide (0.204 g; 3.0 
mmol) in 20.0 ml anhydrous ethanol. The color of the 
reaction mixture change from colorless or pall yellow 
to deep yellow or orange dependent on enol-ester. Then 
the reaction mixture was stirred at room temperature 
for 4-5 hours, the ethanol was then evaporated in vacuo 
(rotavaporator) and the residue treated with 200 ml 
ethyl ether (or 200 ml ethyl acetate in the case of the 
tripeptide). The ether (ethyl acetate) solution was 
washed with 2X75 ml HzO, 2X75 ml satd. NaCl, decol-
orized with carbon and dried over MgS04. After evap-
oration of solvent, the crude product 6.09 g (89.7%) 
was flash chromatographed on silica gel using CHCh: 
Me0H=50:1 v/v. Evaporation of solvent give pure 
Z-Leu-Phe-COOEt (4.08 g; 58.0%) as a thick oil. Single 
spot on TLC, Rp0.60, A; 0.47, M. Mass spectrum, 
FB-MS [(M + l)/Z] =469. 
EXAMPLE PKC28 
PhCO-Abu-OH in 26% yield by the general procedure 45 2-Leu-Nva-COOEt. This was prepared by the pre-
as described above. Purification by flash chromatogra- ceding general procedure. Purification by flash chroma-
phy on silica gel. Eluent CHCh, single spot on TLC, tography on silica gel, eluent CHCh: MeOH= 100:1 
Rp0.60, M. v/v, yield 86.6%, thick, colorless oil, single spot on 
(CH3)2CH(CH2)zCO-Abu-EE. This compound was TLC, Rp0.49, A; 0.37, M. Mass spectrum FB-MS 
prepared from (CH3)zCH(CH2)zCO-Abu-OH in 82% 50 [(M+l)/Z)=421. 
yield by the general procedure as described above. 
Purification by flash chromatography on silica gel. Elu- EXAMPLE PKC29 
ent AcOEt, single spot on TLC, Rp0.72, C. Z-Len-Abu-COOEt. This was prepared by the pre-
(CH3CH2CH2)z CH CO-Abu-EE. This compound ceding general procedure. Purification by flash chroma-
was prepared from (CH3CH2CH2)zCH CO-Abu-OH in 55 tography on silica gel, eluent CHCh, yield 82%, thick, 
100% yield by the general procedure described above. pale yellow oil, single spot on TLC, Rp0.66, A. Mass 
Purification by flash chromatography on silica gel. Elu- spectrum, Cl-MS [(M + 1)/Z] =407. 
ent AcOEt, single spot on TLC, Rp0.78, C; 0.81, K. 
Ph(CH2)6CO-Abu-EE. This compound was prepared 
from Ph(CH2)6CO-Abu-OH in 86% yield by the gen- 60 
eral procedure described above. Purification by flash 
chromatography on silica gel. Eluent AcOEt. Single 
spot on TLC, Rj=0.74, C. 
Z-Leu-4-Cl-Phe-EE. This compound was prepared 
from Z-Leu-4-Cl-Phe-OH in 69% yield by the general 65 
procedure described above. Purification by flash chro-
matography on silica gel. Eluent AcOEt, single spot on 
TLC, Rp0.77, C; 0.78, K. 
EXAMPLE PKC30 
PhCO-Abu-COOEt. This was prepared by the pre-
ceding general procedure. Purification by flash chroma-
tography on silica gel, eluent CHCh:MeOH=50:1 v/v, 
yield 83%, oil, single spot on TLC, Rj=0.44, M. Mass 
spectrum, M/Z 263 (M+); CI-MS, 264((M+1)/Z). 
EXAMPLE PKC31 
(CH3)zCH(CH2)zCO-Abu-COOEt. This was pre-
pared by the preceding general procedure. Purification 
53 
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by flash chromatography on silica gel, eluent AcOEt, 
yield 43%, oil, single spot on TLC, Rp0.56, C. Mass 
spectrum EI-MS M/Z 257 (M+); FB-MS, 
[(M+ 1)/Z]=258. 
EXAMPLE PKC32 
EXAMPLE PKC40 
Z-Leu-NLeu-C02Et. This compound was prepared 
by the above procedure. Pale yellow oil, single spot on 
5 TLC, Rp0.57 (CHCl3:CH30H=50:1), yield 53% 
(from dipeptide), MS (FAE) 434(m+1). 
CH3CH2CH)2CHCO-Abu-COOEt. This was pre-
pared by the preceding general procedure. Purification 
by flash chromatography on silica gel, eluent 
CHC1J;Me0H=50:1 v/v, thick, yellowish oil, yield 10 
66%, single spot on TLC, Rp0.80, C; 0.66, M. Mass 
spectrum El-MS M/Z=285 (M+); CI-MS, 
[(M+ 1)/Z]=286. 
EXAMPLE PKC41 
Synthesis of n-Butyl Oxalyl Chloride. This was pre-
pared by a literature procedure (Warren and Malee, J. 
Chromat. 64, 219-222 (1972)]. N-Butanol (0.1 mol. 7.41 
g) was added dropwise to oxalyl chloride (0.5 mol. 63.5 
g) at -10° C. After the addition was completed, the 
reaction mixture was stirred for 20 min. at r. t. and dis-
EXAMPLE PKC33 15 tilled, giving 15.0 g (91.18 mol. 91%) of the product 
n-butyl oxalyl chloride, bp 58°-60° C. (0.6 mm Hg). Ph(CH2)6CO-Abu-COOEt. This was prepared by the 
preceding general procedure. Purification by flash 
chromatography on silica gel, eluent 
CHCl3:Me0H=50:1 v/v, yield 64%, pale yellow oil, 20 
single spot on TLC, Rp0.29, M. Mass spectrum 
EI-MS M/Z=347 (M+), FB-MS, [(M+l)/Z]=348. 
EXAMPLE PKC34 
Z-Leu-Phe-C02Bu. This compound was prepared 
from Z-Leu-Phe-OH and butyl oxalyl chloride in 43% 
yield by the procedure described for the synthesis of 
Z-Leu-Phe-C02Et, except that butyl oxalyl chloride 
was used in place of ethyl oxalyl chloride and sodium 
butyloxide in butanol was used for enol ester hydrolysis. 
Single spot on TLC, Rp0.54 (CHCl3:CH30H=50:1) 
MS(FAB) m/e=497(m+1), lH NMR (CDCb) ok. 
EXAMPLE PKC42 
Z-Leu-4-Cl-Phe-COOEt. This was prepared by the 25 
preceding general procedure. Purification by flash 
chromatography on silica gel, eluent AcOEt, yield 
100%, colorless oil, single spot on TLC, Rp0.71, C. 
Mass spectrum FB-MS M/Z=503(M+). 
Z-Leu-Abu-C02Bu. This compound was prepared by 
the above procedure. Single spot on TLC, Rp0.53 
(CHCh:CH30H=50:1), yield=36%, pale yellow oil, 
30 MS (FAB) m/e=435 (M+ 1), lH NMR (CDCb) ok. 
EXAMPLE PKC35 
Z-Leu-Leu-Abu-COOEt. This was prepared by the 
preceding general procedure. Purification by flash 
chromatography on silica gel, eluent 
CHC13:Me0H=50:1 v/v, yield 79.2%, very thick, col- 35 
orless oil, single spot on TLC, Rp0.28. M. Mass spec-
trum FB-MS, [(M+ 1)/Z]=520. 
EXAMPLE PKC36 
Z-Leu-Leu-Phe-COOEt. This was prepared by the 40 
preceding general procedure. Purification by flash 
chromatography on silica gel, eluent 
CHCl3:Me0H=50:1 v/v, yield 33%, oil, single spot on 
TLC, Rp0.56, M. Mass spectrum, FB-MS, 
[(M+l)/Z]=582. 45 
EXAMPLE PKC37 
2-NapS02-Leu-Abu-COOEt. This was prepared by 
the preceding general procedure. Purification by flash _0 
chromatography on silica gel, eluent ' 
EXAMPLE PKC43 
Synthesis of Benzyl Oxalyl Chloride. Benzyl alcohol 
(0.15 mol. 16 g) was added dropwise to oxalyl chloride 
(0. 75 mol. 95 g) at 5° -10° C. After the addition was 
complete, the reaction was stirred for 20 min. at r.t. The 
excess oxalyl chloride was distilled and recycled. Then 
the mixture was distilled under vacuo, giving 26 g (0.12 
mol. 86%) ofbenzyl oxalyl chloride, bp. 110°-112° C. 
(0.6 mm-Hg). H1NMR (CDCl3) 7.39 (s, SH), 5,33 
(s.2H). 
Z-Leu-Phe-C02Bzl. This compound was prepared 
from Z-Leu-Phe-OH and benzyl oxalyl chloride in 17% 
yield by the procedure described in the synthesis of 
Z-Leu-Phe-C02Et, except that benzyl oxalyl chloride 
was used in place of ethyl oxalyl chloride and sodium 
benzyloxide in benzyl alcohol was used for enol ester 
hydrolysis. Single spot on TLC, Rp0.63 
(CHCl3:CH30H=50:1). Pale yellow solid, mp 
117°-119° C. MS(FAB) m/e=532(m+1). HlNMR ok. 
EXAMPLE PKC44 CHCl3:Me0H=50:1 v/v, yield 38%, thick oil, single 
spot on TLC, Rp0.71, K; 0.54, A. Mass spectrum 
FB-MS, [(M+ 1)/Z]=463. 
EXAMPLE PKC38 
2-NapS02-Leu-Leu-Abu-COOEt. This was prepared 
Z-Leu-Abu-C02Bzl. This compound was prepared 
by the above procedure. Single spot on TLC. Rp0.51 
55 (CHCb:CH30H=50:1), pale yellow oil, MS(FAB) 
m/e=469 (m+ 1), yield=26%. 
by the preceding general procedure. Purification by 
flash chromatography on silica gel, eluent AcOEt-
:AcOH = 200: l v/v, yield 61%, semi-solid, single spot 60 
on TLC, Rp0.67, K. Mass spectrum FB-MS, 
[(M+ l)/Z]=576. 
EXAMPLE PKC39 
EXAMPLE PKC45 
Z-Leu-Phe-COOH. Dipeptide Ketoacids (General 
Procedure). To a stirred solution of0.53 g (1,13 mmol) 
Z-Leu-Phe-COOEt in 6.0 ml methanol was added 1.27 
ml (1.27 mmol) lM NaOH. The color of the reaction 
mixture turned dark yellow and a small amount of solid 
was deposited. The reaction was run at room tempera-
Z-Leu-Met-C02Et. This compound was prepared by 
the above procedure. Yellow oil, single spot on TLC, 
Rp0.52 (CHCb:CH30H=50:), yield 46% (from di-
peptide), MS (FAB) 454 (m+l). 
65 ture and progress of the hydrolysis was checked on 
TLC. After 24 h. no more substrate was detected. The 
reaction mixture was chilled in one ice bath at 5° C., 
acidified with IM HCl to pH=3 and extracted with 
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AcOEt (2X50 mL). The organic extract were washed 
with 2 X 50 ml H20 and if necessary, decolorized with 
carbon and dried over MgS04. After evaporation of the 
solvent (rotavaporator), the residue (thick oil) were 
titurated with 2 X 25 ml n-hexane and dried in vacuo. 5 
Yield 0.39 g (78%) of colorless, very thick oil. TLC, 
main spot at Rj=0.24, trace of impurity at Rj=0.78, I. 
Mass spectrum, FB-MS [(M+ 1)/Z]=441. 
EXAMPLE PKC46 10 
56 
solid. Chromatography on a silica gel column with 
CHC13/CH30H (30:1 v/v) afford 0.63 g (y=75%) of 
Z-Leu-Phe-CONH-Et. The product was a pale yellow 
solid. Single spot on TLC, Rr-0.60 (CHCl3/CH30H 
20:1); mp 145°-147° C. Anal. calcd. for C26H33N305: 
467.56; C, 66.79; H, 7.11; N,8.99; found: C, 66.59; H, 
7.09; N, 8.95. NMR (CDCl3) ok. MS (FAB) m/e=468 
(M+l). 
EXAMPLE PKC48 
Z-Leu-Phe-CONH-nPr. This compound was synthe-
sized from the protected a-ketoester and propylamine 
in 92% yield by the procedure described in Example 
Z-Leu-Abu-COOH. This compound was prepared 
from Z-L-Leu-Abu-COOEt in 83% yield by the general 
procedure as described above; TLC, main spot at 
Rj=0.14, trace of impurity at Rj=0.73, I. Mass spec-
trum, FB-MS [(M+l)/Z]=379. 15 PKC47. Single spot on TLC, Rr-0.50 
EXAMPLE PKC47 
Z-Leu-Phe-CONH-Et. To a stirred solution of Z-
Leu-Phe-OH (20 g, 48.S mmole), 4-dimethylaminopyri-
dine (0.587 g, 4.8 mmole), and pyridine (15.7 ml, 194 20 
mmole) in anhydrous THF (100 ml) was added ethyl 
oxalyl chloride (11.4 ml, 101.8 mmole) at a rate suffi-
cient to initiate refluxing. The mixture was gently re-
fluxed for 4 hours, cooled to room temperature, and 
water (80 ml) was added. The reaction mixture was 25 
stirred vigorously for 30 min, and extracted with ethyl 
acetate (3 X 100 ml). The combined organic layers were 
washed with water (2X 100 ml), saturated sodium chlo-
ride (2 X 100 ml), decolorized with decolorizing carbon, 
dried over magnesium sulfate, and concentrated, leav- 30 
ing a dark orange oil. Chromatography on a silica gel 
column with CHCb/CH30H (50:1 v/v) afforded 14.63 
g (y=53%) of Z-Leu-Phe-enolester. The product was a 
yellow oil. Single spot on TLC, Rr-0.77 
(CHCL3/CH30H 50:1). NMR (CDCb) ok. 35 
To a stirred pale yellow solution of the Z-Leu-Phe-
enolester (14.63 g, 25.73 mmole) in anhydrous ethanol 
(SO ml) was added a solution of sodium ethoxide (0.177 
g, 2.6 mmole) in ethanol (S ml). The orange solution was 
stirred for 3 hours at room temperature, then the etha- 40 
nol was evaporated and the residue was treated with 
ethyl ether (300 ml). The ether layer was washed with 
(CHCl3/CH30H 50:1); mp 152°-153° C. Anal. calcd. 
for C27H35N305: 481.57; C, 67.33; H, 7.33; N, 8.72. 
Found: C, 67.21; H, 7.38; N, 8.64. NMR (CDCl3) ok. 
MS (FAB) m/e=482(M+1). 
EXAMPLE PKC49 
Z-Leu-Phe-CONH-nBu. This compound was synthe-
sized from the protected a-ketoester and butylamine in 
67% yield by the procedure described in Example 
PKC47. Single spot on TLC, 
Rj=0.50.(CHCIJ/CH30H 50:1); mp 152°-153° C. Anal. 
calcd. for C2sH37N305: 495.59; C, 67.85; H, 7.52; N, 
8.48. Found: C, 67.70; H, 7.57; N, 8.43. NMR (CDCl3) 
ok. MS (FAB) m/e=496 (M+ 1). 
EXAMPLE PKC50 
Z-Leu-Phe-CONH-iBu. This compound was synthe-
sized from the protected a-ketoester and isobutylamine 
in 53% yield by the procedure described in Example 
PKC47. Single spot on TLC, Rr-0.54 
(CHCl3/CH30H 50:1); mp 152° C. Anal. calcd. for 
C2sH37N30s: 495.59; C, 67.85; H, 7.52; N, 8.48. Found: 
C, 67.77; H, 7.56; N, 8.40. NMR (CDCl3) ok. MS (FAB) 
m/e=496 (M+ 1). 
EXAMPLE PKCSl 
water (2X 100 ml), saturated sodium chloride (2X 100 Z-Leu-Phe-CONH-Bzl. This compound was synthe-
ml), dried over magnesium sulfate, and concentrated, sized from the protected a-ketoester and benzylamine 
leaving a orange oil. Chromatography on a silica gel 45 in 40% yield by the procedure described in Example 
column with CHCl3/CH30H (50:1 v/v) afforded 7.76 g PKC47. After reacting overnight, ethyl acetate (60 ml) 
(y=64%) of the a-ketoester Z-Leu-Phe-COOEt. The was added. The mixture was filtered to remove a white 
product was a yellow oil. Single spot on TLC, Rr-0.44 precipitate. The solution was washed with cooled IN 
(CHCl3/CH30H 50:1). NMR (CDCl3) ok. MS (FAB, HCl (3X25 ml), water (1X20 ml), saturated sodium 
calcd. for C26H32N206: 468.6), m/e=469(M+1). 50 chloride (2X20 ml), and dried over magnesium sulfate. 
The a-carbonyl group of Z-Leu-Phe-COOEt was The solution was evaporated leaving a yellow solid. 
protected by following procedure. A solution of Z-Leu- Chromatography on a silica gel column with 
Phe-COOEt (1 g, 2.13 mmole) in S ml of CH2Clz was CHCl3/cH3QH 30:1 v/v) afforded a yellow solid. Sin-
added 1,2-ethanedithiol (0.214 ml, 2.55 mmole), fol- gle spot on TLC, Rr-0.45 (CHc13;cH3QH 30:1); mp lowed by 0.5 ml of boron trifluoride etherate. The solu- 55 160o_162o c. Anal. calcd. for c 31H 35N3o5: 529.61; c, tion was stirred overnight at room temperature. Water 6 (20 1) d h 1 h ( 0 ml) dd d Th . 70.30; H, 6.66; N, 7.93. Found: C, 70.18; H, 6. 7; N, 7.99. m an et yet er 2 were a e . eorgan1c NMR (CDCb) ok. MS (FAB) m/e=S30 (M+l). 
layer was separated, washed with water (2 X 10 ml), 
saturated sodium chloride (2X 10 ml), dried over mag-
nesium sulfate, and evaporated to afford 0.98 g 60 
(y=84%) yellow semisolid. 
The protected a-ketoester (0.98 g, 1.8 mmole) was 
dissolved in ethanol (5 ml), cooled to 0° -5° C. in a ice 
bath, and ethylamine was bubbled through the solution 
until 2.43 g (54 mmole) had been added. The reaction 65 
mixture was allowed to warm to room temperature 
slowly, and stirred overnight. The mixture was filtered, 
a white precipitate was removed, leaving a yellow semi-
EXAMPLE PKC52 
Z-Leu-Phe-CONH-(CH2)2Ph. This compound was 
synthesized from the protected a-ketoester and phen-
ethylamine in 50% yield by the procedure described in 
Example PKC51. Single spot on TLC, Rr-0.50 
(CHCl3/CH30H 30:1); mp 151°-153° C. Anal. calcd. 
for C32H37N305: 543.66; C, 70.70; H, 6.86; N, 7.73. 
Found: C, 70.54; H, 6.88; N, 7.74. NMR (CDCb) ok. 
MS (FAB) m/e=544(M+1). 
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EXAMPLE PKC53 
58 
was washed with water (3 X 20 ml), saturated sodium 
chloride (2 X 20 ml), and dried over magnesium sulfate. 
The solution was evaporated leaving a yellow oil. 
Chromatography on a silica gel column with 
Z-Leu-Abu-CONH-Et. This compound was synthe-
sized from protected a-ketoester derived from Z-Leu-
Abu-C02Et and ethylamine in 64% yield by the proce-
dure described in Example PKC47. Single spot on 
TLC, Rp0.36 (CHCl3/CH30H 50;1); mp 130°-132° C. 
Anal. calcd. for C21H31N305: 405.45; C, 62.20; H, 7.71; 
N, 10.36. Found: C, 61.92; H, 7.62; N, 10.31. NMR 
(CDCl3) ok. MS (FAB) m/e=406(M+1). 
5 CHC]}/CH30H (10:1 v/v) afforded a yellow semisolid, 
which was recrystallized from ethyl acetate/hexane to 
obtain a pale yellow solid. Single spot on TLC, 
Rp0.42 (CHCl3/CH30H 10:1); mp 125°-126° C. Anal. 
EXAMPLE PKC54 
10 calcd. for C26H40N406: 504.63; C, 61.88; H, 7.99; N, 11.10. Found: C, 61,69; H, 7.95; N, 11.07. NMR 
(CDCl3) ok. MS (FAB) m/e=505(M+1). 
EXAMPLE PKC60 
Z-Leu-Abu-CONH-(CH2)1CH3. This compound 
was synthesized from the corresponding protected a-
ketoester and octylamine in 67% yield by the procedure 
described in Example PKC51. It was white solid. Single 
spot on TLC, Rp0.55 (CHCl3/CH30H 30:1); mp 
Z-Leu-Abu-CONH-nPr. This compound was synthe-
sized from the corresponding protected a-ketoester and 
propylamine in 47% yield by the procedure described 15 
in Example PKC47. Single spot on TLC, Rp0.28 
(CHCl3/CH30H 50:1); mp 134°-135 ° C. Anal. calcd. 
for C22H33N305: 419.50; C, 62.98; H, 7.93; N 10.02. 
Found: C, 62.84; H, 7.97; N, 9.94. NMR (CDCl3) ok. 
MS (FAB) m/e=420(M+1). 20 134°-135° C. Anal. calcd. for C21H43N305: 489.66; C, 
66.23; H, 8.85; N, 8.58. Found: C, 66.19; H, 8.81; N, 8.61. 
NMR (CDCb) ok. MS (FAB) m/e=490(M+1). EXAMPLE PKC55 
Z-Leu-Abu-CONH-nBu. This compound was syn-
thesized from the corresponding protected a-ketoester 
and butylamine in 42% yield by the procedure de- 25 
scribed in Example PKC47. Single spot on TLC, 
Rp0.54 (CHCl3/CH30H 50:1); mp 135°-136° C. Anal. 
calcd. for C23H35N305: 433.53; C, 63.71; H, 8.13; N, 
9.69. Found: C, 63.48; H, 8.07; N, 9.67. NMR (CDCl3) 
ok. MS (FAB) m/e=434(M+1). 30 
EXAMPLE PKC56 
Z-Leu-Abu-CONH-iBu. This compound was synthe-
sized from the corresponding protected a-ketoester and 
isobutylamine in 65% yield by the procedure described 35 
in Example PKC47. Single spot on TLC, Rp0.25 
(CHCl3/CH30H 50:1); mp 133°-135° C. Anal. calcd. 
for C23H35N305: 433.52; C, 63.72; H, 8.14; N, 9.69. 
Found: C, 63.46; H, 8.10; N, 9.60. NMR (CDCl3) ok. 
MS (FAB) m/e=434 (M+l). 40 
EXAMPLE PKC57 
EXAMPLE PKC61 
Z-Leu-Abu-CONH-(CH2)20H. This compound was 
synthesized from the corresponding protected a-keto-
ester and ethanolamine in 29% yield by the procedure 
described in Example PKC59. The product was a white 
sticky solid. Single spot on TLC, R1-0.42 (CHCl3/CH30H 10:1); mp 151°-153° C. Anal: calcd. 
for C21H31N306: 421.49; C, 59.84; H, 7.41; N, 9.97. 
Found: C, 59.11; H, 7.44; N, 9.81. NMR (CDCl3) ok. 
MS (FAB) m/e=422(M+1). 
EXAMPLE PKC62 
Z-Leu-Abu-CONH-(CH2)zO(CH2)20H. This com-
pound was synthesized from the corresponding pro-
tected a-ketoester and 2-(2-aminoethoxy)ethanol in 
34% yield by the procedure described in Example 
PKC59. The product was white sticky solid. Single spot 
on TLC, Rp0.42(CHC1}/CH30H10:1); mp 103°-105° 
C. Anal.: calcd. for C23H35N307: 465.55; C, 59.34; H, 
7.58; N, 9.03. Found: C, 59.23; H, 7.58; N, 9.01. N1vIR 
CDCb) ok. MS (FAB) m/e=466(M+1). 
EXAMPLE PKC63 
Z-Leu-Abu-CONH-(CH2)17CH3. This compound 
was synthesized from the corresponding protected a-
Z-Leu-Abu-CONH-Bzl. This compound was synthe-
sized from the corresponding protected a-ketoester and 
benzylamine in 29% yield by the procedure described in 45 
Example PKC51. Single spot on TLC, Rp0.56 
(CHCl3/CH30H 30:1); mp 140°-141° C. Anal. calcd. 
for C26H33N305: 467.54; C, 66.79; H, 7.11; N, 8.99. 
Found: C, 66.65; H, 7.07; N, 8.93. NMR (CDCb) ok. 
MS (FAB) m/e=468(M+1). 50 ketoester and octadecylamine in 12% yield by the pro-
cedure described in Example PKC51. The product was 
a pale yellow solid. Single spot on TLC, Rp0.54 
(CHCl3/CH30H 30:1); mp 134°-136° C. Anal: calcd. 
EXAMPLE PKC58 
Z-Leu-Abu-CONH-(CH2)2Ph. This compound was 
synthesized from the corresponding protected a-keto-
ester and phenethylamine in 51 % yield by the proce- 55 
dure described in Example PKC5 l. Single spot on 
TLC, Rp0.44 (CHC1}/CH30H 30:1); mp 156°-157° C. 
Anal. calcd. for C21H35N305: 481.59; C, 67.34; H, 7.33; 
N, 8.72. Found: C, 67.38; H, 7.33; N, 8.78. NMR 
(CDCb) ok. MS (FAB) m/e=482(M+1). 
EXAMPLE PKC59 
60 
Z-Leu-Abu-CONH-(CH2)3-N(CH2CH2)20. This 
compound was synthesized from protected a-ketoester 
and 4(3-aminopropyl)morpholine in 33% yield by the 65 
procedure described in Example PKC47. After reacting 
overnight, ethyl acetate (80 ml) was added. The mixture 
was filtered to remove a white precipitate. The solution 
for C31H63N305: 629.92; C, 70.55; H, 10.08; N, 6.67. 
Found: C, 70.71; H, 10.14; N, 6.75. NMR (CDC!}) ok. 
MS (FAB) m/e=630.2(M+1). 
EXAMPLE PKC64 
Z-Leu-Abu-CONH-CH2-C6H3(0CH3)2. This 
compound was synthesized from the corresponding 
protected a-ketoester and 3,5-dimethoxybenzylamine in 
45% yield by the procedure described in Example 
PKC51. The product was yellow sticky solid. Single 
spot on TLC, Rp0.44 (CHCl3/CH30H 30:1); mp 
153°-155° C. Anal.: calcd. for C2sH37N307: 527.62; C, 
63.74; H, 7.07; N, 7.96. Found: C, 63.66; H, 7.09; N, 7.92. 
NMR (CDCJ3) ok. MS (FAE) m/e=528.8 (M+l). 
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EXAMPLE PKC65 ycarbonyl (Boe). The diazomethyl ketone is prepared by reaction of diazomethane with the appropriate acid 
activated by means of dicyclohexylcarbodiimide 
(DCCI), by the mixed anhydride method. 
Unblocked amino acid chloromethyl ketones can be 
prepared by reaction of benzyloxycarbonyl blocked 
derivatives with HBr or HOAc, trifluoroacetic acid, or 
by hydrogenation. 
Synthesis of peptide chloromethyl ketones can be 
Z-Leu-Abu-CONH-CH2-C4H4N. This compound 
was synthesized from the corresponding protected a-
ketoester and 4-(aminomethyl)pyridine in 45% yield by 5 
the procedure described in Example PKC59. The prod-
uct was greenish yellow solid. Single spot on TLC, 
Rp0.55 (CHCl3/CH30H 10:1); mp 124°-126° C. Anal: 
calcd. for C2sH32N405: 468.55; C, 64.08; H, 6.88; N, 
11.96. Found: C, 63.88; H, 6.87; N, 11.96. NMR 
(CDCb) ok. MS (FAB) m/e=469 (M+l). 
10 accomplished simply by coupling an appropriate pep-
tide or amino acid with an unblocked amino acid chlo-
romethyl ketone. A few dipeptides can be converted 
directly to the chloromethyl ketone using the mixed 
D. HALO-KETONE PEPTIDES 
Halomethyl ketone peptides are irreversible inhibi-
tors for serine proteases and cysteine proteases. This 
class of compounds includes peptides having a variety 15 
of halomethyl groups at their C-terminus. These halo-
methyl groups include -CH2X, -CHX2 and CX3, 
where X represents any halogen. A number of analo-
gous compounds have been synthesized, including the 
amino-halo ketones and the diazo-ketone peptides. Al- 20 
though these analogous compounds are chemically 
distinguishable, all of these haloketone compounds are 
believed to have a similar mechanism of action. Accord-
ingly, for simplicity, all of the foregoing compounds 
will be referred to collectively herein as the "Halo- 25 
Ketone Peptides." 
The reactivity of haloketones has generally been 
found to be in the order l>Br>Cl>F. However, in-
creasing the reactivity of the haloketone in this way can 
lead to acceleration of competing side effects. Thus, it is 30 
preferable to increase the reactivity of the halomethyl 
ketone peptides by altering the peptide structure. 
In selecting a proper inhibitor for Calpain, the same 
basic peptide structure selection techniques as used for 
the Peptide Keto-Compounds can be used. Once a pep- 35 
tide structure has been identified, the most effective 
C-terminus grouping can be empirically determined 
through kinetic inhibition studies of each of the com-
pounds with Calpain. 
Many of the Halo-Ketone Peptides are available com- 40 
mercially. For example, Leu-CH2Cl, Phe-CH2Cl, Z-
lys-CH2Cl, Tosyl-LysCH2Cl (TLCK), Tosyl-
PheCH2Cl (TPCK), Z-Gly-Leu-Phe-CH2Cl, Z-Phe-
Ala-CH2Cl, z-Phe-Phe-CH2Cl, D-Phe-Pro-Arg-
CH2Cl, Me0Suc-Phe-Gly-Gly-Ala-CH2Cl, MeoSuc- 45 
Ala-Ala-Pro-Ala-CH2Cl, Me0Suc-Ala-Ala-Pro-Val-
CH2Cl, Ala-Ala-Pro-Val-CH2Cl, Ala-Ala-Phe-CH2Cl, 
Suc-Ala-Ala-Pro-Phe-CH2Cl and D-Val-Leu-Lys-
CH2Cl are all available from suppliers such as Enzyme 
Systems Products of Livermore, Calif. From the same 50 
suppliers, the following diazomethyl ketone peptides 
are available: Leu-CHN2, Z-Phe-Phe-CHN2, Z-Phe-
Ala-CHN2, Z-Phe-Pro-CHN2, Z-Lys-CHN2 and Gly-
Phe-CHN2. In addition, the production of a-amino 
fluoro ketone peptides has been described in U.S. Pat. 55 
No. 4,518,528 to David W. Rasnick, the disclosure of 
which is hereby incorporated by this reference. 
The preparation of various Halo-Ketone Peptides is 
reviewed in Methods in Enzymology, 46:197-208 (1977), 
the disclosure of which is hereby incorporated by refer- 60 
ence. Briefly, halomethyl ketone derivatives of blocked 
amino acids are readily prepared by the reaction of 
mineral acids (hydrohalic) with the corresponding 
diazomethyl ketone. Iodomethyl ketones are prepared 
by reaction of a halo-ketone with Nal, since reaction 65 
with HI with a diazomethyl ketone yields the methyl 
ketone. A number of different blocking groups can be 
used, including benzyloxycarbonyl (Z) and t-butylox-
anhydride and CH2N2 followed by HCI. 
Various synthetic problems are encountered in the 
preparation of chloromethyl ketone derivatives of basic 
amino acids. The side chain usually must be blocked 
during synthesis, and difficulties are often encountered 
during removal of the blocking group. Use of trifluoro-
acetic acid or HF was eventually found to give a good 
conversion to product. 
A number of examples of the preparation of Halo-
Ketone Peptides have been reported in the literature, 
including a comprehensive review of over 100 amino 
acid derivatives and approximately 60 peptide deriva-
tives listed in J. C. Powers, in "Chemistry and Biochem-
istry of Amino Acids, Peptides and Proteins," Vol. 4, 
Dekker, N.Y. (1977), the disclosure of which is hereby 
incorporated by reference. Those of skill in the art will 
recognize how to locate a multitude of examples of the 
production of the Halo-Ketone Peptides. Accordingly, 
no additional examples are provided herein. 
E. IN VITRO USES 
In addition to the foregoing classes of compounds 
now discovered to possess Calpain inhibitory activity, 
we believe that a large number of other such com-
pounds exist. In view of the large number of inhibitors 
of Calpain of different classes we disclose herein, all of 
the known, newly discovered and yet undiscovered 
inhibitors of Calpain shall be referred to hereinafter 
collectively, using the term "Calpain Inhibitor." 
The Calpain Inhibitors may be used in vitro for a 
variety of purposes to inhibit unwanted Calpain activ-
ity. For example, the Calpain Inhibitors may be used in 
vitro to prevent proteolysis that occurs in the process of 
production, isolation, purification, storage or transport 
of peptides and proteins. 
The Calpain Inhibitors described herein can also be 
used in vitro to prevent further degradation of tissue 
samples from occurring after preparation of the sam-
ples. This in vitro prevention of degradation can be 
especially useful in the preparation of assays for neu-
rodegeneration wherein the assay comprises a test for 
the products of Calpain activity in the tissues, such as 
assays for breakdown products (BDP's) of cytoskeletal 
components such as spectrin, MAP2, actin binding pro-
tein and tau. P. Seubert et al., in Neuroscience, 31:195 
(1989), the disclosure of which is hereby incorporated 
by reference, disclose an exemplary method of quanti-
tating the amount of spectrin BDP's as an indication of 
Calpain activity. 
The Calpain Inhibitors of this invention are also use-
ful in a variety of other experimental procedures where 
proteolysis due to Calpains is a significant problem. For 
example, inclusion of the Cal pain Inhibitors in radioim-
munoassay experiments can result in higher sensitivity. 
The use of the Calpain Inhibitors in plasma fraction-
ation procedures can result in higher yields of valuable 
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plasma proteins and can make purification of the prote-
ins easier. The Calpain Inhibitors disclosed here can be 
used in cloning experiments utilizing recombinant or 
transfected bacterial or eukaryotic cell cultures in order 
to increase yield of purified recombinant product. 
To use the Calpain Inhibitors in vitro, the Calpain 
Inhibitors are dissolved in an organic acid, such as di-
methylsulfoxide (DMSO) or ethanol, and are added to 
and the amount of acid-soluble radioactivity released by 
the action of Calpain was measured. The ICso values 
were determined as the concentration of Heterocyclic 
Compound compound at which 50% of the Calpain 
5 
activity was inhibited. Table IA shows ICso values for 
various Isocoumarin Compounds. 
an aqueous solution containing the protease which is to 
be inhibited, such that the final concentration of organic 10 
solvent is 25% or less. The Calpain Inhibitors may also 
be added as solids or in suspension. 
F. TREATMENT OF NEURODEGENERA TION 
We have discovered that the Calpain Inhibitors are 
useful in vivo to treat pathologies in which excess prote- 15 
olysis by Calpains is involved. Such pathologies are 
believed to include neuropathologies such as neurode-
generation resulting from excitotoxicity, HIV-induced 
neuropathy, ischemia, denervation, injury, subarach-
noid hemorrhage, stroke, multiple infarction dementia, 20 
Alzheimer's Disease (AD), Huntington's Disease, surg-
ery-related brain damage, Parkinson's Disease, and 
other pathological conditions. 
1. Identification of Inhibitors 
In order to identify Calpain Inhibitors that are useful 25 
in the practice of the present invention for treatment or 
inhibition ofneurodegenerative conditions and diseases, 
it is important to identify those inhibitors posessing 
significant Calpain inhibitory activity. It is also impor-
tant to identify those Calpain Inhibitors having a high 30 
degree of specificity for inhibition of Calpain, in order 
to avoid interference with other biological processes 
when the Calpain Inhibitor is introduced into a mammal 
requiring treatment for neurodegeneration. Because all 
thiol proteases are believed to exert their effect through 35 
a similar mechanism of action, our primary concern was 
to identify those Calpain Inhibitors having substantial 
inhibitory activity against Calpain, but relatively weak 
or no activity against other thiol proteases. Accord-
ingly, in order to identify such Calpain Inhibitors, we 40 
tested a variety of Calpain Inhibitors for their ability to 
inhibit calpains I and II, and compared this data with 
the ability of the same Calpain Inhibitors to inhibit Ca-
thepsin B, another thiol protease. Those Calpain Inhibi-
tors with high in vitro inhibitory activity against Cal- 45 pain and a relatively lower activity against Cathepsin B 
are believed to be most useful for in vivo therapy. Ex-
amples lA through IC show the results of these studies 
for a variety of Calpain Inhibitors. 
EXAMPLE IA 50 
Inhibition by Substituted Heterocyclic Compounds 
The isocoumarins are irreversible inhibitors of Cal-
pain. We obtained ICso values for a variety of these 
Calpain Inhibitors as a kinetic analysis of these com- 55 
pounds. Purified Calpains can be assayed using the 
fluorogenic substrate succinyl-leucine-tyrosine-
methylaminocoumarin (available commercially) or by 
measuring the release of acid-soluble peptides from 
casein because we have found that the isocoumarins 60 
inhibit casein proteolysis by Calpain. 
Calpains I and II were purified by the method of 
(Yoshimura, et al. 1983). (Kitahara 1984) provides an 
alternative purification scheme. Calpain II may alterna-
tively be purchased from Sigma Chemical Co. as "Cal- 65 
cium Activated Neutral Protease." In this assay, puri-
fied Calpain was incubated with 14C-methylated casein 
in the presence of various Heterocyclic Compounds 
TABLElA 
INHIBITION OF CALPAINS 
BY SUBSTITUTED ISOCOUMARINS 
ICso(µM) 
Calpain I Calpain II 
CiTprOIC 100 70 
NH2-CiTPrOIC (ACITIC) IO 120 
PhCH2NHCONH-CiTPrOIC 80 30 
CH3CONH-CiTPrOIC 700 80 
L-Phe-NH-CiTPrOIC 30 
BOC-L-Phe-NH-CiTPrOIC no inhibition >200 
PhCH2NHCONH-CiTEtOIC 90 
PhCH2CONH-CiTEtOIC 30 
D-Phe-NH-CiTEtOIC 200 
Thus, it can be seen from Table IA that a variety of 
the Isocoumarin Compounds have significant Calpain 
inhibitory activity at low concentrations. 
EXAMPLE lB(i) 
Protease Inhibition by Peptide Keto-Compounds 
The Peptide Keto-Compounds are reversible inhibi-
tors of Calpains and other thiol proteases. The K;values 
for the inhibition of calpain I, calpain II and Cathepsin 
B were determined for several Peptide Keto-Com-
pounds, Inhibition of calpain I from human erythro-
cytes and calpain II from rabbit muscle were assayed 
using Suc-Leu-Tyr-amidomethylcoumarin as substrate 
in an assay buffer of 20 mM HEPES pH=7.2, 10 mM 
CaC}z, 10 mM ,B-mercaptoethanol. Cathepsin B from 
bovine spleen was assayed using Z-Lys-4-nitrophenyl-
phosphate as substrate. 
Table lB(i) shows the results of the studies of Exam-
ple lB(i). The Ki value for the inhibition of Calpains 
and cathepsin B by several Peptide Keto-Compounds 
are shown in µM (micromolar). The values for leupep-
tin, which is commercially available from Calbiochem 
of La Jolla, Calif., are shown for comparison. 
TABLE 1B(i) 
Kj VALUES FOR PEPTIDE KETO-COMPOUNDS 
Inhibitor Calpain I Calpain II Cathepsin B 
Leupeptin 0.32 0.43 6 
Z-Ala-Ala-Ala-C02Me 200 1.5 
Z-Ala-Ala-Abu-C02Et 50 200 0.9 
Z-Leu-Phe-C02Et 0.23 0.4 >50 
Z-Leu-Nie-C02Et 0.12 0.18 18 
Z-Leu-Abu-C02Et 0.04 0.4 14 
Z-Leu-Nva-COOEt 1.2 30 
It can be seen from the results in Table IB(i) that the 
Peptide Keto-Compounds inhibit Calpain with Ki val-
ues similar or superior to leupeptin. In particular, Z-
Leu-Phe-C02Et, Z-Leu-Nle-C01Et and Z-Leu-Abu-
C02Et were found to possess greater Calpain inhibitory 
activity than leupeptin. In addition, these particular 
compounds were highly specific to Calpain, with lower 
inhibitory activity toward Cathepsin B than leupeptin. 
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EXAMPLE lB(ii) PhCH2NHCS- would also result in good inhibitor structures. 
Protease Inhibition of Peptide Keto-Compounds EXAMPLE lB(iii) 
We tested the ability of an additional group of Pep-
5 Stability of Peptide Keto-Compounds tide Keto-Compounds to inhibit several proteases in 
order to evaluate their specificity for Calpain. The re- We determined the haft-life of several Peptide Keto-
sults of these studies are shown in Table lB(ii). Compounds in both plasma and liver homogenates. The 
TABLE lB(ii) 
Inhibition of Ca!Eain I, Ca!Eain II, CatheEsin B, PP Elastase and PaEain 
K 
elasta 
Inhibitor Calpain I Calpain II CathB Chym se pa pain 
Z-Leu-Abu-COOEt 4.5 0.4 30 >100 >100 220 
Z-Leu-Abu-COOnBu 1.8 4 >100 25 10 
Z-Leu-Abu-COOBz 9.5 0.47 4 40 >100 40 
Z-Leu-Leu-Abu-COOEt 1.8 2.6 22 >100 25 
2-NapSOz-Leu-Leu-Abu-COOEt 16 1.4 25 35 47 
2-NapCO-Leu-Leu-Abu-COOEt 0.09 >300 28 
Tos-Leu-Leu-Abu-COOEt 33 69 25 28 
Ph-(CH3)2-CO-Leu-Abu-COOEt 1.2 
Z-Leu-Abu-COOH 0.075 0.022 1.5 >150 >150 
Z-Leu-Abu-CONHEt 0.5 0.23 2.4 >150 65 
Z-Leu-Abu-CONHnPr 0.25 8 >300 2 
Z-Leu-Abu-CONHnBu 0.2 13 >300 5 
Z-Leu-Abu-CONHiBu 0.14 4 >300 40 
Z-Leu-Abu-CONHBz 0.35 2 >300 
Z-Leu-Abu-CONH-(CH2)2-Ph 0.022 
Z-Leu-Abu-CONH-(CH2)3-Mpl 0.041 
Z-Leu-Abu-CONH-(CH2)7CH3 0.019 
Z-Leu-Abu-CONH-(CHz)zOH O.D78 
Z-Leu-Abu-CONH- 0.16 
(CH2)zO(CH2)20H 
Z-Leu-Phe-COOEt 1.8 0.4 340 0.025 >100 75 
Z-Leu-Phe-COOnBu 5.0 !.I 15 0.15 >100 15 
Z-Leu-Phe-COOBz 3.4 1.6 45 1.6 >100 45 
Z-Leu-Leu-Phe-COOEt 1.4 1.9 42 0.26 >100 15 
Z-Leu-Phe-COOH 0.0085 0.0057 4.5 76 >150 
Z-Leu-Phe-CONHEt 7.0 0.32 6 73 >150 
Z-Leu-Phe-CONHnPr 15.0 0.05 3 18 >300 
Z-Leu-Phe-CONHnBu O.OZ8 3 8 >100 
Z-Leu-Phe-CONHiBu 0.065 4 24 
Z-Leu-Phe-CONHBz 0.046 
Z-Leu-Phe-CONH(CH2)2Ph 0.024 (2) 
Z-Leu-Nle-COOEt 0.18 20 2.2 190 
Z-Leu-Nva-COOEt 1.4 1.2 25 160 2.3 150 
Z-Leu-Met-COOEt 1.0 1.5 55 1.75 >100 140 
Z-Leu-4-Cl-Phe-COOEt <4.0 0.4 50 0.9 >100 150 
Table IB(ii) shows the inhibition constants (K1) for 
cathepsin B, calpain I, and calpain II with peptide 
ketoamides. Dipeptide Ketoamides with Abu and Phe 45 
in the P1 site and Leu in the P2 site are potent inhibitors 
of calpain I and calpain II. Z-Leu-Abu-CONH-Et is a 
better inhibitor of calpain I than Z-Leu-Phe-CONH-Et 
results of the determinations of s.tability of the com-
pounds in plasma and liver homogenates are shown in 
Table lB(iii). 
by 14 fold. Replacement of the Z group 
(PhCH20CO-) by similar groups such as 50 
PhCH2CH2CO-, PhCH2CH2S02-, 
PhCH2NHCO-, and PhCH2NHCS- would also re-
sult in good inhibitor structures. The best inhibitor of 
calpain II is Z-Leu-Abu-CONH-(CH2)2-Ph. Changing 
the R3 and R4 groups significantly improves the inhibi- 55 
tory potency toward calpain IL The best Dipeptide 
Ketoamide inhibitors are those which have long alkyl 
side chains (e.g. Z-Leu-Abu-CONH-(CH2)7CH3), 
alkyl side chains with phenyl substituted on the alkyl 
group (e.g. Z-Leu-Abu-CONH-(CH2)z-Ph), or a alkyl 60 
groups with a morpholine ring substituted on the alkyl 
group [e.g. Z-Leu-Abu-CONH-(CH2)3-Mpl, 
Mpl=-N(CH2CH2)zO]. Dipeptide a-ketoamides with 
a small aliphatic amino acid residue or a Phe in the P1 
site are also good inhibitors for cathepsin B. The best 65 
inhibitor is Z-Leu~Abu-CONH-Et and replacement of 
the Z (PhCH20CO-) by PhCH2CH2CO-, 
PhCH2CH2S02-, PhCH2NHCO-, and 
TABLE IB(iii) 
Stability in Plasma and in Liver of PeEtide Keto-Com!?Clunds. 
Inhibitor 
Z-Leu-Abu-COOEt 
2-NapS02-Leu-Leu-Abu-COOEt 
2-NapCO-Leu-Leu-Abu-COOEt 
Tos-Leu-Leu-Abu-COOEt 
Z-Leu-Abu-COOH 
Z-Leu-Abu-CONHEt 
Z-Leu-Abu-CONHnPr 
Z-Leu-Abu-CONHnBu 
Z-Leu-Abu-CONHiBu 
Z-Leu-Abu-CONHBz 
Z-Leu-Phe-COOEt 
Z-Leu-Phe-COOnBu 
Z-Leu-Phe-COOBz 
Z-Leu-Phe-COOH 
Z-Leu-Phe-CONHEt 
Z-Leu-Phe-CONHnPr 
Z-Leu-Phe-CONHnBu 
Z-Leu-Phe-CONHiBu 
Z-Leu-Phe-CONH(CHz)zPh 
Z-Leu-Nle-COOEt 
plasma 
2.8 
>60 
25 
30 
>60 
>60 
>60 
>60 
>60 
>60 
7.8 
7.7 
1.9 
>60 
>60 
>60 
>60 
>60 
>60 
3.7 
liver 
>60 
>60 
>60 
>60 
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TABLE lB(iii)-continued 
Stability in Plasma and in Liver of Peptide Keto-Compounds. 
t~ 
Inhibitor 
Z-Leu-Nva-COOEt 
Z-Leu-Met-COOEt 
plasma 
2.8 
8 
liver 
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Z-gly-leu-ala-CH2Cl were found to possess significant 
Calpain inhibitory activity. In addition, Boc-gly-leu-
phe-CH2Cl was shown to be somewhat specific to Cal-
pain, with lower inhibitory activity.toward Cathepsin B 
5 or Papain than toward Calpain. The results shown in 
the table reveal that Z-gly-leu-phe-CH2Cl and Boc-gly-
leu-phe-CH2Cl produce similar inhibitory effects. Thus, 
the blocking group is not shown to have a great effect 
It can be seen from the data in Table lB(iii) that the 
Peptide Keto-Compounds are generally quite stable in 10 
plasma and liver homogenates. However, it is also 
shown that the Peptide a-ketoamides were substantially 
more stable in both plasma and liver than the corre-
sponding peptide a-ketoesters 
on Calpain inhibitory activity. 
The kinetic constants of other irreversible Calpain 
Inhibitors include the following with Kappl[I] in paren-
theses: E-64 (7500), E64-d (23000) and Z-leu-leu-tyr-
CHN2 (230000). E-64 is commercially available from 
Sigma Chemical Co., and is shown here to be a poor 
EXAMPLE lC 
Protease Inhibition by Halo-Ketone Peptides 
15 inhibitor of Calpain. Z-leu-leu-tyr-CHN2 is a diazo-
methyl peptide compound, here shown to possess sig-
nificant Calpain inhibitory activity. 
The Halo-Ketone Peptides, like the substituted 
isocoumarins, are irreversible inhibitors of Calpain. We 
determined the Kapp![I] values for various members of 20 
this class of compounds against Calpains I and IL For 
comparison, we also determined these values against the 
additional thiol proteases Papain and Cathepsin B for at 
least one Halo-Ketone Peptide. These Kapp values are 
not directly comparable to the K; or IC50 values deter- 25 
mined above for other classes of inhibitors. 
2. Inhibition of Calpain in Neural Tissues 
In order to evaluate the inhibition of Calpain by the 
various Calpain Inhibitors in neural tissues, we assayed 
the Calpain Inhibitors using the known ability of Cal-
pain to cleave spectrin, a protein component of neuro-
nal and other tissue, into BDP's. In this assay, more 
effective Calpain Inhibitors will prevent the conversion 
of spectrin into BDP's. Example 2 is one example of 
such an assay. 
EXAMPLE2 
Inhibition of Calpain in Crude Brain Extracts by 
Calpain Inhibitors 
The activity of Calpain in crude brain extracts was 
measured by examining the Ca2+-stimulated proteolysis 
of the endogenous substrate spectrin. Brain tissue was 
We assayed Calpain I and II using Suc-leu-tyr-
amidomethylcoumarin. Papain was assayed using benz-
oyl-arg-4-nitroanilide, and Cathepsin B (bovine) was 
assayed using CBZ-lys-4-nitrophenyl ester. We fol- 30 
lowed the progress curve method of Tian and Tsou, 
Biochemistry, 21:1028-1032 (1982), the disclosure of 
which is hereby incorporated by reference, to derive 
kinetic data. Briefly, this method makes use of the equa-
35 homogenized in 10 mM Tris pH=7.4, 0.32M sucrose, 1 
mM EGTA, 1 mM dithiothreitol and the nuclei and 
debris removed by low speed centrifugation. Various 
Calpain Inhibitors were added to the supernatant in a 
DMSO vehicle and a calcium salt (final effective con-
tion: 
V[S]IK 
[P,,] = (I + [S]IK)A[Y] 
where [P 00 ] represents the concentration of product 40 
formed at a time approaching infinity, A is the Kapp in 
the presence of substrate (S), K is the Michaelis con-
stant and [Y] is the concentration of the inhibitor. Since 
[S] and [Y] are known and V and K can be determined, 
Kapp can be readily determined. 45 
centration about 1.2 mM) added to start the reaction. 
Proteolysis of spectrin was evaluated by western blot as 
described by Seubert, et at. (Brain Research, 
459:226-232, 1988), the disclosure of which is hereby 
incorporated by reference. Briefly, a known quantity of 
a spectrin-containing sample treated with Calpain is 
separated by SDS-PAGE and immunoblotted with The Kappl[I] for various Halo-Ketone Peptides are 
shown in Table lC. 
TABLE IC 
KINETIC PARAMETERS OF Halo-Ketone Peptides 
Inhibitor CI CU 3 P CB 
Z-Gly-Leu-Phe-CH2Cl 
Boc-Gly-Leu-Phe-CH2CI 
Z-Leu-Phe-CH2Cl 
Z-Gly-Leu-Ala-CH2CI 
Ac-Leu-Phe-CH2Cl 
Z-Val-Phe-CH2CI 
Z-Ala-Phe-CH2CI 
Ac-Ala-Ala-Ala-Ala-CH2Cl 
946000 
902000 
585000 
21000J 
540000 290000 
CI= Calpain I 
err = Calpain u 
P = Paoain 
CB = Cathepsin B 
1
-Rat 
2
- Human 
3
- Rabbit 
2250002 
259001 33400 
27200 
2400 
1300 
It can be seen from the results in Table lC that the 
Halo-Ketone Peptides inhibit Calpain with relatively 
high Kappl[I] values. In particular, Z-gly-leu-phe-
CH2Cl, Boc-gly-leu-phe-CH2Cl, Z-leu-phe-CH2Cl and 
anti-spectrin antibody. The amount of spectrin immuno-
reactivity found corresponding to the characteristic 
BDP's is indicative of the amount of spectrin activity 
50 present in the sample. An examplary method for quanti-
tating BDP's is to assay Spectrin BDP's by homogeniz-
ing brain parts in 20 mM Tris pH=7.2, 0.32M sucrose, 
50 µM Ac-Leu-Leu-nLeu-H on ice. Homogenates are 
then mixed 1:1with10% SDS, 5% /3-mercaptoethanol, 
55 10% glycerol, 10 mM Tris pH=8.0, 0.5% bromo-
phenolblue, heated to 95° C., and subjected to electro-
phoresis in 4~% polyacrylamide gels. The proteins in 
the gels are transferred to nitrocellulose and the spec-
trin and BDP's detected using a rabbit polyclonal anti-
60 spectrin antibody and established immunodetection 
methods. The amount of spectrin and BDP's in each 
sample can be quantitated by densitrometric scanning of 
the developed nitrocellulose. 
Due to Calpain's requirement for Ca2 +, in the ab-
65 sence of Ca2+ little or no spectrin proteolysis occurred, 
regardless of the presence of inhibitor, while in the 
presence of Ca2+ the spectrin was >95% cleaved to 
BDP's within 40 min. if no Calpain Inhibitor is added. 
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Both leupeptin and Cil showed inhibition in the sys-
tem of Example 2. In addition, the following com-
pounds of the Substituted Heterocyclic Compounds 
were found to produce significant inhibition at 100 µM: 
3-chloroisocoumarin 
3,4-dichloroisocoumarin 
3-benzyloxy-4-chloroisocoumarin 
7-(acetylamino )-4-chloro-3-(propoxy )-isocoumarin 
4-chloro-3-(3-isothiureidopropoxy)isocoumarin 
7-amino-4-chloro-3-(3-isothiureidopropoxy)isocouma-
rin 
7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(phenylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(acetylamino )-4-chloro-3-(3-isothiureidopropox-
y )isocoumarin 
68 
leupeptin, to inhibit neurodegeneration in gerbils sub-
jected to transient ischemia. 
As stated above, leupeptin is poorly membrane per-
meant. Therefore, leupeptin is not expected to cross the 
5 blood-brain barrier ("BBB") very well. Accordingly, in 
order to provide the brain with sufficient leupeptin to 
adequately inhibit Calpain activation, we used brain 
infusion techniques. Through the use of these tech-
niques we were able to subject brain tissues to intimate 
10 contact with leupeptin for sustained periods of time. 
15 
Example 3A is provided to show the in vivo protection 
from neurodegeneration found during one such study. 
EXAMPLE3A 
In Vivo Protection Against Neurodegeneration 
7-(3-phenylpropionylamino )-4-chloro-3-(3-isothiureido-
propoxy)isocoumarin 20 
A small cannula was implanted in the right lateral 
ventricle of adult gerbils, and secured to the skull with 
dental cement. An Alzet micro-osmotic pump was at-
tached to the cannula for intracerebroventricular perfu-
sion. The pump was filled with either saline alone (con-
trol) or leupeptin (20 mg/ml in saline). After three days 7-(phenylacetylamino )-4-chloro-3-(3-isothiureido-
propoxy)isocoumarin 
7-(L-phenylalanylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 25 7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureidoe-
thoxy )isocoumarin 
perfusion with either the control solution or with the 
leupeptin solution, transient ischemia was induced by 
bilaterally clamping the carotid arteries for a period of 
ten minutes. Core temperatures were taken during and 
7-(phenylcarbamoylamino )-4-chloro-3-(3-isothiureidoe-
thoxy )isocoumatj.n 
7-(D-phenylalanylamino )-4-chloro-3-(3-isothiureidoe-
thoxy )isocoumarin. 
following ischemia, with no differences noted between 
control and leupeptin treated animals. Fourteen days 
later, the animals were sacrificed by Nembutal overdose 
30 and transcardial perfusion of a 10% solution of para-
formaldehyde in PBS. Coronal sections of the brain 
were stained with cresyl violet and were examined for 
The following compounds of the Halo-Ketone Pep- the extent of neuronal loss. The control gerbils exhib-
tides were also found to produce significant inhibition at ited the typical damage found in the CAI field follow-
100 µM: 35 ing ischemia, with a 72% loss of neurons. However, the 
leupeptin treated gerbils showed far less neurodegener-
Z-Leu-Phe-CH2Cl ation, with only a 15% loss of neurons. 
Ac-Leu-Phe-CH2Cl The results of Example 3A cannot be explained by 
Z-Gly-Leu-Phe-CH2Cl changes in thermoregulation, since core temperatures 
Boc-Gly-Leu-Phe-CH2Cl 40 did not differ between the groups. Accordingly, we 
Ac-Val-Phe-CH2Cl believe that the Calpain inhibitory activity ofleupeptin 
Z-Gly-Leu-Ala-CH2Cl. is responsible for the observed differences in neuronal 
In addition, the following compounds of the Peptide 
Keto-Compounds were found to produce significant 45 
inhibition at 100 µM: 
cell loss. In order to further quantitate the differences, 
and verify that leupeptin produced a Calpain inhibitory 
effect within the observed regions of the brain, we per-
formed a related series of experiments. In this series of 
Bz-DL-Phe-COOEt 
Z-Leu-Nva-COOEt 
Z-Leu-Nle-COOEt 
Z-Leu-Phe-COOEt 
Z-Leu-Abu-COOEt 
Z-Leu-Met-COOEt 
Z-Ala-Ala-DL-Abu-COOEt 
MeO-Suc-V al-Pro-DL-Phe-COOMe 
Z-Ala-Ala-Ala-DL-Ala-COOEt 
MeO-Suc-Ala-Ala-Pro-DL-Abu-COOMe. 
Z-Leu-Phe-COOEt 
experiments, spectrin BDP's were measured in the leu-
peptin treated and control animals. As discussed above, 
these BDP's are indicative of the amount of Calpain 
50 activity occurring within the tissue. Example 3B is pro-
vided to demonstrate the results of these experiments. 
EXAMPLE3B 
In Vivo Inhibition of Calpain Activity 
55 Implantation surgeries and clamping of the carotid 
arteries were performed as above with a control-
ischemia group (n=4) and a leupeptin-ischemia group 
(n=5). A third group of animals (n=4) received im-
plantation with pumping of saline, but was not sub-
Thus, the Substituted Heterocyclic Compounds, Pep- 60 jected to ischemia. Animals were sacrificed by decapita-
tide Keto-Compounds and Halo-Ketone Peptides, in tion 30 minutes after clamping of the arteries. The 
addition to leupeptin and Cll, provide inhibition in brains were rapidly removed and placed in cold homog-
brain homogenates. enization buffer (0.32M sucrose, 10 mM Tris-HCl, 2 
3. In Vivo Inhibition of Neurodegeneration through mM EDT A, 1 mM EGT A, 100 µM leupeptin and 1 
Infusion Techniques 65 µg/ml of the Halo-Ketone Compound, tos-phe-CH2Cl 
In order to demonstrate that the inhibition of Calpain (TPCK)). The CAl region of the hippocampus was 
activity alone is sufficient to inhibit neurodegeneration then dissected. The samples from both control and leu-
in vivo, we tested the ability of the Calpain Inhibitor, peptin treated animals were then prepared for SDS-
69 
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PAGE and immunoblotting with labeled anti-spectrin 
antibody, as described above in connection with in vitro 
uses of the Calpain Inhibitors. The control animals ex-
hibited a marked increase in the levels ofBDP's relative 
to the gerbils not subjected to ischemia. These BDP's 5 
co-migrated with BDP's observed after in vitro proteo-
lysis of spectrin with Cal pain. The brain tissue from the 
leupeptin treated gerbils exhibited approximately 25% 
70 
mM EDTA-citrate contammg 10 units heparin, and 
centrifuged 30 minutes at 1600 rpm at room tempera-
ture. The plasma was resuspended in 15 ml buffer 1 (136 
mM NaCl, 2.7 mM KCl, 0.42 mM NaH2P04, 12 mM 
NaHC03, 2 mM MgCh, 2 mg/ml BSA (Sigma), 5.6 mM 
glucose, 22 mM Na3Citrate pH 6.5) and platelets were 
isolated at 2200 rpm at room temperature of 25 minutes. 
Platelets were resuspended to 107 cells/ml in buffer 2 
(136 mM NaCl, 2.7 mM KCl, 0.42 NaH2P04, 12 mM of the BDP's observed in the control ischemia treated 
gerbils. 10 NaHC03, 2 mM MgCl, 1 mg/ml BSA, 5.6 mM glucose, 
20 mM HEPES pH 7.4) and allowed to "rest" for a 
minimum of 10 minutes at room temperature before use. 
Another group of gerbils (n=3) were sacrificed im-
mediately after ischemia without leupeptin treatment in 
order to observe the effects of ischemia without reox-
ygenation. These gerbils exhibited a similar amount of 
increase of BDP's as the control-ischemic gerbils ob- 15 
served after a 30 minute reperfusion period. 
Thus, the results of Example 3B indicate that leupep-
tin exerts its neuroprotective effect through the inhibi-
tion of Calpain activation. The results also indicate that 
the observed proteolysis of spectrin was an effect of 20 
ischemia, and not secondary to the reoxygenation. Ac-
cordingly, the results indicate that inhibition of Cal pain 
activity in vivo produces a neuroprotective effect. 
Although the foregoing studies demonstrate that 
leupeptin can inhibit neurodegeneration in vivo, leupep- 25 
tin is not the therapeutic drug of choice because of the 
need to infuse the drug directly into the brain for an 
extended period of time to exert its neuroprotective 
effect. This is due to the relatively poor ability of this 
compound to cross the BBB. Accordingly, it is believed 30 
that a more therapeutically practical way to inhibit 
neurodegeneration would be to use more membrane 
permeant Inhibitor of Calpain. 
4. Platelet Permeability 
In accordance with our discoveries demonstrated in 35 
Examples 3 and 3A, we believe that having a compound 
cross the BBB and enter CNS tissue is a key characteris-
tic of a therapeutically useful approach to treat or in-
hibit neurodegeneration within the CNS. Use of Cal-
pain inhibitors that have enhanced membrane permea- 4D 
bility is one such approach. Thus, we measured the 
ability of various Calpain inhibitors to penetrate the 
platelet membrane and inhibit Calpain that is normally 
contained in platelets. As shown below in the following 
examples, our results indicate that particular com- 45 pounds of the Heterocyclic Compounds, Peptide Keto-
Compounds and Halo-Ketone Peptides, in addition to 
the Peptide Aldehyde, Cll, exhibit good membrane 
permeability. 
As an indication of the membrane permeability of the 50 
various Calpain Inhibitors, we measured the ability of 
various Calpain Inhibitors to penetrate platelet mem-
branes and inhibit the Calpain normally found within 
platelets. The membrane of platelets is believed to have 
many similarities to the BBB and accordingly, such 55 
experiments are believed to provide a good indication 
of the ability of the various Calpain Inhibitors to cross 
the BBB. Example 4 shows the results of some of these 
platelet experiments using the Calpain Inhibitors of the 
present invention. 60 
EXA.MPLE4A 
Membrane Permeation of Calpain Inhibitors 
Platelets were isolated by a modification of the 
method of Ferrell and Martin, J Biol. Chem., 65 
264:20723-20729 (1989), the disclosure of which is 
hereby incorporated by reference. Blood (15-20 ml) 
was drawn from male Sprague-Dawley rats into 100 
Platelets were incubated for 5 minutes in the presence 
of inhibitor. In order to provide sufficient intracellular 
calcium to activate Calpain, the calcium ionophore 
A23187 was added to a final concentration of 1 µM. 
After a further 5 minute incubation, the platelets were 
harvested by centrifugation (1 min 10,000Xg) and re-
suspended in 10% sodium dodecyl sulfate, 10 mM Tris 
pH=8.0, 5% ,B-mercaptoethanol, 0.02% bromophenol 
blue, and heated to 95° C. for 5 min. Samples were 
subjected to SDS-PAGE on 6% mini gels and trans-
ferred to nitrocellulose (Schleicher and Schuell BAS3) 
for 2 hours at 100 mA/gel in an LKB Novablot. Filters 
were blocked for 10 minutes in 0.25% gelatin, 1 % BSA, 
0.25% Triton XlOO, 0.9% NaCl, 10 mM Tris-Cl pH 7.5, 
incubated overnight in the same solution containing 
antibody to rat spectrin, washed 3 X 10 minutes with 10 
mM Tris-Cl pH 7.5, 0.5% Triton XlOO, incubated 4 
hours in wash buffer plus alkaline phosphatase conju-
gated goat anti-rabbit antibody (Biorad), and washed as 
above. Filters were developed using the Biorad AP 
conjugate substrate kit. Spectrin immunoreactivity on 
the filters was quantitated by densitometry. 
The inhibition of Calpain within platelets as measured 
by the proteolysis of the endogenous Calpain substrate 
spectrin in the presence of inhibitors was assayed for a 
variety of Calpain Inhibitors. The poorly permeant 
inhibitors leupeptin and E-64 had little effect on intra-
cellular Calpain. In contrast, the highly membrane per-
meant Heterocyclk Compounds, Peptide Keto-Com-
pounds, and Halo-Ketone Peptides effectively inhibited 
platelet Calpain. 
The following Heterocyclic Compounds were found 
to produce significant inhibition at 100 µM in the sys-
tem of Example 4: 
3-chloroisocoumarin 
4-chloro-3-(3-isothiureidopropoxy)isocoumarin 
7-amino-4-chloro-3-(3-isothiureidopropoxy)isocouma-
nn 
7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(phenylcarbamoylamino)-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(acetylamino)-4-chloro-3-(3-isothiureidopropox-
y )isocoumarin 
7-(3-phenylpropionylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(phenylacetylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(L-phenylalanylamino )-4-chloro-3-(3-isothiureido-
propoxy )isocoumarin 
7-(benzylcarbamoylamino )-4-chloro-3-(3-isothiureidoe-
thoxy )isocoumarin 
7-(pheny lcarbamoy !amino )-4-chloro-3-(3-isothiureidoe-
thoxy )isocoumarin 
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7-(D-phenylalanylamino )-4-chloro-3-(3-isothiureidoe-
thoxy)isocoumarin. 
The following Halo-Ketone Peptides were found to 
produce significant inhibition at 100 µMin the system 5 
of Example 4: 
Z-Leu-Phe-CH2Cl 
Ac-Leu-Phe-CH2Cl 
Z-Gly-Leu-Phe-CH2Cl 
Boc-Gly-Leu-Phe-CH2Cl. 
The following Peptide Keto-Compounds were found 
10 
to produce significant inhibition at 100 µM in the sys- 15 
tern of Example 4: 
Z-Ala-Ala-D,L-Abu-COOEt 
Z-Ala-Ala-Ala-D,L-Ala-COOEt 
MeO-Suc-Ala-Ala-Pro-D,L-Abu-COOMe 
Z-Leu-Phe-COOEt 
Z-Leu-Nle-COOEt 
Z-Leu-Nva-COOEt 
Z-Leu-Abu-COOEt 
Z-Leu-Abu 
20 
25 
72 
TABLE4B 
Platelet Assay of Peptide Ketoamides, Ketoesters and Ketoacids 
Inhibitor ICso 
Z-Leu-Abu-COOEt 42 
Z-Leu-Abu-COOnBu 28 
Z-Leu-Abu-COOBz + + 
Z-Leu-Leu-Abu-COOEt 40 
2-NapS02-Leu-Leu-Abu-COOEt 100 
Tos-Leu-Leu-Abu-COOEt 30 
Z-Leu-Abu-COOH 8 
Z-Leu-Abu-CONHEt 1.5 
Z-Leu-Abu-CONHnPr 
Z-Leu-Abu-CONHnBu 
Z-Leu-Abu-CONHiBu 
Z-Leu-Abu-CONHBz 
Z-Leu-Phe-COOEt 
Z-Leu-Phe-COOnBu 
Z-Leu-Phe-COOBz 
Z-Leu-Leu-Phe-COOEt 
Z-Leu-Phe-COOH 
Z-Leu-Phe-CONHEt 
Z-Leu-Phe-CONHnPr 
Z-Leu-Phe-CONHnBu 
Z-Leu-Phe-CONHiBu 
Z-Leu-Phe-CONH(CH2)2Ph 
Z-Leu-Nle-COOEt 
Z-Leu-Nva-COOEt 
Z-Leu-Met-COOEt 
Z-Leu-4-Cl-Phe-COOEt 
70 
2.0 
28 
1.5 
42 
+++ 
++ 
++ 
6.5 
1.7 
24 
38 
22 
3.0 
20 
40 
+ 
+ 
Table 4B shows that peptide a-ketoamides and ketoa-
cids were much more effective than corresponding 
Z-Leu-4-Cl-Phe-COOEt 
Z-Leu-Leu-Abu-COOEt 
Z-Leu-Leu-Phe-COOEt 
2-NapS02-Leu-Abu-COOEt 
2-NapS02-Leu-Leu-Abu-COOEt 
Z-Leu-Met-C02Et 
Z-Leu-NLeu-C02Et 
Z-Leu-Phe-C02Bu 
Z-Leu-Abu-C02Bu 
30 peptide ketoesters in this platelet assay. Extending the 
R3 group to an alkyl group or an alkyl group substituted 
with a phenyl group increased the membrane permea-
bility of the inhibitors as indicated by increased potency 
in the platelet assay. In view of these results, Applicants 
35 believe that extending the R group to include longer 
alkyl groups or alkyl groups substituted with phenyl 
groups would increase the membrane permeability of a 
given inhibitor. 
Z-Leu-Phe-C02Bzl 
Z-Leu-Abu-C02Bzl 
Z-Ala-Ala-D,L-Abu-COOBzl 
Z-Leu-Phe-COOH 
Z-Leu-Abu-COOH. 40 In view of the foregoing, the results of Examples 4A 
and 4B support our belief that Cll and the Substituted 
Heterocyclic Compounds, Peptide Keto-Compounds 
and Halo-Ketone Peptides are believed to be membrane 
Among those compounds found to exhibit Calpain 
inhibitory activity in the homogenate system of Exam-
ple 2, we found at least three compounds which failed permeant and therefore, are expected to be effective in 
crossing the BBB subsequent to in vivo administration 
of the compounds. 
5. Glutamate Toxicity 
To further identify those Calpain Inhibitors likely to 
possess pharmacologically active neuroprotective abil-
ity, we tested the ability of the Calpain Inhibitors to 
protect against glutamate excitotoxicity. Excess extra-
cellular glutamate is thought to play a key role in the 
induction of neuropathology in ischemia, which is ac-
companied by Calpain activation. In support of this role 
to exhibit Calpain inhibitory activity in the platelet 45 
system of Example 4. These compounds are leupeptin, 
MeO-Suc-Val-Pro-D,L-Phe-COOMe and Bz-D,L-Phe-
COOEt. Leupeptin is known to be poorly membrane 
permeant, thus confirming that the platelet assay will 
exclude known poorly membrane permeant com- 50 
pounds. Accordingly, the two Peptide Ketocompounds 
found not to provide Calpain inhibitory activity within 
platelets are also believed to be poorly membrane per-
meant, and would not be expected to cross the BBB. 
55 for excess glutamate, cultured NlS-RE-105 (a neurob-
lastoma-retinal hybrid) cells can be killed by the addi-
tion of glutamate into the culture medium. This gluta-
mate-mediated cytotoxicity is calcium dependent and 
EXAMPLE4B 
Quantitative Studies of Platelet Membrane Permeability 
We performed additional quantitative or semi-quan-
titative studies on several Peptide Keto-Compounds 60 
using the assay of Example 4A, except that IC50 values 
were determined as the concentration at which 50% of 
the Calpain activation present in controls occurred. 
Results are shown in Table 4B. For the semi-quantita-
tive assays, indicated with + 's in Table 4B, "+" indi- 65 
cates detectable inhibition at 100 µM, "+ +" indicates 
significantly more inhibition than "+ ", and "+ + +" 
indicates no detectable activation of Calpain detected. 
can be reduced through a number of mechanisms, in-
cluding free radical scavengers, blockers of the N-type 
voltage-sensitive calcium channel, and quisqualate-sub-
type glutamate antagonists. Thus, glutamate-mediated 
killing of NlS-RE-105 cells is an in vitro model for 
neuropathology. 
Accordingly, we tested the ability of the Calpain 
Inhibitors to inhibit glutamate-induced cell death in 
these cells in order to establish that the Calpain Inhibi-
tors can decrease or prevent glutamate-induced death 
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Of N l 8-RE-105 cells. Some of these tests are shown in 
Example 5. 
EXAMPLES 
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teased away with tissue forceps and blunt tip tissue 
scissors using a spread method. The right common ca-
rotid artery was isolated away from the vagus nerve 
and tied off with a single suture (3.0 silk). The external 
Inhibition of Glutamate-Induced Cell Death 
Stock cultures of Nl8-RE-105 cells were maintained 
5 carotid was permanently occluded by suturing. The 
bifurcation of the internal carotid and pterygopalatine 
arteries was exposed and a single microaneurysm clip 
was placed on the pterygopalatine. Another microan-
in Dulbecco's modified Eagle's medium (DMEM) con-
taining 10% fetal bovine serum (FBS) and supple-
mented with hypoxanthine, aminopterin and thymidine 
(HAT). Subconfluent cultures were split and plated into 10 
96-well plates. Twenty-four hours after plating the cells 
were exposed to fresh media containing glutamate and 
various concentrations of Calpain inhibitors. Control 
cells were not treated with glutamate. The treated cells 
received 5 mM glutamate and leupeptin (5 µg/ml) or 15 
the other Calpain Inhibitors listed in FIG. 1 at 3 µg/ml. 
Conversion of MTT was measured 19 hours later as 
described. Nineteen hours after the onset of exposure, 
cell viability was quantitated by measuring the extent to 
which the cells convert 3(4,5-dimethylthiazol-2-yl)-2-5- 20 
diphenyltetrazolium bromide (MTT) to a blue formazan 
product, which occurs in the mitochondria of living but 
not dead cells (Pauwels et al., 1988). A higher absor-
bance is indicative of greater cell viability. 
FIG. 1 shows the percent of blue formazan product 25 
remaining after treatment with glutamate, relative to 
control where no glutamate was added. Thus, it can be 
seen that with vehicle plus glutamate but no inhibitor, 
less than 70% of the mitochondrial activity remains. 
However, FIG. 1 shows that several Calpain inhibitors, 30 
including leupeptin, CI 1 and representatives of the Het-
erocyclic Compounds, Peptide Keto-Compounds and 
Halo-Ketone Peptides protect N18-RE-105 cells against 
glutamate toxicity. The Peptide Keto-Compound Cal-
pain inhibitor, Z-Ala-Ala-Abu-C02Et, the Substituted 35 
Heterocyclic Compounds, CITPrOIC and ACITIC, 
and the Halo-Ketone Peptide, TPCK completely 
blocked the toxic effects of glutamate, resulting in 100% 
or greater of the formazan product as seen with cells not 
treated with glutamate. Thus, Example 5 shows that 40 
these Calpain Inhibitors effectively block cell death in 
an in vitro model for neuropathology. Accordingly, this 
data further supports our discovery that Calpain Inhibi-
tors are neuroprotective in vivo. 
6. Reduction of Infarction upon MCA Occlusion 45 
Stroke is a significant health problem in the human 
population. Strokes are occlusions of cerebral arteries 
producing a decreased blood flow to brain regions, 
which cause cell death through oxygen and nutrient 
deprivation. This type of lesion can be modeled in rats 50 
by surgical occlusion of the middle cerebral artery 
(MCA). Several models for MCA occlusion have been 
developed, and all give substantially similar results. 
MCA occlusion produces a large volume ofinfarcted 
brain tissue 24 hours after occlusion. Previous studies 55 
have shown that the size of the infarct as judged by 
TIC staining does not increase after the first 24 hours 
post-occlusion. Thus, we used an MCA occlusion 
model in order to test the ability of Cal pain inhibitors to 
prevent neurodegeneration. This model is described in 60 
Example 6. 
EXAMPLE6 
MCA Occlusion Model for Neurodegeneration 
Male Sprague-Dawley albino rats weighing approxi- 65 
mately 250-300 grams were anesthetized with pentobar-
bital (70 mg/kg, i.p.). The neck region was shaven and 
a 2 cm incision was made. The superficial fascia was 
eurysm clip was placed on the common carotid just 
proximal to the external/internal bifurcation. A suture 
was placed loosely around the common carotid and a 
lumen was made in the vessel with the tip of a 25 g 
needle. A 40 mm nylon suture was prepared by melting 
the tip to smooth the pointed end and marked with a dot 
exactly 17.5 mm from the melted end. The suture was 
inserted into the lumen of the artery as far as the vessel 
clip, the clip is removed and the suture advanced until 
the marking was at the bifurcation of the internal and 
external carotid arteries. This places the end of the 
suture in the circle of Willis just beyond the source of 
the middle cerebral artery and occludes this artery. The 
loose suture around the carotid is tied lightly to keep the 
nylon suture in place. The microaneurysm clip on the 
pterygopalatine artery was removed, the incision is 
closed and the animals are allowed to recover in heated 
recovery cages. 
Twenty-four hours after occlusion, the brains of these 
animals were removed and sliced into 2 mm sections. 
The sections were stained using 2,3,5-triphenyltet-
razolium chloride (see Lundy, E. F., Solik, B. S., Frank, 
R. S., Lacy, P. S., Combs, D. J., Zelenock, G. B., and 
D'Alecy, L. G., Morphometric evaluation of brain in-
farcts in rats and gerbils, J. Pharmacol. Meth. 
16,201-214, 1986). Absence of red color development 
indicated tissue damage or death. The sizes of the in-
farcted tissue zone (area with red stain) and impaired 
zone (area with partial development of red color) were 
evaluated using quantitative morphometry. 
Drugs or vehicle were administered by infusion into 
the femoral vein. All animals received the same volume 
of drug or vehicle (20% dimethyl sulfoxide/80% prop-
ylene glycol) via a catheter attached to an Alzet os-
motic minipump (24 hr pump, 8 ul/hr, 90 ul total vol-
ume). 
The model of Example 6 was used to determine the 
size ofinfarcted area for control (vehicle, i.v.) and with 
administration of each of two Cal pain inhibitors: Z-Leu-
Phe-CONH-Et (CX269) and Z-Leu-Abu-CONH-Et 
(CX275). These results are depicted graphically in FIG. 
2. It can be seen that administration of either of the 
Calpain inhibitors Z-Leu-Phe-CONH-Et (CX269) or 
Z-Leu-Abu-CONH-Et(CX275) produces a reduction in 
the size of the infarcted area. 
7. Inhibition of Anoxic and Hypoxic Damage 
The CAl region of hippocampus is a brain area par-
ticularly vulnerable .to ischemic damage and other in-
sults involving excitatory amino acids. The hippocam-
pus is also a major focus of cell degeneration in Alzhei-
mer's disease. Neural cells in slices degenerate follow-
ing hypoxia through the same chain of events (including 
reperfusion effects) observed in vivo during and after 
ischemia. We believe that studies of degeneration of 
neural slices in the presence of the various Calpain 
Inhibitors is an effective indicator of the membrane 
permeance of the Calpain Inhibitors. Accordingly, we 
believe that these studies provide a model for the treat-
ment and inhibition ofneurodegeneration in vivo. Simi-
75 
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to elicit 50% of their . pre-anoxia evoked response. In 
accordance with this finding, few if any recover upon 
reoxygenation. FIG. 3 also shows that when Cll or 
CX218 are added to the ACSF, the slices are protected 
lar studies for determining the efficacy of compounds 
useful in the treatment of neurodegeneration in accor-
dance with the present invention can be performed 
using other models, such as protection against degener-
ation in platelets or cells in culture. 5 from the effects of anoxia, evidenced by a substantial 
proportion of slices eliciting evoked potentials. It is believed that hypoxia is a major cause of neuro-
toxicity in a variety of neurodegenerative diseases and 
conditions, such as stroke and head injury. Thus, we 
conducted further studies using hippocampal slices to 
show that the various Calpain inhibitors, advanta-
geously, can increase survival of hippocampal nerve 
cells during exposure to hypoxic or anoxic conditions. 
An initial screening procedure was first used to qualita-
tively determine whether the various Calpain Inhibitors 
can provide neuroprotection from anoxia in hippocam- 15 
pal slices. An example of these initial screening proce-
dures is shown by Example 7 A. 
Finally, it can be seen that CX218 is significantly 
more effective in protecting against anoxia and prevent-
ing degradation of slices at the minimal 1 hour incuba-
10 tion time, and at lower concentrations than Cll. This 
effect is believed to be due to the superior membrane 
permeance of the Peptide Keto-Compounds. 
EXAMPLE7A 
Initial Screen for Inhibition of Anoxic Damage 20 
Hippocampal slices (400 um) were prepared from 
Sprague Dawley rats (6 to 7 weeks) and maintained in 
an interface chamber at 35° C. using conventional tech-
niques, i.e., the lower surface of the slice received a 
constant perfusion (0.5 ml/min) of ACSF, while the 25 
upper surface was exposed to a moist atmosphere of 
02:C02(95%:5%) exchanged at a rate of2 L/min. The 
ACSF medium contains (in mM): NaCl (124), KC! (3), 
KHP04 (2.5), CaCl (3.4), NaHC03 (26) and D-Glucose 
(10). Field excitatory post-synaptic responses were re- 30 
corded from stratum radiatum of CA!b in response to 
stimulation of Schaffer-commissural fibers in CAla or 
CAie. The depth of the recording electrode was opti-
mized and evoked responses were collected at a rate of 
one evoked response every 30 seconds. 35 
For the initial screening procedure, 14 to 16 slices are 
harvested from the hippocampus of a single rat and 
placed in a common ACSF bath. Each slice is tested in 
sequence to determine the magnitude of its pre-anoxic 
evoked response. Five stimulation pulses (each 0.1 ms 40 
(millisecond) in duration) were presented over a 15 
second interval. The largest evoked response was noted 
and recorded for each slice. 
Following this, the slices were incubated for one 
hour, with either drug or vehicle alone added to the 45 
ACSF. After the one hour drug incubation period, the 
oxygen-enriched atmosphere of the chamber was made 
anoxic by substituting nitrogen for oxygen (N2=95%; 
C02=5%). The slices were retained in this anoxic envi-
Table 7 A shows further data from the studies of Ex-
ample 7A. 
Compound 
Control 
Leupeptin 
Cll 
CX13 (SHC) 
CX89 (CKP) 
TABLE7A 
PERCENT OF SLICES 
SURVIVING TEN MINUTES ANOXIA 
Dose (µ.M) Incubation Time 
I hour 
1000 3 hours 
200 2 hours 
20 I hour 
50 I hour 
CX218 (PKC) 100 I hour 
Survival 
<1% 
50% 
53% 
50% 
50% 
70% 
It can be seen from the data in Table 2 that all of the 
Calpain Inhibitors tested provide increased survival. 
CX13 (ACITIC, a Substituted Heterocyclic Compound 
(SHC)), CX89 (Boc-Gly-Leu-Phe-CH2Cl, a Halo-
Ketone Peptide (HKP)) and CX218 ((Z-Leu-Abu-
C02Et, a Peptide Keto-Compound (PKC)), are each 
shown to be highly effective in influencing survival 
times. Leupeptin is seeri to be the least effective neuro-
protective. Thus, we believe that CX13, CX89 and 
CX218 (Z-Leu-Abu-C02Et) are more effective in influ-
encing survival because of their membrane permeabil-
ity. Accordingly, the results shown in Table 7A support 
our belief that Calpain Inhibitors with membrane per-
meability are effective neuroprotectants. 
To further elucidate the ability of Calpain Inhibitors 
to provide neuroprotection to hippocampal slices, and 
to provide a more quantitative indication of the mem-
brane permeability of these Cal pain Inhibitors, we mea-
sured the effect of various Calpain Inhibitors on the 
evoked response on a single neuronal slice before, dur-
ing and after anoxia. These studies are shown in Exam-
ple 7B. 
EXAMPLE7B 
ronment for 10 minutes, following which the oxygen- 50 Inhibition of Anoxic Damage 
enriched atmosphere (02=95%; C02=5%) was rees-
tablished. As in Example 7A, hippocampal slices (400 µm) were 
The slices were given the opportunity to recover for prepared from Sprague Dawley rats (6-7 weeks) and 
30 minutes following reoxygenation whereupon each maintained in an interface chamber at 35° C. using con-
was stimulated and the maximum evoked potential de- 55 ventional techniques, i.e. the lower surface of the slice 
termined, as described above during the pre-anoxia received a constant perfusion (0.5 ml/min) of an artific-
period. Those slices which, after anoxia, produced a ial cerebrospinal fluid (ACSF), while the upper surface 
maximum evoked potential of greater than 50% of that was exposed to a moist atmosphere of 02:C02 
observed prior to anoxia were defined as surviving (95%:5%) exchanged at a rate of 2 L/min. The ACSF 
slices. 60 medium contains (in mM): NaCl (124), KC! (3), 
Results of the studies of Example 7 A are shown in KHP04 (1.25), MgS04 (2.5), CaC}i (3.4), NaHC03 (26) 
FIG. 3. FIG. 3 shows the effects of CX218 (Z-Leu- and D-Glucose (10). Field excitatory post-synaptic re-
Abu-C02Et, a Peptide Keto-Compound), and Cll rela- sponses were recorded from stratum radiatum of CAlb 
tive to control slices on survival of hippocampal slices in response to stimulation of Schaffer-commissural fi-
exposed to 10 minutes exposure of anoxic atmosphere. 65 bers in CA la or CAlc. The depth of the recording 
As seen in this figure, when the control slices are de- electrode was optimized and evoked responses were 
prived of oxygen for 10 minutes in the absence of drug, collected at a rate of one evoked response every 30 
virtually all fail to survive, as measured by their ability seconds. 
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After establishing a stable baseline of evoked re-
sponses (approximately 10 minutes), ACSF containing 
Calpain Inhibitor was washed into the chamber and 
slices were incubated for a period of one hour. After 
incubation, evoked responses were again recorded and 5 
the change in the amplitude of the responses from base-
line levels was noted. No effect of the inhibitors tested 
on baseline evoked responses was observed. 
For anoxia experiments, incubation in the drug-con-
taining medium was followed by replacement of the 10 
02:C02 (95%:5%) atmosphere with Nz:C02 (95%:5%). 
Slices were exposed to this anoxic environment until 
disappearance of the pre-synaptic fiber volley and for 
two minutes (severe anoxia) longer (total time in anoxic 
environment approximately 7-8 minutes in control 15 
case). Effects of Calpain Inhibitors on the functional 
recovery of the slices after the anoxic episode were then 
measured. Recovery of the evoked potential (EPSP) 
slope and amplitude by the drug treated slices can be 
compared to control slices to determine the relative 20 
efficacy of various Calpain Inhibitors. 
FIG. 4 shows the EPSP amplitude in millivolts for 
control, Cll treated and CX218 (a Peptide Keto-Com-
pound) treated hippocampal slices in the studies of Ex-
ample 7B. It can be seen in FIG. 4 that the control slices 25 
deprived of oxygen in the absence of drug display a 
gradual reduction of EPSP and abruptly lose fiber vol-
ley activity about 5-6 minutes after the beginning of 
anoxia. Reoxygenation at or before this point leads to 
complete functional recovery after about 20 minutes of 30 
reoxygenation, but reoxygenation after this point does 
not. In the latter case the recovered EPSP slope and 
amplitude become progressively reduced as the dura-
tion of anoxia post-fiber volley disappearance (post-
FVD) increases. After severe anoxia (2 minutes post- 35 
FVD), slices recover only 15% of the EPSP slope. 
In contrast to the control slices, recovery begins to 
occur shortly after the end of anoxia for the treated 
slices. FIG. 4 shows a comparison of the effects on 
EPSP amplitude produced in the presence of no inhibi- 40 
tor; the Peptide Keto-Compound, CX218, (Z-Leu-Abu-
C02Et) and Cll. CX218 produces a recovery from 
severe anoxia superior to that seen with Cll. 
FIG. 5 shows the percent recovery of EPSP from 
severe hypoxia using the peptide ketoester CX 216 (Z- 45 
Leu-Phe-C02Et) and its corresponding peptide ketoa-
mide CX269 (Z-Leu-Phe-CONH-Et). These studies 
were performed in a manner similar to that of Example 
7B, except using a hypoxic environment in place of the 
anoxia of Example 7B. It can be seen that use of the 50 
peptide ketoamide results in essentially complete (near 
100%) recovery from hypoxia while the peptide keto-
ester produces a partial recovery. The control slices 
experienced little or no recovery. 
An interesting characteristic that we have discovered 55 
for certain Calpain Inhibitors is their ability to lengthen 
the period of exposure to anoxia required to produce 
fiber volley disappearance (FVD). Typically, under 
control anoxia conditions, fiber volley disappearance 
occurs in less than six minutes (FIG. 6). The Peptide 60 
Keto-Compound, CX-216, substantially lengthens the 
period of exposure to anoxia required to produce FVD. 
This is an important advantage of the use of this Peptide 
Keto-Compound for neuroprotection because slices can 
be expected to recover completely if reoxygenated 65 
before fiber volley disappearance. Thus, treatment with 
this Peptide Keto-Compound is expected to produce a 
greater percentage of recovery of cells from incipient 
78 
neurodegenerative conditions. It is believed that other 
representatives of the Peptide Keto-Compounds as well 
as of other classes of Cal pain Inhibitors also provide this 
effect. 
Table 7B shows the percentage of recovery of pre-
anoxia synaptic transmission (evoked potential ampli-
tude) of slices treated with various Calpain Inhibitors or 
of control slices. All of these slices were exposed to ten 
minutes of anoxia according to the protocol of Example 
7B. 
TABLE 7B 
PERCENT RECOVERY OF 
SYNAPTIC TRANSMISSION AFTER ANOXIA 
Compound Concentration % Recovery 
Control 15 
CI! 200 35 
CX13 (SHC) 20 60 
CX89 (CKP) 50 30 
CX216 (PKC) 100 38 
CX218 (PKC) 100 55 
The results shown in Table 7B provide further evi-
dence that the peptide aldehyde, Cll, as well as the 
Substituted Heterocyclic Compounds, Peptide Keto-
Compounds and Halo-Ketone Peptides are sufficiently 
membrane permeant to provide neuroprotection 
through Calpain inhibition. 
Cll, which is at least partially membrane permeant, 
produces some effect, however, does not significantly 
lengthen the period of anoxia required to suppress elec-
trical activity. Thus, compared to control, or even com-
pared to leupeptin and Cll, the Substituted Heterocy-
clic Compounds, Peptide Keto-Compounds and Halo-
Ketone Peptides can increase the degree of recovery 
after anoxic episodes while producing the additional 
advantage of extending the amount of time slices can 
tolerate anoxia (and thereby recover completely). 
An important effect of the Peptide Keto-Compounds 
and other membrane permeant Calpain Inhibitors is that 
they are significantly more effective in lower doses than 
less permeable Calpain Inhibitors such as Cll. Al-
though Cil is shown to be at least somewhat membrane 
permeant due to its ability to affect slice survival, the 
more membrane-permeant inhibitors provide signifi-
cantly increased protection. Thus, the more highly 
membrane-permeant Calpain Inhibitors are believed to 
be especially effective in treating and inhibiting neu-
rodegeneration. 
The results of the studies of Examples 7 A and 7B 
show that the Substituted Heterocyclic Compounds, 
Peptide Keto-Compounds and Halo-Ketone Peptides 
are membrane-permeant Calpain Inhibitors which are 
believed to be especially effective in treating and inhib-
iting neurodegeneration. The results also show that 
Peptide Keto-Compounds, and perhaps representatives 
of other classes, can extend the duration of anoxia re-
quired to suppress electrical activity in hippocampal 
slices. As discussed above, these effects are important 
advantages of these compounds. 
8. In Vivo Neuroprotection by Calpain Inhibitors 
As discussed above, therapeutics useful for influenc-
ing the function of cells within the CNS must cross the 
BBB to reach their targets within the CNS. Non-BBB 
permeant compounds might, in addition to the brain 
infusion techniques described above, be administered 
via intraventricular administration, but this also se-
verely limits their usefulness in practice. In order to test 
the in vivo effectiveness of the Calpain Inhibitors to 
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cross the BBB and become therapeutically useful, we 
tested the ability of intraperitoneal injection of the Cal-
pain Inhibitors to protect against excitotoxic damage in 
vivo. Protection was measured by evaluating changes in 
behavior of rats after injection with kainate. These stud- 5 
ies are shown in Example 8A. 
EXAMPLE 8A 
tion was that even those treated animals that exhibited 
severe seizures had significantly less spectrin break-
down than untreated animals subjected to kainate. Thus 
Calpain Inhibitor treatment reduced both the behavi-
oral/ convulsive effects of kainate and the activation of 
calpain in the most severely affected animals. 
9. Conclusion 
All of the foregoing studies support our discovery 
that Calpain Inhibitors provide in vivo protection Protection Against Behavioral Changes from 
Excitotoxic Damage by Peripherally Administered 
Calpain Inhibitors 10 against neurodegeneration associated with anoxia, ex-citotoxicity and other causes. Thus, these Calpain inhib-
itors possess neuroprotective activity against a variety 
of in vivo neurodegenerative diseases and conditions, 
Rats (male Sprague-Dawley, 200±5 gms) were in-
jected intraperitoneally with 12 mg/kg kainic acid in 
saline vehicle and ether 2001 µl DMSO (dimethylsulf-
oxide) or 4.6 mg calpain inhibitor dissolved in the same 15 
volume ofDMSO. The rats were observed for six hours 
following the injections and the kainate-induced behav-
ioral symptoms and convulsions scored on a scale of0-6 
(O=no symptoms; 1 =wet dog shakes; 2=salivation and 
chewing; 3=at least one convulsive episode; 4=re- 20 
peated or sustained convulsions; 5=convulsions, in-
cluding rearing and falling; 6=convulsions followed by 
death within the 6 hrs post injection). 
FIG. 7 shows the effects ofCil on the behavioral and 
convulsive effects of kainic acid. In the control group, 25 
over haft the animals showed symptoms greater than 
mild behavioral symptoms, and many exhibited overt 
convulsions, presumably reflecting seizure activity 
within the brain. Unexpectedly, in the inhibitor treated 
group, the incidence and severity of convulsions was 30 
reduced. Thus, this data suggests that Calpain Inhibitors 
have an anti-convulsive effect. This effect is a distinct 
advantage in the use of Calpain Inhibitors in epilepsy-
related neurodegenerative conditions and in stroke, 
which is often accompanied by seizures. 35 
In order to more clearly demonstrate that the behav-
ioral and anti-convulsive effects seen with the Calpain 
Inhibitors result from inhibition of Calpain we tested 
the brain tissues of the rats from Example 8A for accu-
mulation of spectrin BDP's. As discussed above, these 40 
BDP's are associated with Calpain activity and with the 
neurodegeneration associated therewith. 
EXAMPLE8B 
including excitotoxicity, HIV-induced neuropathy, 
ischemia following denervation or injury, subarachnoid 
hemorrhage, stroke, multiple infarction dementia, Alz-
heimer's Disease (AD), Huntington's Disease, Parkin-
son's Disease, surgery-related brain damage and other 
pathological conditions. 
Those Calpain Inhibitors which possess significant 
Calpain Inhibitory activity in vitro and also meet at 
least one of the foregoing or different tests for mem-
brane permeability are excellent candidates for treat-
ment of neurodegeneration. 
G. DRUG DELIVERY 
The ability of the various Calpain Inhibitors to pene-
trate plasma membranes is a significant advantage of 
these compounds from a pharmaceutical perspective. 
We believe that this ability, advantageously, allows the 
Calpain Inhibitors to provide excellent permeation of 
the blood-brain barrier. This is in contrast to many 
pharmaceuticals, especially peptides, which often ex-
hibit poor permeation of the blood-brain barrier. Thus, 
we believe that the Calpain Inhibitors will exhibit excel-
lent results as pharmaceutically neuroprotective agents. 
For treatment of neurodegeneration, the Calpain 
Inhibitors can be administered orally, topically or par-
enterally. The term "parenteral" as used herein includes 
all non-oral delivery techniques including transdermal 
administration, subcutaneous injection, intravenous, 
intramuscular or intrasternal injection, intrathecal injec-
tion (directly into the CNS) or infusion techniques. 
The dosage depends primarily on the specific formu-
Protection Against Spectrin Breakdown from 
Excitotoxic Damage by Peripherally Administered 
Calpain Inhibitors 
4S lation and on the object of the therapy or prophylaxis. 
Four days following the injection of kainate in the 
rats from Example 8A, the brains of the rats were re-
moved and assayed for spectrin BDP's. Spectrin BDP's SO 
were assayed by homogenizing brain parts in 20 mM 
Tris pH=7.2, 0.32M sucrose, 501 µM Ac-Leu-Leu-
nLeu-H on ice. Homogenates were mixed 1:1with10% 
SDS, 5% /3-mercaptoethanol, 10% glycerol, 10 mM 
Tris pH=8.0, 0.5% bromophenolblue, heated to 95° C., SS 
and subjected to electrophoresis in 4!% polyacrylamide 
gels. The proteins in the gels were transferred to nitro-
cellulose and the spectrin and BDP's detected using a 
rabbit polyclonal anti-spectrin antibody and established 
immunodetection methods. The amount of spectrin and 60 
BDP's in each sample was quantitated by densitometric 
scanning of the developed nitrocellulose. 
FIG. 8 shows the results of Example 8B. It can be 
seen that kainate stimulated the breakdown of spectrin 
in both Calpain Inhibitor treated and control rats. How- 6S 
ever, treated rats exhibited significantly less BDP's. 
These results verify that Calpain activity in the brains of 
the treated rats was reduced. An unexpected observa-
The amount of the individual doses as well as the ad-
ministration is best determined by individually assessing 
the particular case. However, in preferred composi-
tions, the dosages of Calpain Inhibitors per day are 
preferably in the range of 1 µg/kg total body mass to 
100 mg/kg total body mass, more preferably in the 
range of 10 µg/kg total body mass to 10 mg/kg total 
body mass. 
The pharmaceutical compositions containing the ac-
tive ingredient may be in a form suitable for oral use, for 
example as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules or syrups or elixirs. The amount of 
active ingredient that may be combined with carrier 
materials to produce a single dosage form will vary 
depending upon the host treated and the particular 
mode of administration. However, typically, a single 
dose will contain sufficient Calpain Inhibitor to provide 
a complete day's dosage in a single orally acceptable 
form. 
For injection, the therapeutic amount of the Calpain 
Inhibitors or their pharmaceutically acceptable salts 
will normally be made by subcutaneous injection, intra-
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neurodegeneration associated therewith. For example, 
for surgeries performed under general anesthesia, hyp-
oxic conditions can occur through inadequate perfusion 
of the CNS while under anesthesia. Additionally, many 
major surgeries of the cardiovascular system require 
that a patient's heart be stopped and that perfusion be 
maintained through artificial means. In such surgeries, 
there is an increased danger of hypoxia occurring 
within the CNS, which can also result in neurodegener-
ation. Moreover, during neurosurgeries, there is an 
inherent risk of neurodegeneration resulting from in-
venous, intramuscular or intrasternal injection, or by 
intrathecal injection (directly into the brain). In order to 
provide a single day's dose with a single injection, the 
pharmaceutical compositions for parenteral administra-
tion will contain, in a single dosage form, from about 70 5 
µg to about 7 g of Calpain Inhibitor per dose of from 
about 0.5 ml to about 1 liter of carrier solution. In addi-
tion to the active ingredient, these pharmaceutical com-
positions will usually contain a buffer, e.g. a phosphate 
buffer that keeps the pH in the range from 3.5 to 7 and 10 
also sodium chloride, and can also contain mannitol or 
sorbitol for adjusting the isotonic pressure. In a pre-
ferred form of these compositions, DMSO or other 
organic solvent is added in order to assist the introduc-
tion of the Calpain Inhibitor across membranes. 
Additionally, lipids can be introduced into the phar-
maceutical compositions in order to facilitate entry of 
the Calpain inhibitor compounds into tissue of the CNS. 
These compositions are prepared in accordance with 
methods known to those of skill in the art. Briefly, a 20 
lipid such as, phosphatidyl choline, cholesterol, other 
well-known lipid carrier or mixtures thereof, is mixed 
with the active compound along with a solvent, the 
solvent is dried off and the material reconstituted in 
saline. The compositions can also include other ingredi- 25 
ents known to those of ordinary skill in the art, such as 
detergents, surfactants or emulsifying agents. 
flammation, bleeding, hemorrhaging and the like. Such 
neurodegeneration can be inhibited by infusion with a 
solution containing Calpain Inhibitor. However, neu-
15 rodegeneration resulting from neurosurgery can also be 
reduced prophylactically by administration of a Calpain 
Inhibitor through any of the foregoing administration 
techniques. Such administration is also believed to in-
A composition for topical application or infusion can 
be formulated as an aqueous solution, lotion, jelly or an 
oily solution or suspension. A composition in the form 30 
of an aqueous solution is obtained by dissolving the 
Calpain Inhibitor in aqueous buffer solution of pH 4 to 
6.5 and, if desired, adding a polymeric binder. An oily 
formulation for topical application is obtained by sus-
pending the Calpain Inhibitor in an oil, optionally with 35 
the addition of a swelling agent such as aluminium stea-
rate and/or a surfactant. The addition of DMSO to 
these topical compositions is believed to allow at least 
partial penetration of the active Calpain Inhibitor into 
the blood stream after application of the composition to 40 
the skin of a patient to allow for transdermal administra-
tion. 
For treatment of neurodegeneration resulting from 
excitotoxicity, HIV-induced neuropathy, ischemia fol-
lowing denervation or injury, subarachnoid hemor- 45 
rhage, stroke, multiple infarction dementia, Alzheimer's 
Disease (AD), Huntington's Disease, surgery-related 
brain damage, Parkinson's Disease, and other pathologi-
cal conditions, the Calpain Inhibitors or pharmaceuti-
cally acceptable salts thereof may be administered 50 
orally or parenterally. The dosage depends primarily on 
the specific formulation and on the object of the therapy 
or prophylaxis. The amount of the individual doses as 
well as the administration is best determined by individ-
ually assessing the particular case. 55 
In many acute neurodegenerative conditions and 
events, such as stroke and head injury, it is important to 
deliver the Calpain Inhibitor as soon after injury as is 
practicable. Thus, it is preferable to identify those indi-
viduals who have suffered stroke, head injury or other 60 
hibit or prevent neurodegeneration associated with the 
use of anesthesia or with the use of artifical means of 
perfusion during major surgeries. A surgical patient can 
also have Calpain Inhibitor administered throughout 
surgery through intravenous drip. 
The following examples are intended to illustrate 
certain neuroprotective uses of the Calpain Inhibitors 
within the scope of the present invention. As such, they 
are not meant to limit the invention in any way. 
EXAMPLE9 
A Neuroprotective Composition for Intravenous 
Injection 
500 µ,g 
4ml 
!ml 
CH3CONH-CiTPrOIC from Example SHC2 
Propylene Glycol 
DMSO 
EXAMPLE 10 
A Neuroprotective Composition for Intravenous Drip. 
250 mg 
1000 ml 
JO ml 
Z-Leu-Phe-CONH-Et from Example PKC 47 
Phosphate Buffered Saline (pH 6.0) 
DMSO 
EXAMPLE 11 
A Neuroprotective Composition for Transdermal 
Application 
25 mg 
3 ml 
2 ml 
Z-Leu-DL-Abu-COOEt from Example PKC19 
Phosphate Buffered Saline (pH 6.0) 
DMSO 
EXAMPLE 12 
Neuroprotection after Head Injury 
injury in which neurodegeneration is associated or is A first group of patients who are victims of head 
likely to occur, and to begin administration of a Calpain trauma is given 2 ml of the injectable composition of 
Inhibitor within 1 minute to 2 hours after the event, in Example 9 intravenously within ten minutes of the time 
order to prevent as much neurodegeneration as possi- of injury. A second group of similarly matched patients 
ble. 65 does not receive the composition. The first group of 
A particular application of the Calpain Inhibitors patients exhibits markedly fewer and less severe out-
within the scope of the present invention is the applica- ward symptoms of neurodegeneration, such as demen-
tion of these compounds during surgery to prevent tia, memory loss and paralysis. 
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EXAMPLE 13 
Neuroprotection During Surgery 
C2-12 dialkylamino, Cl-6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 
aa is a blocked or unblocked amino acid of the L or 
D configuration selected from the group consist-
A patient about to undergo a triple bypass heart sur- 5 ing of alanine, valine, leucine, isoleucine, proline, 
gery is administered 500 ml of the composition of Ex- methionine, methionine sulfoxide, phenylalanine, 
ample 10 per hour using an intravenous drip system. tryptophan, glycine, serine, threonine, cysteine, 
During surgery, the patient's heart is stopped and perfu- tyrosine, asparagine, glutamine, aspartic acid, 
sion continued through artificial means. Although com- glutamic acid, lysine, arginine, histidine, phe-
plications develop while restarting the heart and discon- IO nylglycine, beta-alanine, norleucine (nle), norva-
necting the patient from the artificial means of perfu- line (nva), alpha-aminobutyric acid (abu), epsi-
sion, the patient becomes conscious within several lon-aminocaproic acid, citrulline, hydroxypro-
hours of surgery. Within a few days, the patient's men- line, homoarginine, ornithine and sarcosine; 
taI status is normal with no indications ofneurodegener- n is a number from 1 to 20; 
ation. 15 Q is NH; and 
It will be appreciated that certain variations may R is selected from the group consisting ofH, Cl-6 
suggest themselves to those skilled in the art. The fore- alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, ben-
going detailed description is to be clearly understood as zyl, Cl-6 alkyl substituted with phenyl, and 
given by way of illustration, the spirit and scope of this Cl-6 alkyl with an attached phenyl group substi-
invention being interpreted through reference to the 20 tuted with K. 
appended claims. 2. A method as in claim 1, wherein the selecting step 
What is claimed is: comprises selecting a patient who is experiencing or 
1. A method of treating neurodegeneration due to who has experienced ischemia caused by a medical 
ischemia in a mammalian patient, comprising the steps condition, said condition being selected from the group 
of: 25 consisting of stroke, head injury, major heart attack, 
selecting a patient who is experiencing or who has brain seizure, multiple infarct dementia, subarachnoid 
experienced neurodegeneration due to ischemia; hemorrhage, and surgery. 
monitoring said patient for indicia of the onset or 3. The method of claim 1, wherein n is 1. 
existence of neurodegeneration due to ischemia; 4. The method of claim 1, wherein n is 2. 
detecting said indicia; and 30 5. The method of claim 1, wherein n is 3. 
in response to the detecting of any such indicia of the 6. The method of claim 1, wherein n is 4. 
onset or existence of neurodegeneration due to 7. A method of inhibiting or treating neurodegenera-
ischemia, administering to said patient a therapeuti- tion due to ischemia in a mammal, comprising adminis-
cally efficacious amount of a Peptide Ketoamide tering to said mammal a therapeutically efficacious 
compound, or a pharmaceutically acceptable salt 35 amount of a Peptide Ketoamide compound that has 
thereof, together with a pharmaceutically accept- Calpain inhibitory activity or a pharmaceutically ac-
able carrier, said Peptide Ketoamide compound ceptable salt thereof, said Peptide Ketoamide com-
having the general formula M-(aa)n-CO-Q-R, pound having the general formula M-(aa)n-CO--
wherein: . . 40 Q-R, wherein: 
M is selected from the group cons1stmg of NH2-- M is selected from the group consisting of NH2--
CO-, NH2-CS-, NH2-S02-, X-N- CO-, NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, X-CO-, X-CS-, X-S02-, X-0-CO-, 
X-0-CS-, H, acetyl, carbobenzoxy ("Z"), 45 X-0-CS-, H, acetyl, carbobenzoxy ("Z"), suc-
succinyl, methyloxysuccinyl, and butyloxycar- cinyl, methyloxysuccinyl, and butyloxycarbonyl; 
bonyl; Xis selected from the group consisting ofCl-6 alkyl, 
X is selected from the group consisting of Cl-6 Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 
alkyl, Cl-6 fluoroalkyl, Cl-6 alkyl substituted Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
with J, Cl-6 fluoroalkyl substituted with J, 1- 50 9-fluorenyl, phenyl, phenyl substituted with K, 
admantyl, 9-fluorenyl, phenyl, phenyl substi- phenyl disubstituted with K, phenyl trisubstituted 
tuted with K, phenyl disubstituted with K, with K, naphthyl, naphthyl substituted with K, 
phenyl trisubstituted with K, naphthyl, naphthyl naphthyl disubstituted with K, naphthyl trisubstitu-
substituted with K, naphthyl disubstituted with ted with K, Cl-6 alkyl with an attached phenyl 
K, naphthyl trisubstituted with K, Cl-6 alkyl 55 group, Cl-6 alkyl with two attached phenyl 
with an attached phenyl group, Cl-6 alkyl with groups, Cl-6 alkyl with an attached phenyl group 
two attached phenyl groups, Cl-6 alkyl with an substituted with K, and Cl-6 alkyl with two at-
attached phenyl group substituted with K, and tached phenyl groups substituted with K; 
Cl-6 alkyl with two attached phenyl groups J is selected from the group consisting of halogen, 
substituted with K; 60 COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
J is selected from the group consisting of halogen, alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, 0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
Cl-6 alkylamine, Cl-6 dialkylamine, Cl-6 al- alkyl-S-; 
kyl-0-CO-, Cl-6 alkyl-0-CO-NH, and K is selected from the group consisting of halogen, 
Cl-6 alkyl-S-; 65 Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
K is selected from the group consisting of halogen, N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, C2-12 dialkylamino, Cl-C6 acyl, Cl-6 alkoxy-
N02, CN, OH, C02H, amino, Cl-6 alkylamino, CO-, and Cl-6 alkyl-S-; 
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aa is a blocked or unblocked amino acid of the L or D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 5 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva), alpha-
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, IO 
ornithine and sarcosine; 
n is a number from 1 to 20; 
Q is NH; and 
R is selected from the group consisting of H, Cl-6 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 15 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
8. The method of claim 7, additionally comprising the 
step of identifying, prior to the administration of said 
compound, a mammal in which neurodegeneration of 20 
the CNS due to ischemia is occurring or has occurred. 
9. The method of claim 7, wherein the neurodegener-
ation due to ischemia is associated with a condition 
selected from the group consisting of subarachnoid 
hemorrhage, stroke, brain seizure, major heart attack, 25 
multiple infarct dementia, surgery, and head injury. 
10. The method of claim 7, wherein the administering 
step comprises parenteral administration of said com-
pound in a pharmaceutically acceptable carrier. 
11. The method of claim 10, wherein the administer- 30 
ing step comprises transdermal administration, subcuta-
neous injection, intravenous, intramuscular or intraster-
nal injection, intrathecal injection directly into the CNS 
or infusion techniques. 
12. The method of claim 7, wherein the administering 35 
step comprises oral administration of said compound in 
a form suitable for oral use. 
13. The method of claim 7, wherein n is 1. 
14. The method of claim 7, wherein n is 2. 
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Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted With K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
C2-12 diakylamino, Cl-C6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 
aa is a blocked or unblocked amino acid of the L or D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva), alpha-
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, 
ornithine and sarcosine; 
n is 1; 
Q is O; and 
R is selected from the group consisting of H, Cl-6 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
20. The method of claim 19, wherein said neurode-
generation due to ischemia is associated with a medical 
15. The method of claim 7, wherein n is 3. 
16. The method of claim 7, wherein n is 4. 
40 condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
17. A method of intervening early in the process of 
neurodegeneration due to ischemia occurring in the 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 45 
Peptide a-Ketoacid selected from the group consisting 
of Bz-DL-Lys-COOH and Bz-DL-Ala-COOH. 
21. A method of intervening early in the process of 
neurodegeneration due to ischemia occurring in the 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 
Peptide Ketoester or a pharmaceutically acceptable salt 
thereof, said Peptide Ketoester having the formula M-
18. The method of claim 17, wherein said neurode-
generation due to ischemia is associated with a medical 
condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
50 (aa)nCO-Q-R, wherein: 
19. A method of intervening early in the process of 
neurodegeneration due to ischemia occurring in the 55 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 
Peptide Ketoester or a pharmaceutically acceptable salt 
thereof, said Peptide Ketoester having the formula M-
(aa)n-CO-Q-R, wherein: 60 
M is selected from the group consisting of NH2--
CO-, NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, 
X-0-CS-, H, acetyl, carbobenzoxy ("Z"), sue- 65 
cinyl, methyloxysuccinyl, and butyloxycarbonyl; 
Xis selected from the group consisting of Cl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 
M is selected from the group consisting of NH2--
CO-, NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, 
X-0-CS-, H, acetyl, carbobenzoxy ("Z"), suc-
cinyl, methyloxysuccinyl, and butyloxycarbonyl; 
Xis selected fromthe group consisting of Cl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 
Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 
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J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; S 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
C2-12 dialkylamino, Cl-C6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 10 
aa is a blocked or unblocked amino acid of the L or D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, IS 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva), alpha-
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, 20 
ornithine and sarcosine; 
n is 2; 
Q is O; and 
R is selected from the group consisting of H, Cl-6 2s 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
22. The method of claim 21, wherein the peptide 
ketoester is selected from the group consisting of Z- 30 Leu-Nva-COOEt, Z-Leu-Nle-COOEt, Z-Leu-Abu-
COOEt, Z-Leu-Met-COOEt, Z-Leu-Phe-COOEt, and 
MeO-Suc-Ala-DL-Ala-COOMe. 
23. The method of claim 21, wherein said neurode-
generation due to ischemia is associated with a medical. 3s 
condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
24. A method of intervening early in the process of 40 
neurodegeneration due to ischemia occurring in the 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 
Peptide Ketoester or a pharmaceutically acceptable salt 
thereof, said Peptide Ketoester having the formula M- 4S 
(aa)n-CO-Q-R, wherein: 
M is selected from the group consisting of NH2--
CO-, NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, so 
X-0-CS-, H, acetyl, carbobenzoxy ("Z") , 
succinyl, methyloxysuccinyl, and butyloxycarbo-
nyl; 
Xis selected from the group consisting ofCl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, SS 
Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu- 60 
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 6S 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
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0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
C2-12 dialkylamino, Cl-C6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 
aa is a blocked or unblocked amino acid of the L or D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva), alpha-
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, 
ornithine and sarcosine; 
n is 3; 
Q is O; and 
R is selected from the group consisting of H, Cl-6 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
25. The method of claim 24, wherein the Peptide 
Ketoester is selected from the group consisting of Z-
Ala-Ala-D L-Ala-COOEt, Z-Ala-Pro-DL-Ala-COOEt, 
Z-Ala-Ala-DL-Abu-COOEt, Z-Ala-Ala-DL-Abu-
COOBzl, and MeO-Suc-Val-Pro-DL-Phe-COOMe. 
26. The method of claim 24, wherein said neurode-
generation due to ischemia is associated with a medical 
condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
27. A method of intervening early in the process of 
neurodegeneration due to ischemia occurring in the 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 
Peptide Ketoester or a pharmaceutically acceptable salt 
thereof, said Peptide Ketoester having the formula M-
(aa)n-CO-Q-R, wherein: 
M is selected from the group consisting of NH2-
CO-, NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, 
X-0-CS-, H, acetyl, carbobenzoxy ("Z"), suc-
cinyl, methyloxysuccinyl, and butyloxycarbonyl; 
Xis selected from the group consisting of Cl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 
Cl-6 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, 
phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
5,444,042 
89 
C2-12 dialkylamino, Cl-C6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 
aa is a blocked or unblocked amino acid of the L or D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methio- 5 
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva), alpha- 10 
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, 
ornithine and sarcosine; 
n is 4; 
Q is O; and 15 
R is selected from the group consisting of H, C 1-6 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
28. The method of claim 27, wherein the peptide 20 
ketoester is selected from the group consisting of MeO-
Suc-Ala-Ala-Pro-D L-Abu-COOMe and Z-Ala-Ala-
Ala-DL-Ala-COOEt. 
29. The method of claim 27, wherein said neurode-
generation due to ischemia is associated with a medical 25 
condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
30. A method of intervening early in the process of 30 
neurodegeneration due to ischemia occurring in the 
neural tissue of a mammal comprising administering to 
said mammal a pharmaceutically acceptable form of a 
Peptide a-Ketoamide or a pharmaceutically acceptable 
salt thereof, said Peptide Ketoamide compound having 35 
the general formula M-(aa)n-CO-Q-R, wherein: 
M is selected from the group consisting of NH2--
CO-NH2-CS-, NH2-S02-, X-N-
H-CO-, X-NH-CS-, X-NH-S02-, 
X-CO-, X-CS-, X-S02-, X-0-CO-, 40 
X-0-CS-, H, acetyl, carbobenzoxy ("Z"), suc-
cinyl, methyloxysuccinyl, and butyloxycarbonyl; 
Xis selected from the group consisting of Cl-6 alkyl, 
Cl-6 fluoroalkyl, Cl-6 alkyl substituted with J, 
Cl-6 fluoroalkyl substituted with J, 1-admantyl, 45 
9-fluorenyl, phenyl, phenyl substituted with K, 
50 
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phenyl disubstituted with K, phenyl trisubstituted 
with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstitu-
ted with K, Cl-6 alkyl with an attached phenyl 
group, Cl-6 alkyl with two attached phenyl 
groups, Cl-6 alkyl with an attached phenyl group 
substituted with K, and Cl-6 alkyl with two at-
tached phenyl groups substituted with K; 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, Cl-6 alkoxy, Cl-6 
alkylamine, Cl-6 dialkylamine, Cl-6 alkyl-
0-CO-, Cl-6 alkyl-0-CO-NH, and Cl-6 
alkyl-S-; 
K is selected from the group consisting of halogen, 
Cl-6 alkyl, Cl-6 perfluoroalkyl, Cl-6 alkoxy, 
N02, CN, OH, C02H, amino, Cl-6 alkylamino, 
C2-12 dialkylamino, Cl-C6 acyl, Cl-6 alkoxy-
CO-, and Cl-6 alkyl-S-; 
aa is a blocked or unblocked amino acid of the Lor D 
configuration selected from the group consisting of 
alanine, valine, leucine, isoleucine proline, methio-
nine, methionine sulfoxide, phenylalanine, trypto-
phan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, 
lysine, arginine, histidine, phenylglycine, beta-ala-
nine, norleucine (nle), norvaline (nva) alpha-
aminobutyric acid (abu), epsilon-aminocaproic 
acid, citrulline, hydroxyproline, homoarginine, 
ornithine and sarcosine; 
n is a number from 1 to 20; 
Q is NH; and 
R is selected from the group consisting of H, Cl-6 
alkyl, Cl-6 fluoroalkyl, Cl-6 chloroalkyl, benzyl, 
Cl-6 alkyl substituted with phenyl, and Cl-6 alkyl 
with an attached phenyl group substituted with K. 
31. The method of claim 30, wherein n is 1. 
32. The method of claim 30, wherein n is 2. 
33. The method of claim 30, wherein n is 3. 
34. The method of claim 30, wherein n is 4. 
35. The method of claim 30, wherein said neurode-
generation due to ischemia is associated with a medical 
condition selected from the group consisting of stroke, 
head injury, major heart attack, brain seizure, surgery, 
multiple infarct dementia, and subarachnoid hemor-
rhage. 
* * * * * 
